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Abstract 
 
DNA damage can pose an irreversible steric block to RNA polymerase II (RNAPII), 
preventing transcription. RNAPII becomes stalled at DNA lesions, blocking normal 
repair. As a ‘last-resort’ mechanism to clear the stalled polymerase - and repair the 
damage - the largest subunit of RNAPII is poly-ubiquitylated and degraded. In 
yeast, this process is dependent on the Def1 protein, through a previously 
unresolved mechanism. Using a combination of yeast genetic, biochemical and cell 
biological techniques this thesis reports the molecular mechanism of Def1 in this 
process. 
 
Upon DNA damage induced RNAPII stall, Def1 becomes ubiquitylated and partially 
proteolytically processed by the 26S proteasome. This creates a biologically active, 
shorter form of Def1, termed pr-Def1. Removal of the C-terminus of Def1, which 
usually promotes nuclear export, results in nuclear accumulation of the N-terminal 
processed fragment. Nuclear pr-Def1 binds to stalled, mono-ubiquitylated RNAPII 
and recruits the Elongin-Cullin ubiquitin ligase complex, promoting RNAPII poly-
ubiquitylation and degradation. Interestingly, Def1’s ubiquitin-binding CUE domain 
and a novel ubiquitin homology domain in the Elongin complex mediate this 
interaction. 
 
These results outline the multi-step mechanism of RNAPII poly-ubiquitylation, 
elucidate Def1 activation and function, and identify an atypical ubiquitin-like domain 
in the yeast Elongin complex. 
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Chapter 1. Introduction 
 
1.1 Ubiquitin and Ubiquitylation 
 
1.1.1 Ubiquitin as a post translational modification 
 
Ubiquitin is an 8.5 kDa, 76-residue protein that commonly forms post-translational 
modifications on cellular proteins. As its name suggests, ubiquitin is universally 
expressed and highly conserved in eukaryotes (Figure 1.1, upper). Ubiquitylation 
creates an iso-peptide bond between the C-terminus of ubiquitin and the ε-amino 
lysine group of a target protein. Unlike other post-translational modifications, 
ubiquitin can be further modified itself; ubiquitin contains 7 lysine residues (Figure 
1.1, lower) (Vijay-Kumar et al., 1987) and a solvent exposed N-terminus, all of 
which can be conjugated to another ubiquitin molecule, creating chains. Ubiquitin 
chains can pose an extremely complicated signal on a protein. Not only can 
multiple lysine residues on the same protein be mono-ubiquitylated, but also the 
ubiquitin itself can form chains of differing linkages, which targets a protein to 
different cellular fates. Chains are typically formed using the same target lysine, but 
mixed linkage chains have been reported (Peng et al., 2003, Kim et al., 2007). The 
flexibility of ubiquitin signalling helps to explain its importance in numerous cellular 
pathways. 
 
Ubiquitin is added to a substrate protein at the end of an enzymatic activation 
cascade. Uba1 (the only E1 activating enzyme in S. cerevisiae) forms a high-
energy thioester linkage with ubiquitin in an ATP-dependent process. Next, 
ubiquitin is transesterified onto a Ubc (E2 conjugating) enzyme (Olsen and Lima, 
2013) and is finally transferred directly or indirectly to the substrate by an E3 ligase 
(Figure 1.2). The ubiquitin conjugation machinery determines ubiquitylation site 
usage and chain topology (Hofmann and Pickart, 1999, Petroski and Deshaies, 
2005). 
 
Chapter 1. Introduction 
15 
 
 
Figure 1.1: The structure of ubiquitin 
 
(upper) Comparison of the primary sequence of ubiquitin from yeast and human, with non-
conserved residues are highlighted in red. Sites of ubiquitin attachment are highlighted in green. 
The hydrophobic patch Leu-8, Ile-44 and Val-70 residues are highlighted in blue. 
(lower) The structure of ubiquitin (pdb 1UBQ; (Vijay-Kumar et al., 1987), with residues 
highlighted as above. The ubiquitin ββαββαβ roll is a commonly found superfold (Kiel and 
Serrano, 2006), whereby the beta barrel (front) grasps the long α-helix (rear). The percentages 
refer to relative abundance of chain linkage in yeast (Xu et al., 2009a). Inspired by Komander 
2009. 
 
 
E2 conjugating enzymes do not play a benign role in the final ubiquitylation reaction. 
Instead, E2s help to determine the chain topology for E3s (Suryadinata et al., 2013, 
Eddins et al., 2006) and may even aid in substrate selection (Somesh et al., 2007, 
Bernier-Villamor et al., 2002). Different E2s preferentially pair with different E3s; for 
example, Cullin E3s bind to E2s with long C-terminal basic extensions (Pierce et al., 
2009, Kleiger et al., 2009a). 
 
There are between 60-100 E3 ubiquitin ligases in S. cerevisiae (Finley et al., 2012). 
E3s can be split into two catalytically separate families, RING domain and HECT 
domain-containing E3s. HECT E3s directly transfer ubiquitin to substrate, from an 
active site cysteine. The HECT domain comprises an N-terminal E2 binding lobe 
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and C-terminal catalytic lobe. Rsp5 is the only essential HECT E3 in yeast and has 
the most identified functions (Kaliszewski and Zoladek, 2008, Huibregtse et al., 
1995). 
 
 
 
Figure 1.2: The ubiquitylation cascade 
 
Ubiquitin is transferred from an E1 activating enzyme to an E2 conjugating enzyme and finally 
to substrate, directly (RING E3) or via an active HECT thioester (HECT E3). The directionality of 
the cascade is ensured through the use of a common binding interface (Eletr et al., 2005) and 
the relative affinities for Ubi-E2 and E2 (Pickart and Rose, 1985, Saha and Deshaies, 2008). 
 
 
RING E3s bind to, and stimulate thioester transfer from a ubiquitin loaded E2, via 
altering the conformation of the E2 (Ozkan et al., 2005) and promoting the correct 
catalytic orientation (Duda et al., 2008). The largest sub-class of RING E3s is the 
modular Cullin-RING ligases (CRLs). CRLs are formed from one of three cullins in 
yeast (Cdc53, Rtt101 and Cul3), which fold as a ~110 Å elongated scaffold (Zheng 
et al., 2002). The C-terminal end of the cullin binds to the dynamic catalytic RING 
finger protein, Rbx1/Hrt1 (Duda et al., 2008). The N-terminal cullin repeats provide 
a platform to bind substrate adaptors (Figure 1.2), which allow a broad variety of 
targets to be ubiquitylated. The substrate adaptor component is typically a 
heterodimer comprised of a Skp1-like adaptor protein (either Skp1, Elc1 or Mms1) 
and one of a number of different substrate receptors: either an F-box protein, 
SOCS-box protein or DCAF-like protein. The 50-residue F-box motif is typically N-
terminal in a protein and binds to Skp1 or Elc1, freeing the C-terminus for substrate 
interaction (Bai et al., 1996, Skowyra et al., 1997). 
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CRL activities are highly controlled. Rub1 (NEDD8 in humans), a ubiquitin-like 
modifier with 80% homology to ubiquitin, covalently links to, and activates CRLs 
(Duda et al., 2008). Lag2 (CAND1 in humans) binds and inactivates CRLs 
(Siergiejuk et al., 2009), in part through promoting the dissociation of substrate 
adaptor proteins (Pierce et al., 2013). 
 
Chains are typically formed by the sequential addition of ubiquitins, requiring 
E2/HECT ubiquitin reloading (Kleiger et al., 2009b, Maspero et al., 2013). As a 
result, the poly-ubiquitylation and mono-ubiquitylation steps can often be 
separated; different E2 (Chen et al., 1993, Rodrigo-Brenni and Morgan, 2007) and 
E3 ligases (Hwang et al., 2010, Parker and Ulrich, 2009, Harreman et al., 2009) 
can be employed to perform poly-ubiquitin chain formation. 
 
Thousands of proteins in yeast are ubiquitylated (Peng et al., 2003, Beltrao et al., 
2012), each in a controlled manner through recognition of a degron signal. 
Substrate recruitment for the E3s can be mediated through the same polypeptide 
chain as the ligase domain. For example, Rsp5 contains three protein-interacting 
WW domains, which bind to proteins with PY-motifs (Sudol, 1996, Chang et al., 
2000). This limits the possible list of substrates, so both HECT E3s and RING E3s 
utilise substrate adaptors to increase the number and specificity of potential 
ubiquitylation targets (Sullivan et al., 2007, Finley et al., 2012). 
 
 
1.1.2 De-ubiquitylating enzymes (DUBs) 
 
Poly-ubiquitylation is antagonised by de-ubiquitylating enzymes (DUBs). 20 DUBs 
have been found in yeast (Finley et al., 2012), which catalyse the hydrolysis of 
isopeptide bonds on substrate or in chains (reviewed by Komander et al., 2009). 
Unlike E3s, no singular DUB–activity is essential for viability in yeast and some 
DUBs have a broad range of enzymatic activity (Schaefer and Morgan, 2011). 
Indeed, upon cell lysis there is rapid reversal of all ubiquitylation, due to 
uncontrolled DUB action (Wilson et al., 2012, Finley et al., 2012). However, linkage 
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specificity has been reported for some DUBs (Edelmann et al., 2009, Mevissen et 
al., 2013, Ye et al., 2012, Chai et al., 2004). 
 
DUBs have a critical role in providing free ubiquitin for ubiquitylation reactions, but 
also have key roles in antagonising ubiquitin signalling. DUBs can be controlled 
through interacting partners and post-translational modifications: for example, the 
DUB, Ubp3, is only active upon association with Bre5 (Cohen et al., 2003). Ubp3 is 
also further stimulated by phosphorylation upon osmotic stress (Sole et al., 2011). 
Another DUB, Ubp2, forms a complex with Rsp5 via Rup1, specifically 
antagonizing Rsp5 Lys-63 chain formation (Kee et al., 2005, Kim and Huibregtse, 
2009, Kee et al., 2006). 
 
 
1.1.3 Ubiquitin binding domains 
 
Ubiquitin recognition poses a unique problem to cells: Ubiquitin itself is much larger 
than other post-translational modifications, making it impractical for a single domain 
to bind to both the ubiquitin and the ubiquitylated protein. In addition, the 
complexity of multiple chain topologies needs to be decoded. Different linkages 
lead to different cellular fates, requiring specific chain recognition. Ubiquitin 
recognition can be mediated through small, independently folding ubiquitin binding 
domains (UBDs) (Hofmann, 2009) or short ubiquitin-interacting peptide segments 
(Fradet-Turcotte et al., 2013). 
 
UBDs have been divided into 20 or more distinct families depending upon 
sequence and fold (Husnjak and Dikic, 2012). S. cerevisiae contains 39 proteins 
with confirmed UBDs (some examples are listed in Table 1.1). Often these are 
involved in the ubiquitin conjugation reaction - by helping to orientate invading 
ubiquitin moieties during ligation (Polo et al., 2002, Shih et al., 2003, Hoeller et al., 
2007) - or preventing the poly-ubiquitylation of a substrate (Herrador et al., 2013). 
Due to the broad function of ubiquitin in other cellular processes, UBDs are an 
integral part of signalling platforms (Hofmann, 2009, Acconcia et al., 2009). 
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Table 1.1: List of UBDs in S. cerevisiae 
 
UBD Binding mode Ubiquitin motif Example Function Reference 
UIM Single α helix Hydrophobic patch Rpn10 Proteasome 
subunit 
(Elsasser et 
al., 2004) 
UBA Three helix 
bundle 
Hydrophobic patch Rad23 
Dsk2 
NER/ 
Proteasome 
shuttling factor 
(Raasi et al., 
2005) 
UEV Extended loop Hydrophobic patch Mms2 Lysine-63 
conjugation 
(Tsui et al., 
2005) 
PFU Four β-strands 
and two α-helices 
Hydrophobic patch Doa1 Cdc48 adaptor (Pashkova et 
al., 2010) 
SH3v Hydrophobic 
groove 
Hydrophobic patch Sla1 Actin 
cytoskeleton 
(Stamenova et 
al., 2007) 
UBZ Inverted Single α 
helix  
Hydrophobic patch/ 
C-terminus 
Rad30 
 
Translesion 
synthesis 
(Bomar et al., 
2007) 
UBC Catalytic core/β-
sheet 
C-terminus/ 
Hydrophobic patch 
Ubc4 E2 enzymes (Cook et al., 
1993) 
UBM Helix turn helix Hydrophobic patch Rad2 NER (Bomar et al., 
2010) 
CUE Three helix 
bundle 
Hydrophobic patch Vps9 
 
Def1 
ER 
Ubiquitylation 
Rpb1 
degradation 
(Shih et al., 
2003) 
 
(Ponting, 
2002) 
PRU Three loops of PH 
domain 
Hydrophobic patch Rpn13 Proteasome 
subunit 
(Husnjak et al., 
2008) 
 
Many structural studies have examined the interaction of ubiquitin and UBDs 
(Table 1.1). Ubiquitin recognition is mediated through a number of different folds, 
but tends to focus on the hydrophobic patch of ubiquitin (Winget and Mayor, 2010). 
The hydrophobic patch is formed by residues Val8-Ile44-Leu70 (Figure 1.1). 
Mutation of the isoleucine to alanine tends to ablate UBD interactions (the only 
reported exception has been presented in Bomar et al., 2010). Whist key residues 
in the hydrophobic patch mediate the majority of the interactions with UBDs, other, 
specific contacts are also important. For example, mutation of the β5 strand of 
ubiquitin ablates only the UIM-UBD interaction (Haririnia et al., 2008). Domains 
within the same family often display subtly different binding to ubiquitin. These 
subtle differences can lead to large functional consequences, in both the affinity to 
ubiquitin and recognition mode (Raasi et al., 2005, Komander et al., 2008). 
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As the UBD-Ubi interaction surface is small and principally hydrophobic, affinities 
tend to be low (Hurley et al., 2006). UBD interactions are often co-ordinated with 
other protein interaction motifs to help confer specificity and ensure robust protein 
interactions (Panier et al., 2012, Parker et al., 2007). 
 
Whilst most UBDs have been identified through their binding to mono-ubiquitin in 
vitro, in their proper, cellular context they often display linkage specificity 
(Funakoshi et al., 2002, Raasi et al., 2005). The linkage specificity of UBDs is 
achieved through selection of the ubiquitin chain topology. Different chain 
conformations, whilst relatively dynamic (Ryabov and Fushman, 2006) have 
preferred states that can be fixed through the binding of UBDs (Husnjak and Dikic, 
2012, Ye et al., 2012). Lys-6, -11, -27 and -48 ubiquitin chains preferentially form a 
closed conformation (Varadan et al., 2002), whilst Lys-29, -33, -63 and Met-1 linked 
chains form open, elongated structures (Varadan et al., 2004, Fushman and 
Walker, 2010). 
 
Chain recognition can be achieved by individual UBDs: Rad23’s second ubiquitin 
associated (UBA) domain preferentially binds to Lys-48 over Lys-63 chains (Raasi 
et al., 2005). This is achieved through the UBA sandwiching between two Lys-48 
linked ubiquitins, using an additional ubiquitin-binding surface (Varadan et al., 
2005). The NEMO UBD binds linear chains with 100x greater preference than other 
chain linkages, through direct binding to the glycine-methionine, C-N terminal 
linkage (Rahighi et al., 2009). Alternatively, using multiple UBDs both increases the 
relative avidity of ubiquitin interaction and can possibly lead to chain–linkage 
specificity (Sims and Cohen, 2009, Zhang et al., 2009). The length and flexibility of 
linker regions between repeated UBDs helps to determine specificity. For example, 
the two UIMs of RAP80 bind to Lys-63 linked chains (Sobhian et al., 2007), 
whereas Ataxin-3, which also has two UIMs, is a Lys-48 specific DUB (Chai et al., 
2004). Swapping the linker region between the UIMs of RAP80 and Ataxin-3 
reverses their inherent linkage specificity (Sims and Cohen, 2009). 
 
The Dsk2 UBA domain was one of the first studied both biochemically and 
structurally (Hofmann and Bucher, 1996, Ohno et al., 2005), and displays one of 
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the highest UBD affinities reported (Raasi et al., 2005, Ohno et al., 2005). UBA 
domains wrap three helices around the ubiquitin hydrophobic patch (Dieckmann et 
al., 1998, Ohno et al., 2005). In vivo and ex vivo Dsk2 binds to Lys-48 linked chains 
(Funakoshi et al., 2002), fitting its function as a proteasome shuttle factor. However, 
the Dsk2 UBA domain does not exhibit any particular linkage preference on its own 
(Raasi et al., 2005), nor bind in a manner to exert such preference (Ohno et al., 
2005). The Lys-48 selectivity of Dsk2 may be due to the interaction of more than 
one Dsk2 protein per ubiquitin chain (Lowe et al., 2006); the UBA domain of Dsk2 
can dimerise (Sasaki et al., 2005).  
 
The coupling of ubiquitin conjugation to ER degradation (CUE) UBD was identified 
from two studies of Vps9 binding to ubiquitin (Donaldson et al., 2003, Shih et al., 
2003). CUE domains can bind to both to mono-ubiquitin and ubiquitin chains (Shih 
et al., 2003, Liu et al., 2012, Bagola et al., 2013). The CUE domain has a very 
similar fold to UBA domains (Prag et al., 2003, Kang et al., 2003), with a conserved 
mode of ubiquitin binding. 
 
 
1.1.4 Ubiquitin-mediated proteolysis 
 
Ubiquitylation is the main targeting signal for protein degradation. On a 
macroscopic scale, whole organelles and large protein complexes are targeted for 
autophagy through ubiquitylation (Nakatogawa et al., 2009).  
 
Tagging with ubiquitin was originally identified to alter the half-life of a protein via 
ATP dependent proteasome degradation (Hershko et al., 1980). Further work 
elucidated that tagging by at least 4 ubiquitin moieties was required to target a 
protein for degradation (Thrower et al., 2000). All chain linkages except Lys-63 can 
lead to degradation (Xu et al., 2009a, Zhao and Ulrich, 2010). However, if the 
tagged polypeptide is shorter than 150 amino acids, even a single mono-ubiquitin is 
sufficient for proteasome-mediated proteolysis (Shabek et al., 2012). Furthermore, 
ubiquitin-independent proteasomal degradation has also been reported for a 
number of proteins (Jariel-Encontre et al., 2008, Ha et al., 2012). 
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The 26S proteasome is a 2.5 MDa complex comprised of 33 subunits (Finley, 2009, 
Beck et al., 2012); arranged into a 20S catalytic core particle capped with two 19S 
regulatory particles (Figure 1.3). The solvent accessible 20S barrel physically 
sequesters the proteolytic sites (Heinemeyer et al., 1997); the combination of three 
broad specificity proteases leads to the degradation of any entering polypeptide 
chain (Elsasser and Finley, 2005, Lee et al., 2001a). 
 
 
 
Figure 1.3: The 26S yeast proteasome 
 
(Left) schematic representation of the 26S proteasome with labelled subunits. The ubiquitin 
interacting subunits Rpn10 and Rpn13 are coloured green, DUBs Ubp6 and Rpn11 are 
coloured brown and ATPase subunits Rpt1-6 are coloured red. In the core, the α -subunits 
Pre5-6, Pre8-10, Pup2 and Scl1 are coloured dark blue, whilst the β-subunits Pre1-4, Pre7, 
Pup1 and Pup3 are coloured light blue. Substrate (grey) is modelled as in Lander et al, 2012  
(right) Cryo EM reconstruction of the yeast 26S core particle from (Beck et al., 2012)(pdb 4B4T) 
coloured according to resolution from blue (6.5 Å) to red (8.5 Å) 
 
The 19S regulatory particle both recognises ubiquitylated substrates and unfolds 
globular proteins, allowing their passage into the 20S (Glickman et al., 1998, Navon 
and Goldberg, 2001). The base of the 19S forms a spiral hexameric ring (Lander et 
al., 2012), creating the dynamic helicase, which unwinds globular proteins in an 
ATP-dependent manner (Schrader et al., 2009, Matyskiela et al., 2013).  
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The 19S contains two associated DUBs; the zinc-metalloprotease Rpn11 cleaves 
the ubiquitin chain close to their base, whilst Ubp6 trims exterior ubiquitins (Verma 
et al., 2002, Guterman and Glickman, 2004). Ubiquitylated proteins are bound 
through the UIM domain of Rpn10 (Elsasser et al., 2004) and the PRU domain of 
Rpn13 (Husnjak et al., 2008); both subunits display a marked preference for poly-
ubiquitin chains (Zhang et al., 2009). Interestingly, the ubiquitin receptors are not 
essential (Glickman et al., 1998). This may be due to redundancy with the 
proteasome shuttling factors: Rad23, Dsk2 and Ddi1 (Schauber et al., 1998, 
Funakoshi et al., 2002, Sirkis et al., 2006), which bind to and target ubiquitylated 
proteins to the proteasome (Elsasser et al., 2002, Rosenzweig et al., 2012). 
 
The ubiquitin, chaperone-like, ATPase Cdc48 helps to deliver or aid unfolding of 
otherwise intractable ubiquitylated proteins to the proteasome (Dantuma and 
Hoppe, 2012). Accessory ubiquitin receptors help to target Cdc48 to multiple 
substrates and these can be subdivided into Ufd1-Npl4-Cdc48 complexes and Ubx-
Cdc48 complexes. For example, the ER tethered transcription factor Spt23 is 
mono-ubiquitylated and partially processed by the proteasome (see 1.1.6; (Hoppe 
et al., 2000). However, the shorter, processed protein is still stably attached to an 
unprocessed protein at the ER membrane. This complex is dissociated by Cdc48-
Ufd1-Npl4 complex, allowing nuclear accumulation of the transcription factor (Rape 
et al., 2001, Hitchcock et al., 2001). 
 
 
1.1.5 Ubiquitin-like and ubiquitin homology domains 
 
Genome-wide genetic analyses revealed a large number of ORFs that contained 
regions with homology to ubiquitin (Welchman et al., 2005). Ubiquitin-like proteins 
(Ubls) do not necessarily share high sequence homology to ubiquitin, but use the 
same β-grasp fold and conjugate to substrates via a C-terminal glycine. Six Ubls 
have been identified in yeast: Smt3 (yeast homologue of human SUMO1/2); Rub1 
(NEDD8); Hub1 (Ubl5); Urm1 (URM1); Atg8 (GATE16) and Atg12 (ATG12). Each 
Ubl has its own conjugation machinery - which acts in a similar manner to the 
ubiquitylation cascade (Figure 1.2) - and targets proteins involved in numerous 
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cellular processes (Finley et al., 2012). Metazoans have evolved multiple Ubls with 
more diverse functions (van der Veen and Ploegh, 2012) 
 
Horizontal gene transfer has also resulted in the formation of proteins containing 
internal ubiquitin homology domains (UbH domains). These domains do not act like 
the Ubls: they are not covalently conjugated to other proteins. Instead, integral UbH 
proteins utilise the ubiquitin fold and components of the ubiquitin machinery for 
their own ends. Whilst a large group of UbH proteins are implicated in ubiquitylation 
and proteasomal degradation, an increasing number have been found to be 
involved in other functions (May et al., 2004, Takai et al., 2001, Garrett et al., 1995). 
 
Original classifications of UbH domains were based on sequence homology 
(Garrett et al., 1995); however, at a structural level the ubiquitin fold is extremely 
common (Kiel and Serrano, 2006). The broad in silico definitions have identified 
many possible internal UbH domains, most of which have not yet been validated 
structurally or biochemically. Where structural studies have been performed, the 
UbH domains invariably have a ubiquitin-like, β-grasp, superfold (Harper et al., 
2011, Faesen et al., 2011). Integral UbH domains can also be referred to as 
ubiquitin fold domains (UFDs) (Faesen et al., 2012) or Ubls (Grabbe and Dikic, 
2009), for clarity in this thesis the nomenclature UbH will be used. 
 
The majority of work on integrated UbH proteins has focused on the UbH-UBA 
proteasome shuttle factors. Dsk2 and Rad23 simultaneously interact with the 
proteasome and ubiquitin chains, through their UbH and UBA domains respectively 
(Schauber et al., 1998, Wilkinson et al., 2001, Saeki et al., 2002). These proteins 
can protect ubiquitylated proteins from DUBs (Raasi and Pickart, 2003, Ng et al., 
2003) and are essential for the degradation of a number of proteins (Verma et al., 
2004). Rad23 is also involved in transcription-coupled nucleotide excision repair 
(TC-NER), independently of its UBA and UbH domains (see 1.4.2.2). 
 
In metazoa, the majority of USP family DUBs contain UbH domains (Zhu et al., 
2007). These domains do not share a common role (Faesen et al., 2012). In 
USP7/HAUSP two of the five UbH domains bind to the active site increasing the 
affinity for ubiquitin and the DUBs catalytic activity (Faesen et al., 2011), whereas 
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USP4 is catalytically inhibited by its UbH domain (Luna-Vargas et al., 2011). The 
N-terminal UbH in hUSP14 has no direct role on catalysis, but does help recruit the 
protein to the proteasome (Peth et al., 2009), whereas the equivalent yeast protein, 
Ubp6, is not recruited through its UbH domain (Rosenzweig et al., 2012).  
 
UbH domains can bind to UBDs (Walters et al., 2003, Chartron et al., 2012). Apart 
from Rad23, these interactions are typically of much higher affinity than Ubi-UBD 
interactions; the normal Ubi-UBD hydrophobic contacts are aided by extra 
hydrogen bonding and electrostatic interactions (Chartron et al., 2012, Zhang et al., 
2009). 
 
Alternatively, UbH proteins interact via domains that do not usually bind Ubiquitin. 
These can bind to the normal hydrophobic patch on the UbH (Hanzelmann et al., 
2010) or to an alternate position on the ubiquitin superfold (Pacold et al., 2000, 
Lowe et al., 2006). For example, the human UbH elongation factor Elongin B (see 
1.3.1.2), binds to its interaction partner, Elongin C, via the β-sheet back face of the 
ubiquitin superfold (Brower et al., 1999, Babon et al., 2008). This interaction leaves 
the hydrophobic patch free and allows the formation of a stable heterodimeric 
complex (Kiel and Serrano, 2006).  
 
 
1.1.6 Partial proteasomal processing 
Proteasomes are extremely efficient at digesting substrate protein to short 5-20 
residue peptides (Lee et al., 2001a). However, some studies have identified a small 
number of proteins that escape total degradation upon targeting to the proteasome, 
which are instead partially proteasomally processed. 
 
Only 8 partially proteasomally processed proteins have been identified to date 
(Figure 1.4). In the early 1990s the p50 subunit of NF- κB1 was found to be formed, 
post translationally, from the full-length p105 precursor in an ATP and proteasome-
dependent manner (Fan and Maniatis, 1991, Palombella et al., 1994) (Moorthy et 
al., 2006). The NF-κB2 subunit, p55, was also identified to be processed, from full-
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length p100 protein (Xiao et al., 2001), as were the yeast homologs of NF-κB, 
Spt23 and Mga2 (Hoppe et al., 2000, Shcherbik et al., 2003). Fascinatingly, the 
NF-κB1 p105 protein can also be processed when expressed in yeast cells 
(Palombella et al., 1994, Kravtsova-Ivantsiv et al., 2009), a testament to the 
conserved nature of the processing reaction. Spt23 is processed from a p120 
membrane-tethered fragment to a number of different protein fragments with a 
molecular weight of around 50 kDa (Hoppe et al., 2000). Transcription factors 
Curbitis interuptus (Ci; Aza-Blanc et al., 1997); its vertebrate homologs, Gli2 and 
Gli3 (Pan et al., 2006b, Wang et al., 2000); and mammalian specificity protein 1 
(Sp1; Su et al., 1999) are also partially proteasomally processed. 
 
 
 
Figure 1.4: Schematic of the partially proteasomally processed proteins 
identified to date 
 
Depicted proteins are to scale. An arrowhead identifies the approximate site of processing (note 
that this is highly dynamic). Domains are coloured as follows; red, rel homology/IPT domains; 
light blue glycine rich (GRR) or low complexity region; grey, ankyrin repeats; dark green, 
transmembrane regions; light green, transactivation domains; brown, NLS; dark blue, glutamine 
rich. 
 
 
Whilst all the processed proteins identified to date have been transcription factors, 
the outcome of the processing reaction differs. NF-κB and its homologs, Spt23 and 
Mga2, are activated by the proteasomal degradation of their C-termini. The removal 
of the C-terminal ankyrin repeat regions of NF-κB exposes a nuclear localisation 
signal (NLS) (Orian et al., 1999). Spt23 and Mga2 are both ER-membrane bound 
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and processing liberates the proteins, allowing them to translocate into the nucleus 
(Hoppe et al., 2000, Rape et al., 2001, Hitchcock et al., 2001). Proteasomal 
processing, however, negatively regulates Ci and Sp1. Processing of Ci removes 
the transactivation domain, converting the DNA binding p75 fragment to a 
repressor (Aza-Blanc et al., 1997). 
 
Twenty years of mechanistic studies of partial proteasomal processing has helped 
to elucidate the biochemistry of both partial and total protein degradation by the 
proteasome. The current model of partial proteolytic processing consists of two 
steps: proteasome-initiated cleavage and (bi-directional) degradation up to a 
blocking ‘stop-transfer signal’ (Lin and Ghosh, 1996, Piwko and Jentsch, 2006). 
The cleavage step requires proteasome recognition and an initiator site, which can 
be spatially removed from the final processed site (Schrader et al., 2009, Inobe et 
al., 2011). Initiator sites are thought to occur at unfolded regions of low complexity, 
close to the site of ubiquitylation (Prakash et al., 2004, Inobe et al., 2011), which 
may be inside the protein (Piwko and Jentsch, 2006, Liu et al., 2003). Internal 
initiation site usage appears to favour incomplete proteolysis (Kraut and 
Matouschek, 2011).  
 
Proteasome recognition is principally mediated through ubiquitylation (Palombella 
et al., 1994, Inobe et al., 2011). Ubiquitin was directly shown to be required in 
extract-based in vitro reactions for p105 processing (Palombella et al., 1994, Orian 
et al., 1995, Sears et al., 1998) and lysines at the C-terminus of p105 are crucial for 
processing in vivo (Orian et al., 1999). Despite the frequent observation of poly-
ubiquitin chains on processed proteins (Orian et al., 1999, Hoppe et al., 2000, 
Shcherbik et al., 2003), only mono-ubiquitylation is required for processing 
(Kravtsova-Ivantsiv et al., 2009, Rape et al., 2001). Ubiquitin remains attached to 
Spt23 and Mga2 after proteasomal processing, but it is not found on the partially 
processed proteins of higher eukaryotes, possibly due to the removal by 
proteasome associated DUBs during processing.  
 
Partially processed proteins differ from normally degraded proteins in their ability to 
block the proteasome after the initiation of degradation. The cleaved C-terminal 
fragment has not been detected in any of the native processed proteins, suggesting 
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efficient complete proteasomal degradation of this section (Piwko and Jentsch, 
2006). The N-terminal fragment is rescued by a stop-transfer signal that prevents 
the proteasome from completing degradation. In higher eukaryotes the stop-
transfer signal is formed by the combination of a tightly folded domain followed by a 
simple low complexity region (Tian et al., 2005) (Figure 1.4). Low complexity 
regions have reduced coupling between nucleotide hydrolysis and substrate 
unfolding (Bachmair and Varshavsky, 1989, Daskalogianni et al., 2008). It is 
therefore conceivable that the combination of the 19S-resistant, stable domain 
allows the poorly bound low-complexity region to diffuse away from the proteasome 
mid degradation. Intriguingly, the transcription factor Sp1 lacks any recognisable 
components of this bi-partite stop signal (Figure 1.4). However, Sp1 does have 
glutamine rich regions (Roos et al., 1997), which significantly reduce the 
processivity of the proteasome (Kraut et al., 2012).  
 
In S. cerevisiae the stop signal does not seem to require a region of low complexity. 
The IPT domain of Spt23 is required for processing and this domain forms very 
stable (resistant to up to 2.5M NaCl washing) homo-dimers (Rape et al., 2001). 
These dimerization domains are thought to block the proteasome, but do not have 
a simple coding sequence after them. In agreement with this observation, whilst 
normal p105 processing is observed upon expression in S. cerevisiae, this is not 
prevented by deletion of the GRR (Sears et al., 1998), which is absolutely required 
in mammalian cells (Lin and Ghosh, 1996). The observed discrepancy may be due 
to the inherent lower processivity of yeast proteasomes (Kraut et al., 2012). 
 
Critically, the distance between the stop-transfer signal and newly formed C–
terminus of the protein is not fixed, and can be altered by internal deletions around 
the proposed cleavage site (Sears et al., 1998, Lin and Ghosh, 1996, Piwko and 
Jentsch, 2006). However, the distance between the proteasome recognition signal 
and the initiator signal (Inobe et al., 2011) is crucial, as is the distance and 
orientation between the low complexity region and the tightly folded domain (Tian 
et al., 2005). The exact processing site for all processed proteins, bar Sp1, has not 
been identified (Su et al., 1999).  
 
 
Chapter 1. Introduction 
29 
1.2 Nuclear Transport 
 
The nucleus is the primary defining organelle of the eukaryotic cell, which spatially 
separates the coding DNA from protein translation and effector functions. As many 
nuclear processes require protein catalysts, import and export is required between 
the nucleus and cytoplasm. 
 
The nucleus is encompassed by a phospholipid bilayer termed the nuclear 
membrane. The bilayer is punctuated by numerous aqueous channels, termed 
nuclear pore complexes (NPCs). Ions, small molecules and proteins <40kDa can 
freely diffuse through the NPC (Bonner, 1975), whereas RNA and larger proteins 
require the assistance of nuclear transport factors.  
 
No ATP-driven subunits are part of the NPC. Nuclear transport is instead promoted 
by the relative affinities and concentrations of transport molecules on either side of 
the nuclear membrane (reviewed in Aitchison and Rout, 2012). The direction of 
transport is mediated through the interaction of karyopherins with Ran GTPase 
(Gsp1 in yeast). The GTP hydrolysis activity is spatially separated over the nuclear 
membrane. In the nucleus, Ran is maintained in a GTP-bound state, by the Ran 
guanidine exchange factor (GEF), Srm1 (Akhtar et al., 2001). In the cytoplasm, the 
Ran GTPase Activating Protein (GAP) Rna1 promotes the hydrolysis of GTP to 
GDP (Becker et al., 1995). As a result, transiting Gsp1 is interconverted on 
opposite sides of the nuclear membrane (Figure 1.5). Indeed, the direction of 
nuclear transport can be reversed by inverting the Ran gradient (Nachury and Weis, 
1999). 
 
 
1.2.1 Karyopherin family 
All nuclear carrier proteins identified to date are part of the karyopherin family. 
Karyopherins are typically large with only around 20% sequence identity, but 
contain multiple, 50-residue HEAT repeats (Andrade et al., 2001). Most members 
resemble importin-β (Kap95), whereby each HEAT repeat forms two antiparallel 
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stacking α-helices, which assemble into a banana shaped structure (Xu et al., 
2010).  
 
14 karyopherins have been identified in yeast (Strom and Weis, 2001). The 
karyopherins principally involved in import are called importins. Conversely, export 
proteins are termed exportins and those implicated in two-way traffic are called 
transportins. The substrates and direction of travel for most karyopherins remain 
unclear. Karyopherins, except for Kap60, bind to their cargo directly, and this is the 
rate-limiting step in nuclear transport (Timney et al., 2006). Karyopherins are, by 
necessity, promiscuous and utilise multiple binding interfaces (Lee et al., 2003), 
sometimes used simultaneously (Hodges et al., 2005). There is redundancy 
between karyopherins: Kap123 mediates ribosome import but cells lacking this 
import factor utilise Kap121 (Rout et al., 1997). There are reports of proteins that 
can traverse the NPC without the aid of karyopherins and/or Gsp1 (Yen et al., 2001, 
Hanover et al., 2007), possibly via direct contact with NPC components. 
 
 
1.2.2 Nuclear transport signals 
Despite the large number of karyopherin proteins identified, only four nuclear 
targeting signals have been identified. The classical nuclear localisation signal 
(NLS) is the best-characterised nuclear targeting signal and comes in two flavours - 
mono-partite and bi-partite - both of which bind Kap60 (importin-α), and Kap123 
(Kalderon et al., 1984, Hodel et al., 2001, Robbins et al., 1991). Only 57% of 
nuclear proteins in yeast contain an identifiable classical NLS (Lange et al., 2007). 
 
The study of nuclear export has lagged behind nuclear import. The classical 
nuclear export signal (NES) was originally identified as a leucine rich motif in the 
human Protein Kinase A inhibitor (Wen et al., 1995). The NES is an extremely 
degenerate 15-residue peptide, with 4 hydrophobic residues regularly spaced. Over 
200 proteins in yeast contain a variant of this motif, which binds directly to the 
exportin Xpo1/Crm1 (reviewed by Hutten and Kehlenbach, 2007, Figure 1.5). This 
hydrophobic-rich sequence only describes 40% of the known peptide signals that 
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can target nuclear export (Kosugi et al., 2008). Crm1 can also promote the nuclear 
export of non-NES containing proteins (Macedo-Ribeiro et al., 2009, Chan et al., 
2011). Whilst the majority of nuclear export is mediated through Crm1, a number of 
proteins accumulate in the nucleus in strains defective for Crm1 (Maurer et al., 
2001).  
 
 
 
Figure 1.5: The classical nuclear export of proteins 
 
The outside surface of Crm1 binds directly to the hydrophobic NES peptide, which induces the 
co-operative binding of Gsp1-GTP (Hutten and Kehlenbach, 2007, Dong et al., 2009). The 
complex transfers through the pore in a similar manner to other karyopherins, through 
interactions with NPC FG repeat proteins. Unlike import, GTP hydrolysis inefficiently promotes 
dissociation of the Crm1-Gsp1-cargo complex, which is aided by Yrb1 (Kunzler et al., 2001). 
 
 
Despite early success with the well defined nuclear targeting signals outlined above, 
the other motifs have proved to be more degenerate: typically described instead by 
physiochemical rules, rather than an exact sequence pattern (Xu et al., 2010). 
Unlike other sub-cellular targeting signals found in the cell, nuclear targeting occurs 
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in the context of fully folded proteins. As a result, the dogma of short peptide 
signalling sequences is likely the exception rather than the rule. The karyopherins, 
Cse1 and Los1 specifically recognise the entire conformation of their targets - 
Kap60 and tRNA respectively (Matsuura and Stewart, 2004, Cook et al., 2009). In 
yeast up to 2000 proteins shuttle through the nuclear pore, yet the mechanism for 
this transport has been identified for only a handful of these proteins (Aitchison and 
Rout, 2012). 
 
The shuttling protein need not necessarily have a transport signal, as mediator 
proteins could help specify subcellular localisation. This is often the case for the 
nuclear import of large complexes. Fully formed 12-subunit RNAPII is recognised 
by the NLS containing protein, Iwr1, which targets the complex for nuclear import 
(Czeko et al., 2011). 
 
 
1.2.3 Control of nuclear localisation 
 
Dynamic compartmentalisation, altering the subcellular localisation of a cargo 
protein, is an elegant method of regulation. This can be mediated through post-
translational modification of transport signals, altering karyopherin binding 
(Harreman et al., 2004). For example, Kap121 imports the phosphate response 
transcription factor Pho4 into the nucleus when phosphate is limiting. When 
phosphate levels are restored, Pho4 is phosphorylated within its NLS, preventing 
Kap121 binding, and creating an Msn5 recognition site, promoting Pho4 export 
(Komeili and O'Shea, 1999, Kaffman et al., 1998). 
 
Alternatively, proteins can be tethered to prevent their relocalisation (see 
discussion on Spt23 and Mga2 in 1.1.6; Hoppe et al., 2000). Nuclear pore 
components themselves can be phosphorylated, altering the permeability of the 
nucleus to numerous proteins (Makhnevych et al., 2003). Interestingly, a number of 
proteins accumulate in the nucleus upon transcription inhibition, as they are 
commonly exported with mRNA (O'Hagan and Ljungman, 2004, Lee et al., 1999b). 
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SUMOylated-PTEN and the small ribonucleotide reductase subunits, Rnr2 and 
Rnr4, relocalise to the cytoplasm after DNA damage (Bassi et al., 2013, Yao et al., 
2003, Lee et al., 2008). A whole proteome study recently identified the 
translocation of around 100 proteins between the nucleus and cytoplasm as a 
response to DNA damage (Tkach et al., 2012). The induced transit mechanism for 
most of these proteins is unclear. 
 
 
 
 
1.3 Transcription 
 
In 1958 Francis Crick defined what is now known as the central dogma of biology: 
DNA is transcribed to RNA, which is then translated into an effector protein (Crick, 
1958). A highly conserved, DNA-dependent, RNA polymerase catalyses the 
transcription stage in this process. In eukaryotes three RNA polymerases account 
for transcribing ribosomal RNA (rRNA), messenger RNA (mRNA) and transfer RNA 
(tRNA), respectively. RNAPII - responsible for transcribing mRNA - is arguably the 
most important and highly regulated of these. 
 
RNAPII is a complex of 12 subunits; named Rpb1-Rpb12. Numerous structural 
studies of RNAPII have revealed the subunit architecture and catalytic mechanism 
of the transcription cycle (Gnatt et al., 2001, Cramer et al., 2001, Kettenberger et 
al., 2004, Cheung et al., 2011, Liu et al., 2013) (Figure 1.6 A). DNA is clamped 
between the upper jaw (comprised of Rpb1 and Rpb9) and lower jaw (chiefly Rpb5) 
(Gnatt et al., 2001). Roughly 18 bp of DNA is unwound at the upstream fork loop of 
Rpb2, and the non-transcribed strand (NTS) lies on the outside of the protein 
complex (Gnatt et al., 2001). The rudder and lid structures dissociate the 8-9 bp 
DNA-RNA hybrid, positioning RNA into a separate exit channel (Figure 1.6 B). The 
RNAPII active site is in the centre of the complex, formed between Rpb1 and Rpb2, 
and traversed by the bridge helix (Figure 1.6 B). RNAPII moves by a Brownian 
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ratchet mechanism, indirectly powered by the energy of RNA polymerisation (Bar-
Nahum et al., 2005, Liu et al., 2013). 
 
 
 
 
Figure 1.6: The RNAPII elongation complex 
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A. Overview of the RNAPII elongation complex (taken from Cheung et al., 2011; pdb 4A3F). 
Structure shows Transcribed strand (TS), cyan; Non-transcribed strand (NTS), green; 4 bp of 
RNA, red; Magnesium ion, purple; and bound NTP, orange. The key active site features of the 
trigger loop (navy blue) and bridge helix (yellow) are highlighted. Subunit position shown on the 
right, Rpb8 is behind the complex. Inspired by Kettenberger et al., 2004. 
B. RNAPII catalytic center and transcription bubble. Features coloured as above. Modified from 
(Gnatt et al., 2001). 
 
 
1.3.1 Transcription elongation 
 
Many significant control steps take place during the production of mRNA 
concurrently with transcription elongation. The process of polymerisation is 
extremely processive. RNAPII transcription can continue for Mega bases: the 
human dystrophin gene is 2.3 Mbp long and takes around 16 hours to transcribe 
(Tennyson et al., 1995). Average transcription rates in vivo range from 1.5-4 
kbp/min, dependent on species (Singh and Padgett, 2009), with reported speeds of 
up to 50 kbp/min (Maiuri et al., 2011). This discrepancy is not due to a change in 
the catalytic rate of RNA polymerisation but because RNAPII transcription is not a 
smooth continuous process, with many stochastic pauses and stalls. 
 
1.3.1.1 Transcription pause and stall 
Early footprinting and single-particle studies revealed frequent pausing and stalls of 
RNAPII during transcription (Krummel and Chamberlin, 1992, Zhou et al., 2013). 
RNAPII transcription elongation can be defined by periods of fast productive RNA 
polymerisation, interspersed with short pauses and arrests (Figure 1.7). One 
consequence of the rapid Brownian-ratchet motion of RNAPII transcription is the 
potential for reverse movement of the polymerase (termed backtracking)(Nudler, 
2012). In an arrested, backtracked off-pathway state, the 3’hydroxyl-end of the 
RNA chain is displaced from the RNAPII active site, thus preventing forward 
catalysis. Whilst pauses do not always involve backtracking (Toulokhonov et al., 
2007), a pause is converted into an arrest the longer a polymerase is in the non-
productive state (Gu and Reines, 1995). Over 200,000 yeast genomic sites 
reproducibly lead to RNAPII pausing in vivo, of which 75% are backtracked 
(Churchman and Weissman, 2011). 
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The probability of pausing or stalling is partially dependent upon the transcribed 
sequence: A-T rich regions are hard to transcribe (Hawley et al., 1993, Tornaletti et 
al., 2008), leading to de-stabilisation of the RNA-DNA hybrid and reversal of the 
RNAPII (Nudler et al., 1997). RNAPII stall can also be due to the topology of the 
transcribed DNA (Garcia-Rubio and Aguilera, 2012). Backtracking is not just an off-
pathway state; it is part of the RNAPII fidelity mechanism, which is promoted after 
mis-incorporation of a nucleotide (Nudler, 2012). Interestingly, the stronger a 
promoter is, i.e. the more RNAP is loaded onto a promoter, the faster the overall 
rate of transcription (Epshtein and Nudler, 2003). This can be partly explained 
through a de-chromatinisation of the template (Bintu et al., 2011), but also due to 
the co-operative effect of trailing polymerases pushing paused, leading RNAPII 
(Saeki and Svejstrup, 2009). 
 
DNA must be compacted in order to fit into the nucleus. The most basic unit of 
chromatin compaction is the nucleosome, an octomer comprised of 2 copies each 
of Histone H3-H4 and H2A-H2B. Chromatin can pose a significant block to DNA 
processes, including transcription. However, the rate of transcription observed in 
vivo is similar to that reported in vitro on naked plasmid DNA (Singh and Padgett, 
2009, Izban and Luse, 1992a). Moreover, transcription in vitro is severely inhibited 
by poly-nucleosomal DNA (Orphanides et al., 1998). In vitro, nucleosomes promote 
backtracking of RNAPII (Kireeva et al., 2005), which can be reversed by a trailing 
polymerase (Jin et al., 2010). Chromatin remodellers, histone chaperones, histone 
modifying proteins and transcript cleavage factor TFIIS (see below) can aid the 
inefficient transcription through nucleosomes in vivo (reviewed in Selth et al., 2010) 
.  
1.3.1.2 Basal Elongation factors 
A whole host of protein factors assist in promoting efficient transcription elongation 
(Figure 1.7). Cells deleted for elongation factors are sensitive to RNAPII elongation 
inhibitors such as 6-azauracil (Hartzog et al., 1998). General elongation factors 
work in one of two ways, either by limiting the occurrence of RNAPII pauses or by 
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helping to rescue stalled RNAPII. A few relevant elongation factors are described 
below. 
 
 
 
Figure 1.7: Schematic of RNAPII transcription elongation and backtracking 
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RNAPII shifts from productive transcription to off-pathway states. The factors that bias the 
equilibrium between states are named. RNAPII complex depicted in green, with the largest 
subunit Rpb1 depicted in dark green, active site depicted by a yellow star. 
 
 
TFIIS shortens the length of stalls in vivo (Bengal et al., 1991), and can promote 
the read-through of difficult to transcribe sequences and DNA binding proteins 
blockages (Reines et al., 1992). The re-alignment of the 3’ hydroxyl end of RNA, 
into the active site, is achieved through a weak intrinsic cleavage ability of RNAPII 
(Sigurdsson et al., 2010), which is drastically promoted by TFIIS (Izban and Luse, 
1992b).  
 
The mammalian Elongin ABC heterotrimer reduces the frequency of RNAPII 
pausing (Bradsher et al., 1993, Aso et al., 1995) through an unknown mechanism. 
Elongin A is the transcriptionally active subunit (Aso et al., 1996), which is partially 
redundant with the initiation and elongation factor TFIIF (Moreland et al., 1998). 
Elongin A is required for proper morphogenesis (Gerber et al., 2004, Yasukawa et 
al., 2012) and transcription in response to stress (Kawauchi et al., 2013). The 
Elongin C and Elongin B regulatory sub complex shares homology with Skp1 and 
ubiquitin respectively (Aso et al., 1995), and can form CRLs (Duan et al., 1995; see 
1.5.3.2). The ubiquitin ligase and elongation features of the Elongin ABC complex 
can be separated (Yasukawa et al., 2012). 
 
Clear Elongin A and Elongin C homologs have been identified in yeast, termed 
Ela1 and Elc1 (Aso and Conrad, 1997). However, no UbH domain-containing 
Elongin B homologue has been identified in S. cerevisiae. The Ela1-Elc1 dimer 
does not have any elongation stimulation activities (Koth et al., 2000), but can form 
an active ubiquitin ligase (Harreman et al., 2009). 
 
1.3.1.3 Rpb1 CTD modifications 
The largest subunit of RNAPII, Rpb1, contains a long C-terminal extension, thought 
to project away from the RNAPII complex (Meinhart and Cramer, 2004). The CTD 
consists of a heptapeptide sequence, Y-S-P-T-S-P-S, repeated 26 (yeast) or 52 
(human) times (Liu et al., 2010). All 7 residues can be modified during transcription: 
the prolines are isomerised between cis and trans states and the hydroxyl groups 
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of serine, threonine and tyrosine are phosphorylated (reviewed recently by 
(Heidemann et al., 2013). 
 
 
Figure 1.8: The CTD Phosphorylation cycle over a gene 
 
Adapted from Heidemann et al., 2013, a representation of ChIP data from (Mayer et al., 2010) 
and (Mayer et al., 2012) and (Hintermair et al., 2012) Ser-5 and Ser-7 phosphorylation peak at 
the transcription start site (TSS). Phosphorylation of Ser-2 is the principle mark present during 
transcription elongation. Tyr-1 phosphorylation is concurrent with Ser-2 phosphorylation until the 
termination region, whilst Thr-4 phosphorylation peaks after the polyA signal. 
 
The CTD is a regulatory platform, modulated by the CTD phosphorylation state 
(Figure 1.8). A wide variety of kinases, phosphatases and isomerases modify 
Rpb1’s CTD during transcription, ensuring the correct recruitment of RNA 
processing factors, elongation factors and termination factors at their appropriate 
stages. There is significant cross-talk between the modifications, allowing bivalent 
marks to be recognised on adjacent repeats at specific transcription stages (Egloff 
et al., 2010, Ghosh et al., 2011). 
 
 
1.3.2 Role of ubiquitin and the proteasome in transcription 
 
In order to ensure a transient signal for transcription, many transcription factors are 
poly-ubiquitylated and short-lived (Meimoun et al., 2000, Salghetti et al., 2000). 
Mono-ubiquitylation is also important to activate a number of transcription factors in 
situ (Salghetti et al., 2001). Moreover, ubiquitylation can be required to activate a 
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transcription factor, upstream of transcription (Hoppe et al., 2000; see 1.1.6). 
Furthermore, ubiquitylation can directly affect RNAPII transcription: the Rpb1 and 
Rpb2 subunits are targeted by the E3 ligase Asr1, which leads to the ejection of 
Rpb4 and Rpb7 and RNAPII inactivation (Daulny et al., 2008). 
 
Ubiquitylation of chromatin is essential for transcription elongation; H2B is mono-
ubiquitylated at lysine 120 (Hwang et al., 2003) and this disrupts chromatin 
compaction (Fierz et al., 2011), as well as helping to recruit the numerous 
chromatin-modifying enzymes (Sun and Allis, 2002, Krogan et al., 2003). Efficient 
transcription requires the dynamic addition and removal of H2B ubiquitylation, by 
Rad6-Bre1 and Ubp8/Ubp10 respectively (Hwang et al., 2003, Wyce et al., 2007, 
Emre et al., 2005) 
 
Proteolytic and non-proteolytic functions of the proteasome are used at active 
genes (reviewed by Geng et al., 2012). Genome-wide ChIP identified the genomic 
association of the proteasome with transcription (Auld et al., 2006). The 
proteasome co-immunoprecipitates with transcribing RNAPII and its proteolytic 
activity is important for the normal clearing of RNAPII from yeast termination 
regions (Gillette et al., 2004), but does not seem to be important in situ in other 
organisms (Scharf et al., 2011). The proteasome 19S particle has non-degradative 
roles in transcription initiation and elongation (Gonzalez et al., 2002, Ferdous et al., 
2002). The 19S regulatory particle appears to be particularly important in 
transcription during stress conditions (Sulahian et al., 2006), possibly as the 19S 
alters chromatin by promoting histone acetylation (Lee et al., 2005). 
 
 
 
 
Chapter 1. Introduction 
41 
1.4 DNA Damage and DNA Damage Repair Pathways 
 
1.4.1 Types of DNA damage 
 
DNA forms the basic inheritable genetic material of the cell. In an aqueous 
environment, the large, negative charged phosphate backbone prevents 
spontaneous hydrolytic cleavage, ensuring chemical stability. Nevertheless, 
endogenous damaging sources account for upwards of 10,000 chemical alterations 
on DNA each day, in a single mammalian cell (Lindahl and Wood, 1999, Ciccia and 
Elledge, 2010). This endogenous DNA damage can form as a by-product of normal 
cellular respiration, or base degradation and replication errors. On top of this 
background damage, exogenous sources of damage add to the damage load 
(Ciccia and Elledge, 2010).  
 
The DNA double helix can be altered relatively harmlessly, from small chemical 
addition, up to the extremely toxic breakage of both strands, with a concomitant 
increase in risk of genetic loss. One potentially hazardous exogenous source of 
DNA damage is ultra-violet (UV) light. DNA absorbs UV-B light directly resulting in 
infrequent chemical cross-linking between adjacent thymines or cytosines, creating 
cyclopyrimidine dimers (CPDs), or less commonly, pyrimidine 6–4 pyrimidone 
photoproducts (6-4 photoproduct). CPDs and 6-4 photoproducts alter the normal 
conformation of DNA by 9o and 44o respectively (Kim et al., 1995, Lee et al., 
1999a). Bulky aromatic chemical lesions can also perturb the structure of DNA 
(Kohda et al., 1991). 
 
Mutation occurs when DNA damage remains unrepaired before DNA replication. 
The altered chemistry of the deoxyribose base often leads to the mis-incorporation 
of an incorrect base opposite the lesion. Alternatively, the repair pathways elicited 
are mutagenic themselves (Stallons and McGregor, 2010). One of the more 
immediate effects of DNA damage, often overlooked, is to sterically interfere with 
DNA-dependent processes, such as replication and transcription. 
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1.4.2 Repair of DNA damage 
 
Multiple pathways with overlapping specificity restore damaged DNA to its correct 
state. As a testament to the essential nature of these pathways the presence, if not 
the directly conserved proteins, are present in all domains of life. Most pathways 
directly recognise the lesion and remove the damage through excision and gap 
filling. As it is particularly relevant to the work of this thesis, the basic repair 
pathways for bulky helix distorting lesions will be outlined in the next sections. 
 
1.4.2.1 Direct repair of DNA damage 
The direct reversal of DNA damage is both rapid and accurate (reviewed by Sancar, 
2000). S. cerevisiae Phr1 binds to a CPD lesion by recognising the characteristic 
bend towards the major groove, but is only activated upon chromophore-associated 
absorption of light. A photo-excited electron is transferred to the CPD, splitting the 
unstable cross-linked bond, restoring the original pyrimidine ring and the bases to 
their monomeric forms. A similar enzyme is found in E.coli (Sancar and Rupert, 
1978), as well as a 6-4 photoproduct reversing lyase (Todo et al., 1993). Mammals 
lack these direct reversal enzymes (Li et al., 1993). 
 
1.4.2.2 Global genome nucleotide excision repair (GG-NER) 
NER is the most versatile DNA repair pathway; NER factors recognise structural 
deformities in normal B-form helical DNA, rather than specific DNA lesions. NER 
consists of 4 distinct steps: damage recognition, DNA unwinding around the lesion, 
incision either side of the damage and resynthesis of the single-stranded gap. Two 
pathways for NER exist, global genome-NER (GG-NER; covered here), and 
Transcription coupled NER (TC-NER; discussed in 1.5.2) (Figure 1.9). 
 
In vitro NER dual incision reactions require just six factors (Guzder et al., 1995), but 
over 30 proteins have been implicated in vivo (see Table 1.2). All these factors may 
exist as a single ‘repairosome’ (Svejstrup et al., 1995, Kong and Svejstrup, 2002), 
or associate in a stepwise manner (Prakash and Prakash, 2000). 
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Figure 1.9: Schematic representation of Nucleotide excision repair pathways in 
yeast 
 
Both GG-NER (left) and TC-NER (right) are represented. Key NER proteins are indicated. Not 
to scale. See text for detail. 
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Below, the molecular mechanism of NER is described, with emphasis on the yeast 
proteins. However, the mechanism and factors are conserved in all eukaryotes. 
The damage recognition components Rad7-16 and Rad4-23 bend DNA, facilitating 
binding of the Rad14 zinc finger protein to the lesion (Guzder et al., 1999, Min and 
Pavletich, 2007, Guzder et al., 2006). Rad4 helps to position TFIIH, signalling the 
commitment to excision (Sugasawa et al., 2001). The two helicases in TFIIH open 
up the DNA double helix, whilst the single-strand binding RPA heterotrimer coats 
the undamaged strand. Rad1-Rad10 and Rad2 are structure specific 
endonucleases, which are accurately positioned through their interaction with 
Rad14 (Guzder et al., 1996b) and TFIIH (Lafrance-Vanasse et al., 2012), 
respectively. The final gap-filling step has not been fully elucidated in yeast, but in 
human cells the clamp loader, PCNA, and DNA polymerase δ have been 
implicated, with final ligation catalysed by DNA ligase 1 (Mocquet et al., 2008). 
 
Table 1.2: Yeast and human nucleotide excision repair proteins 
 
Step S. cerevisiae  H. sapiens  Function 
Damage 
recognition 
Rad7-Rad16 
Abf1 
Elc1-Cul3 
RNAPI 
RNAPII 
Rad4-Rad23 
Rad33/34 
? 
? 
? 
? 
? 
RNAPII 
XPC-HR23B 
CEN2 
XPE-DDB2 
ATPase and ubiquitin ligase 
DNA dependent ATPase with Rad7-16 
Ubiquitin ligase with Rad7-Rad16 
Stalls at site of damage? 
Stalls at site of damage 
Binds damaged DNA 
Binds an protects Rad4-Rad23 
Binds damaged DNA, ubiquitin ligase 
DNA 
unwinding 
and 
recruitment 
Rad14 
Rfa1-3 
Rad3 
Rad25 
Rad26 
Rpb9 
Rad28? 
XPA 
RPA 
XPD 
XPB 
CSB 
? 
CSA 
DNA damage binding and verification 
ssDNA binding 
5’-3’ helicase (TFIIH subunit) 
3’-5’ helicase (TFIIH subunit) 
DNA dependent ATPase (TC-NER) 
RNAPII subunit (TC-NER) 
Ubiquitin ligase (TC-NER) 
Incision Rad1-Rad10 
Rad2 
XPF-ERCC1 
XPG 
5’ endonuclease 
3’ endonuclease 
Gap filling 
and 
ligation 
Cdc44 
Dna Pol δ,ε 
Cdc9 
PCNA 
RFC1 
Dna Pol δ,ε 
DNA lig 1 
PCNA 
Clamp loader 
DNA replication 
DNA ligase 
Replication sliding clamp 
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Inactivating or attenuating mutations in components essential for the NER pathway 
in humans leads to the congenital autosomal recessive disorder Xeroderma 
pigmentosa (XP) (de Boer and Hoeijmakers, 2000). XP Patients are severely UV 
sensitive and have an increased risk of skin cancer. Mutations lie in 8 
complementation groups, 7 of which are proteins of the NER pathway (XPA-XPG) 
(Table 1.2). Despite the high conservation between human and yeast NER, some 
important distinctions have been discovered (Boiteux and Jinks-Robertson, 2013). 
Whilst the majority of the identified NER homologs do appear to have homologous 
functions, there are no Rad7-Rad16 homologs in human cells. Similarly, the 
somewhat functionally related XPE-DDB2 factor does not appear to be present in 
yeast. 
 
 
1.4.3  Signalling DNA damage/ The DNA damage checkpoint 
 
Whilst repair of DNA is essential, uncontrolled enzymatic activity on DNA could be 
extremely harmful (Ciccia and Elledge, 2010). Multiple pathways exist to ensure 
correct spatial and temporal activation of repair enzymes. 
 
Signalling is initiated from a broad range of sensing proteins that directly bind to 
DNA damage or repair intermediates. Often these are also part of the effector arm 
of the DNA damage response (DDR). In yeast the critical activator of the DDR is 
the PI3 kinase-related protein Mec1 (Pan et al., 2006a). Mec1 phosphorylates a 
large number of substrates (Albuquerque et al., 2008, Smolka et al., 2007), 
including downstream kinases Rad53 and Dun1 (Sweeney et al., 2005). Together 
these kinases promote damage specific transcription, block cell cycle progression, 
promote dNTP synthesis, and stabilise blocked replication forks (Segurado and 
Diffley, 2008, Zegerman and Diffley, 2010). Both GG-NER and TC-NER require 
Mec1 (Taschner et al., 2010). 
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1.4.3.1 Ubiquitin in DNA damage repair 
Ubiquitin plays a key role in the repair of DNA damage, both as a signalling 
molecule and as a recruitment platform. Different ubiquitylation states of signalling 
molecules affect DNA repair pathway choice, through the recruitment of different 
effector proteins. 
 
The trimeric sliding clamp protein, PCNA, binds to replicative DNA polymerases 
and aid their processivity; if the replication fork meets a blocking lesion then the 
fork stalls. Damage adjacent PCNA remains associated with DNA, and is marked 
by ubiquitylation at Lys 164 by Rad6 (E2) and Rad18 (E3) (Hoege et al., 2002, 
Daigaku et al., 2010). Mono-ubiquitylated PCNA is selectively recognised by 
components of trans-lesion polymerases (Bomar et al., 2007, Parker et al., 2007), 
which catalyse error-prone replication past DNA lesions as an alternative to DNA 
damage repair. PCNA poly-ubiquitylation is mediated by the Rad5 ubiquitin ligase, 
with the Lys-63 specific E2, Mms2-Ubc13 (Parker and Ulrich, 2009), leading to an 
error free, template switching, repair mechanism (Hoege et al., 2002). 
 
Ubiquitylation plays a key role in NER. Elc1-Cul3-Rad7-Rad16 proteins form a 
complex that ubiquitylates Rad4 (Ramsey et al., 2004, Gillette et al., 2006), as well 
as other, unidentified, proteins. Whilst ubiquitylation eventually targets Rad4 for 
degradation, it is also important for its function. Rad23 may directly protect Rad4 
from degradation (Ng et al., 2003), and is both an essential NER protein and a 
proteasome shuttling factor. Rad23 binds to Rad4 outside of both the UbH and 
UBD domains (Min and Pavletich, 2007) and the UBDs are dispensable for NER 
(Bertolaet et al., 2001). However, the UbH domain could help to recruit the 19S 
proteasome cap (Elsasser et al., 2002), which has a role in NER (Reed and Gillette, 
2007). The NER and transcription complex TFIIH - via its Ssl1 subunit - can act as 
a ubiquitin ligase after DNA damage (Takagi et al., 2005b), although the target of 
this ligase is unclear. 
 
The ubiquitin-mediated, inducible degradation of proteins is a critical step in the 
response to DNA damage. Degradation irreversibly shuts off dangerous damage 
repair pathways (Groisman et al., 2006). The key role of degradation of the largest 
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subunit of RNAPII, Rpb1, after stall at transcription lesion is the main subject of this 
thesis and covered in depth below (see section 1.5.3) 
 
 
 
 
1.5 DNA Damage and Transcription 
 
1.5.1 Transcription in the presence of DNA damage 
 
The most immediate effect of DNA damage is not mutation, but creating a steric 
barrier to the normal reading of DNA. In the case of DNA replication a well-
characterised Rad6-dependent pathway exists to bypass the lesion (see 1.4.3.1). 
The replication machinery is - by its very nature - dynamic and not stably 
associated with DNA, allowing polymerase exchange and DNA damage bypass. In 
contrast to replication, RNA polymerase cannot be dissociated from its template 
without loss of the transcript. RNA polymerases form very stable complexes on 
DNA (Kireeva et al., 2000, Dalal et al., 2006). This stability is both a blessing, 
ensuring high fidelity of long transcripts, but also a curse, as transcription can 
become blocked at DNA lesions (Svejstrup, 2007).  
 
Upon UV irradiation transcription is rapidly halted in human cells (Mayne and 
Lehmann, 1982). UV-induced phosphorylation of free RNAPII prevents 
transcription initiation (Rockx et al., 2000, Heine et al., 2008). However, a specific 
transcription program is enacted in response to DNA damage. Microarray studies in 
S. cerevisiae, under a wide variety of cellular insults, found that around 20% of the 
transcriptome was altered, including many genes not implicated in DNA repair 
(Gasch et al., 2001). One branch of NER is reliant upon UV-induced new protein 
synthesis (Al-Moghrabi et al., 2003). 
 
Small DNA lesions in the transcribed strand (TS) and most lesions in the NTS can 
be bypassed by RNA Polymerases (Zhou and Doetsch, 1993, Zhou et al., 1995). 
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Non-bulky, 8-oxoguanine and thymine glycol can inhibit or stall RNAPII 
transcription, but this can be overcome by general elongation factors (Charlet-
Berguerand et al., 2006). Bulky, helix-distorting lesions force persistent RNAPII 
stall, either by steric hindrance or by directly inhibiting active site catalysis. UV 
induced CPDs, 6-4 photoproducts (Donahue et al., 1994), cisplatin adducts 
(Damsma et al., 2007), single strand gaps (Kathe et al., 2004), inter-strand cross-
links (Jung and Lippard, 2006) and acetyl aminofluorine adducts (Donahue et al., 
1996) all block RNAPII progression. In addition, smaller lesions may indirectly block 
RNAPII, through their high-affinity binding of DNA repair factors (Scicchitano, 2005). 
 
Structural studies offer snapshots of RNAPII stalling at these lesions. A CPD 
causes stalling when it reaches the active site (Brueckner et al., 2007). Non-
template adenine followed by a uridine can be fitted opposite the CPD, which 
remains permanently stuck. A recent study showed that a very slow and inefficient 
bypass of CPD lesions can occur in vitro and this may contribute to some 
resistance to UV irradiation in vivo (Walmacq et al., 2012). 
 
Persistently stalled RNAPIIs act as direct sensors of damage. However, no surface 
conformational change is observed in crystal structures of RNAPII stalled at a 
lesion, arguing against this as a model for recruiting repair factors (Brueckner et al., 
2007, Damsma et al., 2007). Direct RNAPII inhibition (Lee et al., 2002), rNTP 
depletion (Somesh et al., 2005) and endogenous transcription roadblocks (Hobson 
et al., 2012) can also induce persistent transcription stall, which may be 
indistinguishable from damage stalled RNAPII. In mammalian cells the DDR is 
activated upon transcription elongation inhibition, independent of DNA damage 
(Derheimer et al., 2007). 
 
RNAPII stalled at a DNA lesion is extremely stable in vitro (t1/2~ 20 hours, Selby et 
al., 1997) and is now doubly dangerous: not only is transcription blocked at this 
gene, but the bulky RNAPII ternary complex also interferes with the normal DNA 
repair pathways. Mammalian RNAPII stalled at a CPD sterically blocks repair by a 
photolyase (Donahue et al., 1994). The cell has evolved two main mechanisms to 
cope with persistently stalled RNAPII: transcription coupled nucleotide excision 
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repair (TC-NER), and Rpb1 poly-ubiquitylation and degradation (Wilson et al., 
2013). 
 
 
1.5.2 Transcription Coupled-NER 
 
TC-NER differs from GG-NER only in the recognition of the lesion; the basic lesion 
processing apparatus is the same (Figure 1.9). Unusually, the preferential repair of 
the transcribed strand was first observed in higher eukaryotes (Bohr et al., 1985), 
before S. cerevisiae (Terleth et al., 1989). RNAPII is the sensor of damage; repair 
is not only preferential for transcribed genes - which could be explained by 
increased chromatin accessibility - but also for the TS over the NTS (Sweder and 
Hanawalt, 1992). TC-NER is more rapid than GG-NER; lesions on the TS of a gene 
are repaired twice as fast as lesions on the NTS in yeast (Taschner et al., 2010). 
The principal UV photolesion, CPDs, are poorly recognised by GG-NER proteins 
(Sugasawa et al., 2001, Min and Pavletich, 2007). RNAPII engaged with DNA is a 
far better sensor of DNA damage than the Rad4 and Rad7-Rad16 complexes, 
which must first scan the entire genome slowly and peripherally (Lindsey-Boltz and 
Sancar, 2007). 
 
TC-NER has two sub-pathways in yeast: one dependent upon Rad26 and the other 
on the non-essential RNAPII subunit, Rpb9. Rad26 was identified by sequence 
homology to the human TC-NER protein, Cockayne syndrome B protein (CSB) 
(van Gool et al., 1994) and is a DNA dependent ATPase (Guzder et al., 1996a). 
Both Rad26 and CSB contain a SNF2-like DNA helicase/translocase domain, but 
no observable helicase activity (Guzder et al., 1996a). Whilst cells lacking Rad26 
are not sensitive to a number of DNA damaging agents (van Gool et al., 1994), 
rad26Δ rad16Δ cells are significantly more UV sensitive than rad16Δ single mutant 
cells (Verhage et al., 1996). 
 
The exact role of Rad26 and CSB at damage-stalled RNAPII is still unclear. The E. 
coli homologue of Rad26, Mfd, directly displaces stalled RNAP away from DNA 
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(Selby and Sancar, 1993). In S. cerevisiae, Rad26 appears to be consistently 
associated with elongating RNAPII (Malik et al., 2010) and might even have some 
histone chaperone roles (Malik et al., 2012, Malik and Bhaumik, 2012). As a result, 
Rad26 could act as a general elongation factor and, in agreement with this 
hypothesis; Rad26 can promote elongation through 8-oxoguanine lesions (Lee et 
al., 2001b). In human cells CSB recruits NER factors and TFIIS in a stepwise 
manner (Fousteri et al., 2006), possibly through a chromatin modifying ability. 
Rad26 is dispensable for TC-NER near the promoter region of genes (Tijsterman et 
al., 1997) - where TFIIH is still resident after transcription initiation - possibly 
suggesting that Rad26’s role is to recruit TFIIH to stalled RNAPII. 
 
Intriguingly, overexpression of Rad26 can lead to increased repair of both TS and 
NTS strands (Bucheli and Sweder, 2004) and Rad26 has a role in the repair of 
repressed genes (Li et al., 2007). This effect may still be mediated through RNAPII, 
as antisense transcription is widespread throughout the genome (Xu et al., 2009b). 
 
rad26Δ cells still have some residual TC-NER activity (Verhage et al., 1996), which 
can be attributed to a separate, Rpb9-dependent pathway (Li and Smerdon, 2002). 
The Rad26-independent pathway also involves the Rpb4 subunit, and is 
suppressed by the C-terminus of Spt5 and the Paf1 complex (Ding et al., 2010, 
Tatum et al., 2011). The contribution of each pathway is dependent upon the level 
of transcription and the position of the lesion within the gene (Li and Smerdon, 
2002, Teng and Waters, 2000). The precise, molecular details of this pathway 
remain obscure. 
 
In humans two autosomal-recessive diseases are directly linked to TC-NER, 
Cockayne syndrome (CS) and the milder UV sensitive syndrome (UVSS). Most 
mutations leading to these syndromes map to Cockayne syndrome proteins CSA 
and CSB, and the recently discovered UVSSA protein (Hanawalt and Spivak, 2008, 
Nakazawa et al., 2012). The phenotype of patients is likely attributable to the roles 
of CSB and CSA in both repair and basal transcription (Gaillard and Aguilera, 
2013). Multiple other accessory proteins have been implicated in the TC-NER 
pathway in mammals, including XAB2 (Kuraoka et al., 2008), HMGN1 (Birger et al., 
2003), USP7 (Schwertman et al., 2012), and p300 (Datta et al., 2001). 
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Cockayne syndrome (CS) presents with severe developmental and 
neurodegenerative symptoms (Hanawalt and Spivak, 2008), but no cancer 
predisposition. Fibroblasts from CS patients cannot restart transcription after DNA 
damage and patients have mutations in CSA, CSB or TFIIH. The CSA protein 
forms a CRL complex with DDB2-CUL4a-RBX1 (Groisman et al., 2003, Fischer et 
al., 2011), which may ubiquitylate CSB at the end of TC-NER (Groisman et al., 
2006). The direct sequence homologue of CSA in yeast is Rad28, which does not 
appear to play a role in TC-NER (Bhatia et al., 1996). UVSS is a less severe human 
syndrome, with patients displaying only mild UV sensitivity, but is similar to CS at 
the molecular level; mutations causing UVSS map to CSA, CSB and UVSSA 
(Spivak, 2005, Nakazawa et al., 2012) 
 
It should be noted that genetic experiments performed in yeast on TC-NER are 
backed up by biochemical data, primarily using human proteins; however, a 
number of differences exist between the two systems (Boiteux and Jinks-Robertson, 
2013). Even among the highly conserved proteins some obvious differences are 
clear. For example, yeast cells lacking Rad26 are not UV sensitive, but cells 
derived from CS patients cannot restart transcription after UV (Mayne and 
Lehmann, 1982) and are extremely sensitive to irradiation (van Hoffen et al., 1999). 
The damage sensing components of the GG-NER pathway are not required for TC-
NER in humans, but in yeast, Rad4 is required for repair in the TS and TC-NER 
(den Dulk et al., 2006). A CSB/CSA-independent pathway has not been described 
in mammals to date. 
 
 
1.5.3 Rpb1 poly-ubiquitylation and degradation 
 
When the TC-NER pathway is either overloaded or unsuccessful, then an alternate 
and separate pathway is required to remove the stalled RNAPII and allow GG-NER 
repair factors access to the lesion. Treatment of mammalian cells with DNA 
damaging agents, such as cisplatin, results in the poly-ubiquitylation and 
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degradation of the largest subunit of RNAPII, Rpb1 (Bregman et al., 1996, Ratner 
et al., 1998, Mitsui and Sharp, 1999). At the time this was thought to be required for 
normal TC-NER, allowing Rpb1 to be removed from sites of damage, allowing 
access for TC-NER factors. Subsequent work in S. cerevisiae has shown that this 
degradation pathway is instead an entirely separate, more drastic ‘last-resort’ back-
up pathway to failed transcription restart. Accordingly, TC-NER impairment leads to 
increased Rpb1 poly-ubiquitylation and degradation (Lommel et al., 2000, 
Woudstra et al., 2002, Chen et al., 2007).  
 
Whilst originally identified as a response to DNA damaging agents that cause bulky 
lesions, Rpb1 poly-ubiquitylation and degradation occurs under all observed 
conditions of persistent RNAPII stall (Somesh et al., 2005, Anindya et al., 2007, 
Sigurdsson et al., 2010). Endogenous causes of stall, such as chromatin and cis 
transcribed sequence, do not lead to long arrests and are likely dealt with 
successfully by the help of elongation factors. However, if elongation factors are 
mutated, ineffective, or if RNAPII transcription elongation is otherwise inhibited, 
then RNAPII stalling persists. For example, treating human cells with the specific 
RNAPII elongation inhibitor α-amanitin leads to robust Rpb1 poly-ubiquitylation and 
degradation (Lee et al., 2002, Anindya et al., 2007). Similarly, depleting cellular 
rNTP pools with 6-azauracil (6-AU) promotes Rpb1 ubiquitylation in yeast (Somesh 
et al., 2005). Naturally occurring RNAPII pause sites are also associated with some 
degradation of Rpb1, such as those caused by clashes between transcription 
complexes during convergent transcription (Hobson et al., 2012). Blocking the 
transcript cleavage ability of RNAPII also induces Rpb1 poly-ubiquitylation 
(Sigurdsson et al., 2010). TC-NER cannot aid these blocked polymerases, as there 
is no damage to be removed and RNAPII remains associated with DNA. Rpb1 
poly-ubiquitylation and degradation, however, strips the RNAPII complex from 
chromatin (Verma et al., 2011). 
 
Rpb1 poly-ubiquitylation has been observed under a number of other conditions. 
This response seems to have been hijacked to prevent transcription by a number of 
viruses, for example (Akhrymuk et al., 2012). Two promising chemotherapeutic 
agents, triptolide and trabectedin, inhibit transcription elongation and induce wide-
scale Rpb1 poly-ubiquitylation (Vispe et al., 2009, Manzo et al., 2012, Aune et al., 
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2008). Rpb1 degradation has also been observed in conditions that have not been 
directly linked to transcription stalling. Treatment of mammalian cells with high 
levels of hydrogen peroxide induces Rpb1 degradation (Inukai et al., 2004), 
although this has been refuted (Mikhaylova et al., 2008). The specific transcription 
program induced upon rapamycin exposure promotes Rpb1 degradation (Jouvet et 
al., 2011). 
 
Since the initial discovery of the ‘last-resort’ pathway it has proven to be more 
complex than originally envisioned. Even in S. cerevisiae, a host of factors are 
required to ensure processive poly-ubiquitylation of persistently stalled RNAPII and 
Rpb1 degradation (Figure 1.10). It is important to note that the poly-ubiquitylation 
can be separated into two catalytically separate steps, mono-ubiquitylation 
catalysed by the HECT E3 Rsp5, and poly-ubiquitylation, catalysed by the Elongin-
Cullin complex (Harreman et al., 2009). 
 
1.5.3.1 Rpb1 mono-ubiquitylation  
The first ubiquitin ligase implicated in Rpb1 degradation was the S. cerevisiae Rsp5 
protein (Huibregtse et al., 1997). Rsp5 is the only essential HECT ubiquitin ligase in 
yeast, with diverse roles, from intracellular trafficking to transcription factor 
activation (Kaliszewski and Zoladek, 2008). RNAPII was found to associate with the 
WW domains of Rsp5 via the CTD repeats of Rpb1 (Huibregtse et al., 1997, Chang 
et al., 2000, Somesh et al., 2005). As Rsp5 is an essential gene, most work has 
focused on the use of a temperature sensitive allele with a mutation of a single 
amino acid of the gene, shown to prevent its catalytic activity at the non-permissive 
temperature (Wang et al., 1999). Reduced levels of functional Rsp5 lead to 
increased steady state levels of Rpb1 and no detectable Rpb1-ubiquitylation in 
response to DNA damage (Beaudenon et al., 1999, Harreman et al., 2009). 
 
Chapter 1. Introduction 
54 
 
 
Figure 1.10: Model of Rpb1 poly-ubiquitylation and degradation in S. cerevisiae 
 
Transcribing RNAPII becomes persistently arrested under a wide variety of conditions. As a last 
resort this can be dealt with by the sequential poly-ubiquitylation of Rpb1 and its degradation. 
See text for details. Modified from (Wilson et al., 2013) 
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As Rsp5 is involved in many cellular processes, it was critical to show a direct 
effect of the protein on Rpb1 poly-ubiquitylation. Indeed, Rsp5 inactivation directly 
leads to reduced levels of free ubiquitin in the cell (Krsmanovic and Kolling, 2004), 
which might potentially explain Rpb1 stabilisation. However, extract-based in vitro 
assays - where Rsp5 is inactivated - are unable to support Rpb1 ubiquitylation, in 
spite of the addition of excess ubiquitin in these assays (Reid and Svejstrup, 2006, 
Harreman et al., 2009). Adding pure Rsp5 back to this assay re-constitutes RNAPII 
poly-ubiquitylation (Harreman et al., 2009). Ubiquitylation of RNAPII can be 
reconstituted in vitro by using Uba1 (E1), Ubc5 (E2) and Rsp5, which together 
create poly-ubiquitin chains on Rpb1 only (Somesh et al., 2005), again suggesting 
a direct role for this enzyme. Rsp5 is known to assemble only single ubiquitin 
modifications or Lys-63 linked chains on substrates both in vitro and in vivo (Kee et 
al., 2005, Kim and Huibregtse, 2009, Kee et al., 2006), which are insufficient for 
proteasomal targeting (Zhao and Ulrich, 2010). Whilst this modified form may have 
a function in response to normal transcription stress (Katya Strasser, personal 
communication), it is not the principal ubiquitin chain found in vivo after DNA 
damage induced RNAPII stalling (Jung and Lippard, 2006). Instead, the Rsp5 
associated DUB, Ubp2 (Kee et al., 2005, Kee et al., 2006), is thought to trim the 
Lys-63 chains back to a single mono-ubiquitin (Harreman et al., 2009)(Figure 1.10). 
 
Many ubiquitin ligases have been implicated in the ubiquitylation of Rpb1 in 
mammalian cells, namely: CSA, BRCA1-BARD1, the VHL-Cullin complex and 
Nedd4. Furthermore, multiple different chain topologies have been reported on 
Rpb1 (Lee and Sharp, 2004, Jung and Lippard, 2006), with different observed 
ubiquitin banding patterns (Inukai et al., 2004). Cells deficient in CSA and CSB, or 
the CSB interacting protein UVSSA, exhibit reduced levels of Rpb1 ubiquitylation 
after DNA damage (Bregman et al., 1996, Nakazawa et al., 2012). This, coupled 
with the observation that CSA can form a ubiquitin ligase (Groisman et al., 2003), 
led to the hypothesis that CSA directly ubiquitylates Rpb1 (Laine and Egly, 2006). 
CSA does interact with RNAPII after UV irradiation, but is selectively inhibited 
directly after DNA damage (Groisman et al., 2003). Furthermore, CS cells do not 
exhibit significant differences in the rate of degradation of Rpb1 after UV induced 
damage (Luo et al., 2001). The reduction in Rpb1 poly-ubiquitylation is now thought 
to be indirect; transcription is rapidly shut down after DNA damage in CS cells and 
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UVSSA deficient cells (Mayne and Lehmann, 1982, Zhang et al., 2012), resulting 
in a reduction in the levels of RNAPII loaded onto chromatin, which reduces the 
amount of available substrate for ubiquitylation (Anindya et al., 2007).  
 
The BRCA1-BARD1 complex has also been implicated in ubiquitylating RNAPII 
(Starita et al., 2005, Kleiman et al., 2005). In these studies a slower migrating band 
can be observed above the hyper-phosphorylated form of Rpb1. It is important to 
note that this cannot be simply interpreted as ubiquitylated Rpb1. A more reliable 
method, outlined in Anindya et. al, 2007, is to enrich for all ubiquitylated proteins 
from the cell, followed by Western blot and specific probing for Rpb1. Using the 
latter method Anindya and colleagues showed that only knock-down of Nedd4, one 
of the mammalian homologs of Rsp5, led to reduced levels of Rpb1-ubiquitylation 
and degradation. Nedd4 was also shown to bind to and ubiquitylate RNAPII in vitro 
and is now considered to have a homologous role to that of Rsp5 in Rpb1 mono-
ubiquitylation (Anindya et al., 2007, Beaudenon et al., 1999).  
 
Mono-ubiquitylated Rpb1 is thought to be constitutive at low levels in the 
unstressed cell (Woudstra et al., 2002, Sigurdsson et al., 2010, Wilson et al., 2012). 
This may be due to transitory stalled RNAPII complexes being recognised and 
mono-ubiquitylated, without being degraded. It is unclear whether this mono-
ubiquitylation might have an additional functional role in RNAPII activity. 
 
 
1.5.3.2 Rpb1 poly-ubiquitylation 
 
After UV induced DNA damage, Rpb1 is poly-ubiquitylated with Lys-48 linked 
ubiquitin chains, removed from DNA and degraded by the proteasome (Ribar et al., 
2006, Harreman et al., 2009, Verma et al., 2011). As Rsp5 only creates Lys-63 
linked chains on substrates in vivo (Kee et al., 2006), another ubiquitin ligase is 
required to create a proteasome-targeting signal. Two papers revealed the role of 
an Elongin-Cullin CRL E3 complex, comprising Elc1 (Ribar et al., 2006), Ela1, Cul3 
and Rbx1 (Ribar et al., 2007), in the poly-ubiquitylation and degradation of Rpb1 
(Figure 1.11). In deletion strains that lacked these proteins, Rpb1 degradation did 
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not occur in response to a range of adduct-forming DNA damaging agents. 
Significantly, whilst there was no observed poly-ubiquitylation of Rpb1, mono-
ubiquitylation was not compromised in these strains (Ribar et al., 2006, Ribar et al., 
2007, Harreman et al., 2009). Elc1 and Cul3 have previously been reported to be 
part of another CRL, with Rad7-Rad16 (Ramsey et al., 2004, Gillette et al., 2006), 
which does not have a role in RNAPII poly-ubiquitylation or TC-NER (Ribar et al., 
2006, Lejeune et al., 2009) 
 
Confusion has surrounded the field over which ubiquitin ligase was the primary 
enzyme responsible for promoting the degradation of Rpb1, with compelling 
evidence for both Rsp5 and the Elongin-Cullin complex. However, work by 
Harreman and colleagues showed that RNAPII poly-ubiquitylation is a two-step 
process, involving both E3 ligases (Harreman et al., 2009). The authors reported 
that only pre-mono-ubiquitylated Rpb1, and not un-modified Rpb1, could be poly-
ubiquitylated in an extract lacking functional Rsp5. They proposed that the Elongin-
Cullin ubiquitin ligase complex, in the extract, acted in tandem with Rsp5 to 
produce a proteasomally competent Rpb1 for degradation. Furthermore, they found 
that a complex containing Elc1-Ela1-Cul3-Rbx1 co-purified and that it can only 
poly-ubiquitylate a pre-mono-ubiquitylated RNAPII in vitro. Whether this poly-
ubiquitylation is an extension of the original mono-ubiquitylation or modification at 
another lysine on the surface of Rpb1 has yet to be determined. Rpb1 is 
ubiquitylated on multiple lysines (Somesh et al., 2007, Peng et al., 2003, Wagner et 
al., 2011, Kim et al., 2011); lysine choice may prove functionally important in 
dissecting the mechanism of action of the two distinct ubiquitin ligases.  
 
 
Figure 1.11: The proposed Elongin-Cullin-E2 complexes in yeast and human 
cells 
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Components of the CRL like ligase and proposed E2 enzyme are coloured: red, the catalytic 
RING finger; brown, the structural scaffold cullin; green, the cullin adaptor protein Elc1 or 
Elongin BC; orange; the substrate adaptor protein Ela1 or Elongin A; light blue, Ubl activating 
protein Rub1 or Nedd8 and dark blue, the proposed E2 conjugating enzyme. Ubiquitin is 
coloured yellow.  Key interaction motifs in the substrate adaptor proteins are highlighted. 
 
 
The human homologue of Ela1-Elc1 is the Elongin ABC heterotrimer. Originally 
characterised as a positive regulator of transcript elongation (see 1.3.1.2), the 
Elongin ABC complex is also part of a CRL, with Cullin5 and Rbx2 (Yasukawa et al., 
2008)(Figure 1.11). Elongin A interacts with the Elongin BC heterodimer via a BC-
box motif: a degenerate 12-residue stretch upstream of the Elongin A 
transcriptional activity domain (Aso et al., 1996). Elongin B, which is absent from 
yeast, is a small protein with high homology to ubiquitin (Koth et al., 2000; see 
1.1.5). Like in yeast, this mammalian complex can only efficiently poly-ubiquitylate 
Rpb1 when Nedd4 is present (Harreman et al., 2009), suggesting that there is an 
evolutional conservation of the two distinct, sequentially acting E3’s in Rpb1 poly-
ubiquitylation (Table 1.3). The mechanism of interaction between the substrate 
adaptor heterodimer differs across species (Figure 1.11). Ela1 contains an N-
terminal F-box, which interacts with the Skp1-like Elc1 (Koth et al., 2000, Botuyan 
et al., 1999). Elongin A interacts with both Cullin-5 and Elongin C via its central 
SOCS-box (Mahrour et al., 2008, Yasukawa et al., 2012). 
 
The Elongin BC heterodimer is known to associate with a wide variety of BC-box 
motif substrate adaptors to form functional CRLs (Duan et al., 1995, Kamura et al., 
2001). Intriguingly, the pVHL-ElonginBC-CUL2-RBX1 complex (which lacks Elongin 
A) can bind to RNAPII after UV induced stress and has been shown to ubiquitylate 
the RNAPII subunits Rpb1-Rpb6. This requires the hyper-phosphorylation of the 
CTD of Rpb1 and hydroxylation of a proline in the linker region of Rpb1 
(Kuznetsova et al., 2003, Mikhaylova et al., 2008). pVHL mediated ubiquitylation 
has been shown to be important in Rpb1 degradation in response to trabectedin 
(Aune et al., 2008) and pVHL catalysed poly-ubiquitylation of Rpb7 can prevent 
transcription (Na et al., 2003). 
 
The Rpb9 subunit of RNAPII appears to play a role in Rpb1 ubiquitylation and 
degradation, as well as mediating the Rad26-independent TC-NER pathway (Chen 
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et al., 2007). Chen and colleagues demonstrated that cells lacking Rpb9 do not 
degrade Rpb1 in response to UV damage. Interestingly, one of the characterized 
sites of Rpb1 ubiquitylation, Lysine 695 (Somesh et al., 2007, Peng et al., 2003), is 
located close to the Rpb9-Rpb1 interaction surface. Rpb9 is required for efficient 
RNAPII elongation in vivo (Hemming et al., 2000); therefore, Rpb9 may help to 
sense the stalling state of the RNAPII complex and help recruit ubiquitylation 
factors. 
 
1.5.3.3 Def1 protein  
The S. cerevisiae protein Def1 (Degradation factor 1) also plays an important role 
in Rpb1 poly-ubiquitylation and degradation. Originally identified as an interacting 
binding partner of Rad26, Def1 is not involved in TC-NER (Woudstra et al., 2002). 
Instead, cells lacking Def1 are unable to degrade Rpb1 under a wide variety of 
transcription stalling conditions (Woudstra et al., 2002, Somesh et al., 2005). 
Consistent with a role in the poly-ubiquitylation of RNAPII, cells lacking Def1 
display normal mono-ubiquitylation, but no poly-ubiquitylation after DNA damage. 
Furthermore, Def1 accelerates Rpb1 ubiquitylation in vitro and associates with 
Rpb1 after DNA damage (Somesh et al., 2005, Reid and Svejstrup, 2004). The 
mechanistic function of Def1 remains to be elucidated, but the protein is not 
absolutely required for catalysis in vitro (Harreman et al., 2009). Intriguingly, 
despite its role on chromatin, Def1 appears to localise primarily to the cytoplasm 
(Huh et al., 2003, Tkach et al., 2012). 
 
Def1 has also been implicated in a number of other cellular processes. Def1 
interacts with the telomere helicase Rrm3, and directly with telomeric DNA, leading 
to long DNA expansions at the end of chromosomes (Chen et al., 2005). Cells 
lacking Def1 are slow growing (Woudstra et al., 2002) and large (Jorgensen et al., 
2002). Whole-genome, genetic studies have also suggested a role for Def1 in 
meiotic cross-over recombination (Jordan et al., 2007), peptide transporter 
subcellular localization (Cai et al., 2006), prion expression (Manogaran et al., 2011) 
and glutathione biosynthesis (Suzuki et al., 2011). Whole-genome tagging studies 
confirmed that Def1 is a fairly abundant protein, with an estimated 3380 copies 
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expressed per cell (Ghaemmaghami et al., 2003). A mammalian homologue of 
Def1 has yet to be identified; however, given the very high degree of conservation 
of the rest of the Rpb1 poly-ubiquitylation pathway (Table 1.3), it seems unlikely 
that this will turn out to be a yeast specific factor. 
 
Table 1.3: Comparison of yeast and human proteins identified in the ‘last-resort’ 
pathway 
 
 S. cerevisiae Mammals 
E1 Uba1 Uba1? 
E2 Ubc4, Ubc5, ? UbcH5c, UbcH7, ? 
First E3 Rsp5 Nedd4 
Second E3 Elc1-Ela1-Cul3-Rbx1 Elongin A-Elongin BC-
CUL5-Rbx2 
VHL-ElonginBC-CUL2-
Rbx1 
Accessory factors Def1 
Rpb9 
? 
RPB9? 
Rescue factors Ubp2 
Ubp3-Bre5 
Usp2? 
USP10-G3BP? 
Degradation factors Cdc48-Ubx4/5 
26S Proteasome 
p97? 
26S Proteasome 
 
1.5.3.4 Rescue of poly-ubiquitylated Rpb1 by DUBs  
Two DUBs have been implicated in the S. cerevisiae Rpb1 poly-ubiquitylation 
pathway. Ubp2 often acts in concert with Rsp5, in a complex to reverse Lys-63 
poly-ubiquitin chains (see above). Ubp2 plays a mechanistic role with Rsp5, which 
ensures proper presentation of mono-ubiquitylated RNAPII (Harreman et al., 2009). 
 
In contrast Ubp3 appears to completely remove Lys-48 linked ubiquitin chains,  
‘rescuing’ Rpb1 from degradation (Harreman et al., 2009, Kvint et al., 2008). Ubp3 
physically interacts with RNAPII and Def1, and cells that lack Ubp3 degrade Rpb1 
at an accelerated rate (Kvint et al., 2008). Whilst this Rpb1 degradation is thought 
to be beneficial in the response to UV irradiation, Ubp3 promotes the stability of 
RNAPII on chromatin under other conditions of temporary transcription stalling. As 
a result, Ubp3 acts as a ‘brake pedal’ for ubiquitylation, allowing the large number 
of factors implicated with the restart of RNAPII to perform their function. Much like 
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many other pathways in the cell, ubiquitylation of Rpb1, if left unchecked, can prove 
more dangerous than simply lacking the pathway in the first place. 
 
1.5.3.5 Rpb1 degradation/clearance 
Poly-ubiquitylation leads to the rapid proteasomal degradation of Rpb1 (Luo et al., 
2001, Ratner et al., 1998, Beaudenon et al., 1999). However, RNAPII is strongly 
and stably associated with chromatin (Kireeva et al., 2000). Elongation complexes 
containing ubiquitylated RNAPII in vitro appear just as stable, and its counterpart is 
present in a salt- and detergent-resistant chromatin cell fraction in vivo (Ratner et 
al., 1998, Lee et al., 2002). Furthermore, High avidity binding to DNA can prevent 
proteasome-mediated degradation (Coppotelli et al., 2011). This suggests that 
additional chromatin-associated machinery may be required to disassemble 
ubiquitylated RNAPII. 
 
The ATPase Cdc48 is required for disassembling the RNAPII ternary complex from 
DNA and for feeding ubiquitylated Rpb1 to the 26S proteasome. Proteasomes from 
Cdc48 mutant cells are clogged with Rpb1 peptides, suggesting that Cdc48 is 
directly required to unwind Rpb1 for complete degradation by the proteasome 
(Verma et al., 2011). Cdc48 works with an adaptor protein, Ubx4 or Ubx5, to strip 
Rpb1 from the ternary complex. Interestingly, the Ufd1-Npl4 Cdc48 adaptor is also 
implicated genetically in the degradation of Rpb1, through an unknown mechanism.  
 
The proteasome itself is recruited to chromatin to directly digest ubiquitylated Rpb1. 
The 26S proteasome is found to be genomically associated with highly active 
genes (Auld et al., 2006), and at sites of RNAPII accumulation (Gillette et al., 2004), 
suggesting that it is recruited to sites of transcription stall. In C. elegans, under 
conditions of transcription inhibition, RNAPII localises to discreet chromatin 
‘degradation centres’ where it is degraded by the proteasome (Scharf et al., 2011). 
 
Rpb1 is the only subunit of the RNAPII complex that is degraded in response to 
DNA damage (Malik et al., 2008, Chen et al., 2007). The other 11 subunits of 
RNAPII are thought to be recycled back into a new RNAPII complex. Other 
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subunits of RNAPII can be ubiquitylated basally and under different cellular 
stresses (Beltrao et al., 2012, Kleiman et al., 2005, Daulny et al., 2008, Na et al., 
2003). 
 
With Rpb1 degraded and the other subunits of RNAPII free to diffuse from 
chromatin, any lesions previously covered by the stalled RNAPII can now be 
repaired, presumably via normal GG-NER mechanisms. 
 
1.5.3.6 Recognition of stalled RNAPII 
It is critical that ubiquitylation and degradation of Rpb1 is confined to RNAPII that is 
persistently stalled, which must pose a different substrate to normally transcribing 
RNAPII or free RNAPII. CPD stalled RNAPII does not appear to undergo any major 
conformational change (Brueckner et al., 2007), which might be detected on the 
surface of the protein. Selection of substrate has been reported via two 
mechanisms. 
 
The hyper-phosphorylated form of Rpb1 is the target for destruction (Mitsui and 
Sharp, 1999, Luo et al., 2001). The chromatin bound RNAPII CTD is cyclically 
phosphorylated during the transcription cycle (see 1.3.1.3). After termination all 
phosphorylation marks are removed, creating free, un-phosphorylated RNAPII 
competent for the next round of transcription (Heidemann et al., 2013).  
 
Only serine-2 CTD phosphorylated RNAPII is ubiquitylated in yeast (Somesh et al., 
2005). Serine-2 phosphorylation is indicative of RNAPII in the elongation phase of 
transcription (Yoh et al., 2007, Mayer et al., 2010). Rsp5 does not bind to the CTD 
when it is phosphorylated at serine-5 in vitro (Somesh et al., 2005). Furthermore, in 
cells lacking the CTD phosphatase Ssu72, which consequently display high serine-
5 phosphorylation in the gene body, Rpb1 degradation was greatly reduced. 
Interestingly, the binding of Rsp5 to the RNAPII CTD can promote Serine-2 
phosphorylation (Sogaard and Svejstrup, 2007). 
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RNAPII is hyper-phosphorylated after DNA damage (Rockx et al., 2000, Mitsui and 
Sharp, 1999, Heine et al., 2008). Whilst serine-2 is hyper-phosphorylated in yeast 
(Ostapenko and Solomon, 2003, Winsor et al., 2013), serine-5 is hyper-
phosphorylated in mammalian cells, after stress (Lee et al., 2002, Zhou et al., 
2000). The cognate E3 ligases in yeast and humans diverge in their specificity to 
phosphorylated Rpb1. Rsp5 recognises the serine-2 phosphorylated form of 
RNAPII, whilst the ElonginABC-CUL5 complex appears to bind specifically to the 
serine-5 phosphorylated form in humans (Yasukawa et al., 2008). This suggests 
that, although the exact details diverge, the mechanism of binding to 
phosphorylated RNAPII in response to stall is highly conserved. 
 
The conformational state of the CTD may play a role in ubiquitin targeting. Rrd1, a 
CTD Proline isomerase, can release RNAPII from chromatin (Jouvet et al., 2010) 
and is required for efficient Rpb1 degradation (Jouvet et al., 2011). The prevalence 
of other CTD phosphorylation patterns, including tyrosine-1, threonine-4, and 
serine-7, are more widespread than previously anticipated. (Mayer et al., 2012, 
Akhtar et al., 2009, Hintermair et al., 2012). The role of these modifications, if any, 
in relation to the ubiquitylation of Rpb1 has not yet been resolved. 
 
As the phosphorylation status of Rpb1’s CTD is not specific to stalled RNAPII other 
recognition methods are required to ensure correct Rpb1 poly-ubiquitylation. 
Ubiquitylation in vitro is far more efficient for RNAPII that has been reconstituted 
into transcription elongation complexes (Somesh et al., 2005); RNAPII undergoes 
significant conformational changes upon incorporation into these RNAPII/RNA/DNA 
ternary complexes (Gnatt et al., 2001). Furthermore, transcribing up to a stall point 
in these elongation complexes - mimicking the in vivo situation – promotes the 
ubiquitylation of Rpb1 further (Somesh et al., 2005). A mechanism for this 
observation has been provided: unique among ubiquitin E2’s so far described, 
Ubc5 plays an active role in the recognition of its substrate, stalled RNAPII. 
ubc4Δubc5Δ mutant cells cannot degrade Rpb1, and Ubc5 supports Rpb1 poly-
ubiquitylation in vitro (Somesh et al., 2005). Ubc5 binds directly to the switch 2 
domain of RNAPII (Somesh et al., 2007) and, critically, this domain is only well 
structured during elongation (Gnatt et al., 2001). By recognising a structural feature 
unique to the stalled-ternary complex, Ubc5 is confined to ubiquitylate off-pathway, 
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stalled RNAPII. In addition, one of the identified ubiquitylation sites in Rpb1, Lysine 
330, is buried in this region. This is very close to the catalytic center of RNAPII, 
therefore, a large 8.5kDa post-translational modification in this region is likely to 
perturb RNAPII transcription activity. 
 
As Rpb1 ubiquitylation is a two-step process, the poly-ubiquitylation apparatus 
must also be correctly targeted. In fact, Rsp5 mediated mono-ubiquitylation is 
constitutive in unstressed cells (Woudstra et al., 2002, Sigurdsson et al., 2010), 
suggesting that this may not be the key control step. Whilst it is not clear how the 
poly-ubiquitylation machinery is regulated in yeast, Def1 is recruited to RNAPII after 
UV damage (Reid and Svejstrup, 2004). In contrast, Elc1 co-immunoprecipitation 
with RNAPII - from crude yeast extracts - is not affected by UV irradiation 
(Harreman et al., 2009), although poly-ubiquitylation only occurs under these 
conditions. The mammalian Elongin ABC-CUL5 ligase co-localises to sites 
enriched with serine-5 phosphorylated RNAPII (Yasukawa et al., 2008). The 
Elongin ABC complex, unlike the yeast equivalents, is associated with RNAPII as 
elongation factors. It is conceivable that the second E3 is recruited to RNAPII in a 
stepwise manner; first, the substrate recognising Elongin ABC binds to RNAPII as 
an elongation factor, prior to recruitment of CUL5-RBX2 upon persistent 
transcription stall. Cdc48 also appears to associate constitutively with RNAPII, 
whilst the substrate adaptor protein Ubx5 (or Ubx4) associates only after DNA 
damage (Verma et al., 2011).  
 
Rsp5 shuttles between the nucleus and cytosol (Cholbinski et al., 2011). When the 
NES of Rsp5 was mutated, leading to nuclear accumulation of Rsp5, degradation 
of Rpb1 was more extensive after UV irradiation, suggesting that the RNAPII 
degradation factors are, at least in part, regulated by their subcellular localisation. 
Dynamic compartmentalisation could offer an alternate way of confining RNAPII 
poly-ubiquitylation to after transcriptional stalling. A number of kinases are 
activated after DNA damage. Indeed, in human cells ATR and p53 are activated 
upon RNAPII stall, in the absence of any induced DNA damage (Derheimer et al., 
2007) . Whilst Mec1 phosphorylation is required for TC-NER (Taschner et al., 
2010), the role of the DDR in RNAPII poly-ubiquitylation is unclear. It is interesting 
to note that Rpb1 has been shown to be inducibly SUMOylated in response to 
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transcription stall (Chen et al., 2009), and this SUMOylation does not directly affect 
the rate of TC-NER or Rpb1 poly-ubiquitylation. SUMOylation does increase in TC-
NER deficient strains and attenuates Rad53 activation.  
 
1.5.3.7 Choice of degradation over TC-NER/restart 
As a non-reversible, wasteful pathway it is imperative that degradation of Rpb1 is 
used as a last resort. The restart and TC-NER machinery must first act to sample 
the stalled RNAPII, with degradation the only option if these pathways fail.  
 
There are different kinetics to transcription restart, TC-NER and degradation of 
Rpb1. Elongation factors that promote restart often travel with elongating 
polymerases (Aso et al., 1995, Otero et al., 1999), and as a result, they are 
localised to the site of stall without the need for ‘time-wasting’ recruitment. There 
are over 200,000 sites of paused RNAPII in the S. cerevisiae genome (Churchman 
and Weissman, 2011), which are most often rapidly reset by backtracking and 
restart. TC-NER is a fast process (Tijsterman et al., 1997, Svejstrup, 2002), with 
the majority of lesions being removed in under one hour in S. cerevisiae (Taschner 
et al., 2010). The degradation of Rpb1 under the same conditions occurs at a much 
slower rate. Degradation may be the least favoured pathway due to the slower 
kinetics of Rpb1 poly-ubiquitylation, suggesting a model whereby the time taken to 
form sufficient Lys-48 chains on Rpb1 for degradation allows TC-NER to progress 
(Daulny and Tansey, 2009). In this model both the slower kinetics of the two-step 
recruitment process, as well as the action of Ubp3 would allow sufficient time for 
DNA repair to be attempted first. 
 
There is kinetic disparity between Rpb1 poly-ubiquitylation and Rpb1 degradation 
in human cells (Anindya et al., 2007). Ubiquitylation is very rapid and potentiated 
for three hours after UV irradiation, whereas levels of Rpb1 do not noticeably 
decrease until the three hour time point. This suggests that the disassembly of the 
ternary complex and proteasomal degradation of Rpb1 may be the rate-limiting 
step in the reaction. Whether this is also the case in yeast is unclear, due to the 
faster overall kinetics of Rpb1 ubiquitylation and degradation.  
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Whilst TC-NER and degradation can be viewed as two separate pathways, this 
does not mean that they are not interconnected. Cells that are unable to 
ubiquitylate and degrade Rpb1 still exhibit normal TC-NER, suggesting that TC-
NER is by far the dominant pathway, and degradation and removal of RNAPII does 
not offer a quick solution to DNA repair. However, cells lacking both TC-NER and 
Rpb1 degradation components are highly UV sensitive. Interestingly, ubiquitylated 
RNAPII is enriched in immunoprecipitations of UVSSA suggesting that the TC-NER 
and Rpb1-ubiquitylation pathways could be overlapping in humans (Nakazawa et 
al., 2012).  
 
Def1 was first identified via its interaction with Rad26 in chromatin (Woudstra et al., 
2002). Rad26 actively antagonises Def1 function, suggesting that degradation can 
only occur when the TC-NER machinery is not present at the stalled RNAPII 
(Woudstra et al., 2002); Rad26 could allow time for the TC-NER pathway to occur 
first. If TC-NER then fails, it is possible that Rad26 diffuses away from the lesion or 
its inhibitory activity is deactivated, allowing the equilibrium to shift promoting Rpb1 
poly-ubiquitylation and degradation, mediated via Def1. The identity of the final 
signal for Rpb1 ubiquitylation over failed TC-NER is unclear. It would be expected 
that multiple signals, including the DDR converge on stalled RNAPII to determine 
which pathway is utilised. 
 
 
 
 
1.6 Aims of this thesis 
 
As outlined above, the ‘last-resort’ Rpb1 poly-ubiquitylation and degradation 
pathway has been well studied since its discovery, over twenty years ago. However, 
some key questions remain. Whilst the catalytic players have been identified in 
both yeast and human systems, how the signal for Rpb1 poly-ubiquitylation is 
activated and controlled is still unclear. The potential regulation through dynamic 
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compartmentalisation and post-translational modification is an intriguing possibility. 
In order to better understand how Rpb1 is degraded, better tools for studying 
protein ubiquitylation ex vivo were required. Chapter 3 outlines the development of 
a ubiquitin specific affinity resin, the MultiDsks. The MultiDsk protein allows the 
efficient protection and isolation of ubiquitylated proteins from extracts. 
 
One essential player in the ‘last-resort’ pathway, Def1, was identified over 10 years 
ago, but its specific role in the Rpb1 poly-ubiquitylation pathway was unclear. 
Results, presented here in Chapters 5-7, have helped to elucidate the central place 
of this protein in the Rpb1 poly-ubiquitylation pathway. Def1 is processed after 
transcription stall, to a shorter, active fragment (Chapter 5). This fragment of Def1 
is created by the proteasome after mono-ubiquitylation and accumulates in the 
nucleus (Chapter 6). Finally, in the nucleus Def1 acts as a bridging molecule 
between Elongin-Cullin ligase and stalled RNAPII substrate to promote efficient 
Rpb1 poly-ubiquitylation (Chapter 7). 
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Chapter 2. Materials & Methods 
 
2.1 Buffers, Media and Solutions 
 
Standard growth media was obtained from the media and cell services unit of the 
London Research Institute, Cancer Research UK. De-ionised water was used for 
all media. Solid media for plates was created by substituting water for agar, to a 
final concentration of 1.5% Agar. All media and solutions were shifted to the 
appropriate temperatures before use: bacteria media, 37oC; yeast media, 30oC; 
purification and assay buffers, 4oC. 
 
 
2.1.1 Bacteria Media 
2.1.1.1 LB (rich medium) 
1 % w/v bacto-tryptone (DIFCO) 
0.5 % w/v yeast extract (DIFCO) 
1 % w/v NaCl 
pH adjusted to 7 
+/- 100µg/ml Ampicillin (Melford Biosciences) 
+/-35µg/ml Chloramphenicol (Sigma-Aldrich) 
 
2.1.1.2 SOC medium (rich medium) 
2 % w/v bacto-tryptone (DIFCO) 
0.5 % w/v yeast extract (DIFCO) 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
pH adjusted to 7 
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2.1.1.3 NZY medium 
10 mg/ml yeast extract (DIFCO) 
5 mg/ml NaCl 
2 mg/ml Glucose 
16 mg/ml NZ-Amine A (Sigma-Aldrich) 
pH adjusted to 7 
 
 
2.1.2 Yeast media 
2.1.2.1 YPD 
1 % w/v yeast extract (DIFCO) 
1 % w/v peptone (DIFCO) 
2 % w/v glucose 
For fluorescence studies supplemented with 24 µg/ml adenine and 10mM Tris pH 
8. 
 
2.1.2.2 Selective drop-out media (SD media) 
2 % sugar (glucose, raffinose or galactose) 
6.7 mg/ml Yeast nitrogen base without amino acids (DIFCO) 
1.4 mg/ml Yeast Synthetic Drop-Out Medium Supplement (Sigma-Aldrich) 
12 µg/ml adenine 
+/- 80 µg/ml leucine 
+/- 40 µg/ml histidine 
+/- 40 µg/ml uracil 
+/- 40 µg/ml tryptophan 
+/- 1 µg/ml 5-Fluoroorotic acid (5-FOA) (Sigma-Aldrich) 
 
2.1.2.3 Sporulation media 
50mM Potassium acetate pH 7.0 
Chapter 2. Materials and Methods 
 
70 
6 µg/ml adenine 
20 µg/ml uracil 
40 µg/ml leucine 
20 µg/ml tryptophan 
20 µg/ml histidine 
 
2.1.2.4 TE/LiOAc 
 
Tris-EDTA pH 7.5 
100 mM lithium acetate 
 
2.1.2.5 PEG/TE/LiOAc 
Tris-EDTA pH 7.5 
100 mM lithium acetate 
40% Polyethylene glycol (PEG) 3350 
 
 
2.1.3 General solutions 
2.1.3.1 Phosphate Buffered Saline (PBS) 
137 mM NaCl 
2.7mM KCl 
10 mM Na2HPO4 
2 mM NaH2PO4 
pH adjusted to 7.5 
 
2.1.3.2 Phosphate buffer 
700mM Na2HPO4 
300 mM NaH2PO4 
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pH adjusted to 7.4 or 8.1 as required 
 
2.1.3.3 PBS TWEEN 
137 mM NaCl 
2.7mM KCl 
10 mM Na2HPO4 
2 mM NaH2PO4 
0.025% TWEEN 20 
 
2.1.3.4 Saline 
137 mM NaCl 
2.7mM KCl 
 
2.1.3.5 Tris-EDTA (TE) 
10 mM Tris-Cl pH 7.5 or pH 8.0 
1 mM EDTA pH 8.0 
 
2.1.3.6 Borate buffer 
40mM Sodium Borate 
70mM Boric Acid 
pH ~9 
 
2.1.3.7 Tris-Borate-EDTA (TBE) 
89 mM Tris-Cl 
89 mM Boric Acid 
2 mM EDTA 
A 10 x stock buffer was routinely used to prepare 1 x TBE. 
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2.1.3.8 5 x DNA loading buffer for agarose electrophoresis 
20 mM EDTA pH 8.0 
30 % glycerol 
0.05 % bromophenol blue 
 
2.1.3.9 1.5 x SDS-PAGE loading buffer 
98 mM Tris-Cl pH 6.8 
15 % glycerol 
3 % SDS 
0.015 % bromophenol blue 
150 mM β-Mercaptoethanol 
 
2.1.3.10  5 x SDS-PAGE loading buffer 
325mM Tris-Cl pH 6.8 
50 % glycerol 
10 % SDS 
0.05 % bromophenol blue 
500 mM β-Mercaptoethanol 
 
2.1.3.11  SDS-PAGE running buffer 
 
A 20x stock solution of MES, MOPS or Tris-Acetate (BioRad or Invitrogen) buffer 
was diluted with dH20. 
 
2.1.3.12  Western transfer buffer 
25mM Tris-base 
192mM Glycine 
20% Methanol 
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0.02% SDS 
 
2.1.3.13 100x Protease Inhibitor (PI) mix  
28.4 µg/ml leupeptin  
137 µg/ml pepstatin A 
17 mg/ml phenylmethylsulfonyl fluoride 
33 mg/ml benzamindine 
Dissolved in ethanol 
 
 
2.1.4 Bacteria Purification Buffers 
2.1.4.1 STE 
10mM Tris pH 8 
1mM EDTA 
100mM NaCl  
1xPI 
 
2.1.4.2 MultiDsk wash buffer 1 
1xPBS 
450mM NaCl 
10% glycerol 
0.1mM EDTA  
0.1% Triton X-100 
1X PI 
2mM Dithiothreitol (DTT) 
 
2.1.4.3 MultiDsk wash buffer 2 
50mM Phosphate buffer pH 7.4 
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50mM NaCl 
10% glycerol 
1mM β-Mercaptoethanol 
1xPI 
0.2% Triton X-100 
 
2.1.4.4 GST lysis buffer 
1xPBS 
15mM Phosphate buffer pH 7.4 
10% glycerol 
0.2% Triton X-100 
1X PI 
2mM β-Mercaptoethanol 
 
2.1.4.5 GST Wash buffer 1 
1xPBS 
250mM NaCl 
10% glycerol 
0.1% Triton X-100 
1X PI 
2mM β-Mercaptoethanol 
 
2.1.4.6 GST wash buffer 2 
50mM Phosphate buffer pH 7.5  
50mM NaCl 
10% glycerol 
0.3% Triton X-100 
1X PI 
1mM β-Mercaptoethanol 
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2.1.4.7 GST Elution buffer 
50mM Phosphate buffer pH 8.1 
300mM KCl 
10% glycerol 
1xPIs 
0.05% Triton X-100 
15mM Glutathione 
pH adjusted to >8.1 
 
2.1.4.8 GST HRV 3C buffer 
50mM Tris pH 7.5 
150mM NaCl 
1mM EDTA 
1mM DTT 
0.01% Triton X-100 
 
2.1.4.9 Nickel lysis buffer 
1xPBS 
15mM Phosphate buffer pH 7.5 
150mM NaCl 
10% glycerol 
0.2% Triton X-100 
1X PI 
2mM β-Mercaptoethanol 
15mM Imidazole 
 
2.1.4.10 Nickel wash buffer 
 
1xPBS 
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450mM NaCl 
10% glycerol 
0.1% Triton X-100 
1X PI 
2mM β-Mercaptoethanol 
20mM Imidazole 
 
2.1.4.11 Nickel elution buffer 
1xPBS 
15mM Phosphate buffer pH 7.5 
150mM NaCl 
10% glycerol 
0.2% Triton X-100 
1X PI 
2mM β-Mercaptoethanol 
300mM Imidazole 
pH adjusted to ~7.5 
 
2.1.4.12  Mono S buffer A 
 
1xPBS 
15mM Phosphate buffer pH 7.4 
10% glycerol 
1X PI 
2mM β-Mercaptoethanol 
 
2.1.4.13  Mono S buffer B 
1xPBS 
900 mM NaCl 
15mM Phosphate buffer pH 7.4 
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10% glycerol 
1X PI 
2mM β-Mercaptoethanol 
 
2.1.4.14  Dialysis buffer 1 
100mM HEPES pH 7.5 
5% glycerol 
2mM DTT 
 
2.1.4.15  Dialysis buffer 2 
50 mM HEPES pH 7.5 
150 mM NaCl 
10% glycerol 
 
 
2.1.5 Yeast purification buffers 
2.1.5.1 Cell lysis buffer 
150 mM Tris-Acetate pH 7.8 
50 mM potassium acetate 
1 mM EDTA 
5 mM DTT 
20 % Glycerol 
0.01 % NP40 
1 x PI 
 
2.1.5.2 Myc wash buffer 1 
150 mM Tris-Acetate pH 7.8 
500 mM potassium acetate 
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1 mM EDTA 
5 mM DTT 
10 % Glycerol 
0.01 % NP-40 
1 x PI 
 
2.1.5.3 Myc wash buffer 2 
50 mM Phosphate buffer pH 7.5 
50 mM NaCl  
1 mM β-Mercaptoethanol 
10% glycerol 
0.01% NP-40 
 
2.1.5.4 TEV cleavage buffer 
50 mM Phosphate buffer pH 7.5 
150 mM NaCl  
1 mM β-Mercaptoethanol 
10% glycerol 
0.01% NP40 
 
 
2.1.6 Assay buffers 
2.1.6.1 Degradation buffer (D-buffer) 
150 mM Tris-Acetate pH7.4 
100 mM potassium acetate 
1 mM EDTA 
0.1% Triton X-100 
10% glycerol 
2mM N-ethylmaleimide (NEM) 
10 µM MG132 
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1x PI 
 
2.1.6.2 Degradation buffer (D250-buffer) 
150 mM Tris-Acetate pH7.4 
250 mM potassium acetate 
1 mM EDTA 
0.1% Triton X-100 
10% glycerol 
2mM N-ethylmaleimide (NEM) 
10 µM MG132 
1x PI 
 
2.1.6.3 High salt degradation buffer (D500-buffer) 
 
150 mM Tris-Acetate pH7.4 
500 mM potassium acetate 
1 mM EDTA 
0.1% Triton X-100 
10% glycerol 
2mM N-ethylmaleimide (NEM) 
10 µM MG132 
1x PI 
 
2.1.6.4 Low salt degradation buffer (D50-buffer) 
 
150 mM Tris-Acetate pH7.4 
50 mM potassium acetate 
1 mM EDTA 
0.2% Triton X-100 
10% glycerol 
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2mM N-ethylmaleimide (NEM) 
10 µM MG132 
1x Protease Inhibitor mix 
 
2.1.6.5 Proteasome buffer (P-buffer) 
25mM Tris pH 7.5 
100mM NaCl 
10% glycerol 
2mM ATP 
5mM MgCl2 
1mM DTT  
0.25mg/ml [4.5 µM] BSA 
 
2.1.6.6 Binding buffer (B-buffer) 
20mM Tris pH 7.5 
200mM NaCl 
0.05% Triton X-100 
1x Protease Inhibitors 
1 mM β-Mercaptoethanol 
15% glycerol 
75ug/ml BSA 
 
2.1.6.7 Binding Phosphate buffer (BP-buffer) 
1xPBS 
50mM NaCl 
0.05% Triton X-100 
1x Protease Inhibitors 
1 mM β-Mercaptoethanol 
15% glycerol 
75ug/ml BSA 
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2.1.6.8 Ubiquitylation buffer (U-buffer) 
25mM Tris pH 7.5 
125mM NaCl 
2mM MgCl2 
1mM DTT 
3.75mM ATP 
 
 
2.1.7 RNA extraction buffers 
2.1.7.1 Buffer Y1 
1M Sorbitol 
100mM EDTA pH 7.4 
0.1% β-Mercaptoethanol 
 
 
 
2.2 DNA Techniques 
2.2.1  Plasmids 
Table 2.1: Plasmids used in this study 
 
Name Description Source 
pRS423 AmpR, 2µ, URA3 (Sikorski and 
Hieter, 1989) 
pRS414-DEF1 AmpR, CEN, TRP; DEF1 expressed from own promoter 
and terminator  
JW 
pRS414-MTH-DEF1 AmpR, CEN, TRP; as above, but 9xMyc-2xTEV-6xHis-
DEF1  
MDW 
pRS414-MTH-DEF1-
TEV 
AmpR, CEN, TRP; as above, but TEV site inserted at 
DEF1 amino acids 522-523 (note: N-terminal TEV sites 
were removed during JSY1191 strain construction) 
JW 
pRS414-def1CUEm AmpR, CEN, TRP; as pRS414-DEF1, but CUE domain 
mutated (I54A, I55A, F33A, P34A) 
MDW 
pRS414-def1Ubm AmpR, CEN, TRP; as pRS414-DEF1, but Def1 mutated 
at K281R, K288R, K328R, K329R  
MH 
YIPlac204-TEV118 AmpR, TRP; pGAL10, NLS-9xMyc-TEV-2xNLS (Uhlmann et al., 
2000) 
pRS425-Myc-TEV AmpR, 2µ, LEU; pGAL10, NLS-9xMyc-TEV-2xNLS  MDW 
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pGEX-6p1 AmpR, GST GE healthcare 
pGEX-Def11-500 AmpR, GST-Def1-1-500-6xHIS. Codon optimised by 
Genscript 
MDW 
pGEX-Def11-500CUEm AmpR, GST- Def1-1-500-6xHIS. CUE mutated at I54A, 
I55A, F33A, P34A 
MDW 
pGEX-Dsk2 AmpR, GST-Dsk2 (Anindya et al., 
2010) 
pGST-MD AmpR, GST-6xHis-MultiDsk (Wilson et al., 
2012) 
pGEX-Rsp5 AmpR, GST-Rsp5 
 
(Somesh et al., 
2005) 
pET21-Ubc5 AmpR, 6xHis-Ubc5 (Parker and 
Ulrich, 2009) 
pST44 AmpR polycistronic low copy number vector (Tan, 2001) 
pST44-Elc1-Ela1 AmpR, His-Elc1, Ela1. Polycistonic, codon optimised by 
Genscript 
MDW 
pST44-Elc1-Ela11-250 AmpR, His-Elc1, Ela1 residues 1-250 MDW 
pST44-Elc1-Ela11-300 AmpR, His-Elc1, Ela1 residues 1-300 MDW 
pST44-Elc1-Ela11-350s AmpR, His-Elc1, Ela1 residues 1-350 MDW 
pGEX-Ubi AmpR, GST-Ubiquitin (Anindya et al., 
2010) 
pGEX-UbiI44A AmpR, GST-Ubiquitin (I44A mutated) (Anindya et al., 
2010) 
pGEX-Ela1250-379 AmpR, GST-Ela1 C-terminus residues 250-379 MDW 
pPS815 AmpR, 2µ, URA, pADH1, SV40 NLS-GFP-LacZ (Lee et al., 1996) 
pPS1372 AmpR, 2µ, URA, pADH1, SV40 NLS-NES-GFP2 (Taura et al., 
1998) 
pBOW3 NLS-GFP-
def1500-738 
AmpR, 2µ, HIS, pADH1, SV40 NLS-GFP-DEF1500-738 MDW 
pBOW3 NLS-GFP2-
def1500-540 
AmpR, 2µ, HIS, pADH1, SV40 NLS-GFP2-def1500-540 MDW 
pYC2/NT AmpR, CEN, URA, pGAL1 Invitrogen 
pYC2-DEF1 AmpR, CEN, URA, pGAL1, DEF1,  MH 
pYC2-def11-500 AmpR, CEN, URA, pGAL1, DEF11-500  MH 
pYC2-def1CUEm AmpR, CEN, URA, pGAL1, DEF1 CUE mutated (I54A, 
I55A, F33A, P34A) 
MDW 
pYC2-def11-500/CUEm AmpR, CEN, URA, pGAL1, DEF11-500 CUE mutated 
(I54A, I55A, F33A, P34A) 
MH 
pYC2-NES-DEF1 AmpR, CEN, URA, pGAL1, Consensus NES, DEF1  MDW 
pYC2-NES-def11-500 AmpR, CEN, URA, pGAL1, Consensus NES, DEF11-500 MDW 
pYM28 AmpR, CEN, HIS, eGFP (Janke et al., 
2004) 
 
Plasmids were created for this study by: MDW = Marcus Wilson; JW = Jane Walker; MH = 
Michelle Harreman 
 
Def1 mutations and N-terminal tags were introduced into a yeast DEF1-expression 
plasmid (pRS414-DEF1) containing the endogenous DEF1 promoter, ORF, and 
terminator regions, using standard PCR methods. For galactose-inducible 
overexpression of DEF1, the appropriate DNA sequence was amplified by PCR 
from these plasmids and cloned into the pYC2 vector (Invitrogen).  
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The MultiDsk construct was created from the coding sequence for the yeast 
Dsk2 ubiquitin binding domain (residues 327-373). This was repeated in tandem 5 
times, incorporating a low complexity 8-amino acid spacer between repeats (Figure 
1A). The sequence was codon optimised and synthesised (GenScript USA, Inc.), 
and cloned into GST fusion expression vector pGs-21a, producing pGST-MD. 
 
The sequence coding for Def1 amino acids 1-500 with a C-terminal 6xHis tag was 
codon-optimised and synthesised by GenScript USA Inc. The coding region was 
sub-cloned into pGEX-6P1 (GE healthcare). Mutation in the CUE domain was 
performed by PCR using mutant primers. Sequences can be provided upon 
request. 
 
The coding regions of Elc1 and Ela1, complete with polycistronic spacer sections 
as described by Tan et al (Tan, 2001), were codon-optimised and synthesized by 
Genscript USA Inc. A 6xHis tag was included at the N-terminus of Elc1 and cloned 
into pST44 polycistronic vector. C-terminal Ela1 deletions were created by 
amplifying the corresponding regions from codon-optimised Elc1-Ela1 and 
subcloning into vector pST44. 
 
Sequences expressing the TEV protease were sub-cloned from construct 118 in 
Uhlmann et al (2000) into pRS425. The TEV recognition site was incorporated 
between amino acid residues 522 and 523 of Def1, inserting the sequence Glu-
Asn-Leu-Tyr-Phe-Gln (using the native Gly-523 residue of Def1 as the final part of 
the TEV recognition consensus site), by site directed mutagenesis. 
 
To create the NLS-GFP-DEF1500-738 plasmid, the DEF1 region coding for amino 
acids 500-738 was first cloned into a pRS423-based plasmid (pBOW3), containing 
the ADH1 promoter and terminator separated by multiple cloning sites. Sequences 
encoding NLS-GFP were amplified from pYM28 (eGFP; EUROSCARF) with the 
SV40 nuclear localization signal (NLS) encoded in the primers, and then cloned in 
frame with DEF1500-738. The construct has 4 amino acid spacers between each 
feature. All final constructs were confirmed by DNA sequencing.  
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2.2.2 Polymerase chain reaction (PCR) 
PCR for cloning and strain creation were performed with the high fidelity KOD Hot 
start DNA polymerase kit (Novagen), as per manufacturer’s instructions. Analytical 
PCR was performed using GoTaq DNA polymerase (Promega), as per 
manufacturer’s instructions. Primers were synthesised upon request by Sigma-
Aldrich or DNA Technologies. Thermal cycling conditions were optimised for each 
PCR. 
 
2.2.3 DNA purification 
DNA was purified from restriction digests, agarose gels or PCR using the QIAquick 
PCR/gel purification kit (Qiagen), following manufacturer’s instructions. 
 
2.2.4 Cloning 
Appropriate Restriction enzymes (New England Biolabs [NEB]) were incubated with 
purified DNA and NEB buffer, at 37oC for 2-4 hours. Cut plasmids were 
dephosphorylated using Calf intestinal phosphatase (NEB). Digested DNA was 
purified using the QIAquick gel purification kit (Qiagen). DNA quantification was 
performed using a Nanodrop spectrophotometer (Thermo Scientific). DNA ligations 
were set up with a 3:1 molar ratio of insert: vector, using Roche T4 DNA ligase and 
reaction buffer. The reaction was allowed to proceed for 3 hours at 25 °C prior to 
bacterial transformation. See Table 2.1 for a description of the plasmids created 
and used in this study. 
 
2.2.5 Mutagenesis 
Point or deletion mutations were created by using the QuikChange II XL kit, or 
mutated primers and 2-step overlap PCR. Site-directed mutagenesis was carried 
out using the QuikChange II XL kit (Stratagene), according to the manufacturer's 
instructions. The presence of point mutations/deletions was confirmed by 
sequencing. 
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2.2.6 Sequencing 
Standard Sanger sequencing reactions were set up using the BigDye sequencing 
kit (Applied Biosystems) using standard conditions. Sequencing was performed at 
the London Research Institute sequencing facility. 
 
2.2.7 Agarose gel electrophoresis 
Horizontal gel electrophoresis was performed to separate DNA, using 0.8-2% 
agarose gels, stained with 0.5µg/ml ethidium bromide (Sigma-Aldrich). Gels were 
run in TBE (see 2.1.3.7) and samples loaded in DNA loading buffer (see 2.1.3.8). 
 
2.2.8 Quantitative PCR 
qPCR reactions were carried out using iQ Custom SYBR Green SuperMix (BioRad), 
with primers used at a final concentration of 0.2µM, and a total final volume of 20 µl. 
Standard thermal cycling and melt curve conditions were used in a CFX-96 Real-
Time System (BioRad). Quantification of Ct values was performed in Excel 
(Microsoft). 
 
 
 
2.3 RNA Techniques 
2.3.1 Extraction of total RNA from cells 
Total cellular RNA was isolated after zymolase (100units) treatment of 1x107 cells 
in buffer Y1 (see 2.1.7.1) for 15 minutes at 30oC, with gentle agitation. Cells were 
lysed and RNA extracted using the RNAeasy mini kit (Qiagen), following 
manufacturer’s specifications. Genomic DNA contaminant was removed by on 
column DNase digestion (Qiagen). 
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2.3.2 Reverse transcription 
Reverse transcription was performed using the Applied Biosystems Taqman RT kit. 
1.5µg of RNA was used per reaction using oligo dT primers. 
 
 
 
2.4 Bacterial Techniques 
 
2.4.1 Transformation of bacterial competent cells 
Top10 (Invitrogen) or XL-10 Gold (Stratagene) competent cells were used for 
transformations of newly ligated plasmids, as per manufacturer’s specifications. BL-
21 DE3 (RIL) (Invitrogen) cells were transformed with plasmid for recombinant 
protein expression, and selected using ampicillin and chloramphenicol containing 
LB-media. 
 
2.4.2 Extraction of plasmid DNA 
Plasmid DNA was extracted from 2ml or 100ml of overnight bacteria cultures using 
the QIAprep miniprep or midiprep kits (Qiagen) respectively, following 
manufacturer’s specifications. 
 
2.4.3 Overexpression of recombinant proteins. 
 Transformed BL-21 DE3 (RIL) cells were grown overnight in starter culture in LB- 
100µg/ml ampicillin-35 µg/ml chloramphenicol, at 37˚C. Typically 600-800 ml of LB-
Ampicillin/chloramphenicol was inoculated with 15ml of overnight starter culture 
and allowed to reach an optical density (OD600) of 0.6. IPTG was added to a final 
concentration of 0.5 or 1 mM, and the culture was shifted to 25˚C or 30˚C for 4 
hours.  Cells were harvested by centrifugation at 6000g for 20 minutes, washed 
once in PBS, and frozen in liquid nitrogen 
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2.5 Yeast Techniques 
 
2.5.1 Yeast strains 
All Saccharomyces cerevisiae strains used in this study were grown and 
manipulated using standard techniques (Sherman, 1991) and congenic with W303-
1A unless stated. 
 
Table 2.2: Yeast strains used in this study. 
 
Strain 
number Strain name Genotype Source 
 W303-1a MATa ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100  
R. Rothstein 
 W303 diploid MATa/MATalpha ura3 leu2-3, 112 his3-11,15  trp1-1  
ade2-1  can1-100 
R. Rothstein 
 Sub592 MAT a lys2–810 leu2–3,-112 ura3–52 his3-Δ200 
trp1–1[am] ubi1-Δ1::TRP1 ubi2-Δ2::ura3 ubi3-Δub-2 
ubi4-Δ2::LEU2 [pUB39] [pUB221-hismyc-ubi] 
(Spence et al., 
2000) 
RJD1144 Pre1-flaghis MATa his3Δ200 leu2-3,112 lys2-801 trp1Δ63 ura3-
52 PRE1FH::Ylplac211 (URA3) 
(Verma et al., 
2000) 
JSY1175 Ubp2-his-tev-
myc 
MATa ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100, Ubp2-6xhis-2xtev-9xmyc::TRP, FLAG-
Rsp5 ::URA 
MDW 
JSY568 Δdef1 ::URA3 
 
W303 MATa leu2-3,112 his3-11,15 trp1-1 ade2-1 
can1-100 ∆def1::URA3 
(Woudstra et al., 
2002) 
JSY645 Δdef1::TRP1 
 
W303 MATa ura3 leu2-3,112  his3-11,15  ade2-1  
can1-100 ∆def1::TRP1   
(Woudstra et al., 
2002) 
JSY1176 def1 1-100 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, def11-100-3HA::HIS3  
MH 
JSY1177 def1 1-200 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, def11-200-3HA::HIS3 
MH 
JSY1178 def1 1-300 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, def11-300-3HA::HIS3 
MH 
JSY1179 def1 1-600 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, def11-600-3HA::HIS3 
MH 
JSY1180 def1 1-700 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, def11-700-3HA::HIS3 
MH 
JSY1181 def1 1-738 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, DEF1-3HA::HIS 
MH 
JSY1182 DEF1/def11-
500-HA 
MATa/MATalpha ura3 leu2-3, 112 his3-11,15  trp1-1  
ade2-1  can1-100, DEF1/def11-500-3HA::HIS3 
MH 
JSY1183 def1 1-530 HA W303 MATa ura3  leu2-3,112  his3-11,15  ade2-1  
can1-100, def11-530-3HA::HIS3 
MH 
JSY1190 Def1 WT As JSY 568, but with DEF1 knock-in (KI) at genomic 
DEF1 locus 
MDW 
JSY1191 Def1-TEV 
 
As JSY568, but with def1-TEV522 KI at genomic 
DEF1 locus 
MDW 
JSY1192 rsp5-1 W303 MATa ura3 leu2-3,112  his3-11,15  ade2-1  
can1-100  rsp5 l733S::pRS303 
(Harreman et al., 
2009) 
GAC202 GAC202 Matα his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pdr5Δ::KanMX6 pre3-Δ2::HIS3 pup1Δ::leu2-HIS3 
[pRS317-pup1-T30A] [YCplac22-pre3-T20A] gal− 
(Collins et al., 
2010) 
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GAC201 GAC201 Matα his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1 
pdr5Δ::KanMX6 pre3-Δ2::HIS3 pup1Δ::leu2-HIS3 
[pRS317-PUP1] [YCplac22-PRE3] gal− 
(Collins et al., 
2010) 
JSY1193 4xUbm As JSY568, but with def1 K281R, K288R, K328R, 
K329R at genomic DEF1 locus 
MDW 
JSY1218 Def1-DHFR MATa ura3 leu2-3, 112 his3-11,15 trp1-1  ade2-1  
can1-100. Def1-DHFR-HA::URA 
MDW 
JSY1194 eGFP-DEF1 As JSY568, but with eGFP-DEF1 at genomic DEF1 
locus 
MDW 
JSY1195 eGFP-DEF1 
GAC202 
Matα his3-11 leu2-3,112 ura3-52 lys2-801 trp1-1, 
but with eGFP-DEF1 at genomic DEF1 locus 
MDW 
 DEF1-GFP MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, DEF1-
GFP::HIS3 
(Huh et al., 2003) 
JSY1196 def1CUEm As JSY568, but with def1 I54A, I55A, F33A, P34A at 
genomic DEF1 locus 
MDW 
JSY1197 eGFP-
def1CUEm 
As JSY568, but with eGFP-def1 I54A, I55A, F33A, 
P34A at genomic DEF1 locus 
MDW 
JSY1198 9xMyc-TEV-
his-DEF1 
As JSY568, but with 9xMyc-2xTEV-6xHis-DEF1 at 
genomic DEF1 locus 
MDW 
JSY1199 9xMyc-TEV-
his-def1CUEm 
As JSY568, but with 9xMyc-2xTEV-6xHis -def1 
I54A, I55A, F33A, P34A at genomic DEF1 locus 
MDW 
JSY642 DEF1-6xHA W303 MATa ura3 leu2-3,112 his3-11,15  ade2-1 
can1-100  def1::pHAHIS304 
(Reid and 
Svejstrup, 2004) 
JSY919 RPB1-3xHA MATa ura3-52, trp1-1, prb1-1122, prc1-407, pep4-3, 
leu2-3, 112 nuc1::LEU2  RPB1-3HA::URA 
(Reid and 
Svejstrup, 2004) 
JSY 951 Rpb3-FLAG W303, MATa ura3-1 leu2-3,112 his3-11,15  trp1-1  
ade2-101 lys2Δ can1-100, RPB3-FLAG::TRP1 
 
 
(Sigurdsson et al., 
2010) 
RAT7-1 Rat7-1 matα ura3-52, leu2∆1, his∆200, rat7-1. (Gorsch et al., 
1995) 
MNY8 Mny8 Mata leu2, his3, trp1, ura3.pDC-CRM1T539C::LEU2 (Neville and 
Rosbash, 1999) 
JSY1201 Mny8, GFP-
Def1 
Mata leu2, his3, trp1, ura3.pDC-
CRM1T539C::LEU2. GFP-Def1::URA 
MH 
JSY1202 Def1 CUEm, 
9xMyc-TEV-
his -Elc1 
As JSY1196 with 9xmyc-2xTEV-6xHis at N-terminus 
of Elc1::URA (see JSY 1116) 
MDW 
JSY 
1116 
9xMyc-TEV-
his -Elc1 
MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100. 9xmyc-2xTEV-6xHis at N-terminus of 
Elc1::URA 
(Harreman et al., 
2009) 
JSY 
1205 
Δela1 
 
MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100. Δela1::URA3 
MDW 
JSY 
1203 
Ela11-250 MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100, Ela1 1-250::HIS 
MDW 
JSY 
1204 
Ela1 WT MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100, Ela1::HIS 
MDW 
JSY 
1206 
Def1-his-TEV-
9xMyc 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, Def1-his-
TEV-9xMyc::HIS 
MT 
JSY1207 Ela11-250-ub MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100, Ela1 1-250-4xgly-UbiquitinG76V::HIS 
MDW 
JSY 
1208 
Def1 del 400-
445 
As JSY568, but with def1 lacking residues 400-445 MDW 
JSY 
1209 
Def1 del 430-
490 
As JSY568, but with def1 lacking residues 430-490 MDW 
JSY 
1210 
Def1 del 480-
520 
As JSY568, but with def1 lacking residues 480-520 MDW 
JSY 
1211 
Def1 del 506-
575 
As JSY568, but with def1 lacking residues 506-575 MDW 
JSY1212 Def1 del 400-
500 
As JSY568, but with def1 lacking residues 400-500 MDW 
JSY 
1213 
Def1 del 400-
600 
As JSY568, but with def1 lacking residues 400-600 MDW 
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JSY1214 Def1 del 500-
600 
As JSY568, but with def1 lacking residues 500-600 MDW 
JSY1215 9xMyc-TEV-
his -Elc1, Ela1 
WT 
MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100, 9xmyc-2xTEV-6xHis at N-terminus of 
Elc1::URA, Ela1::HIS 
MDW 
JSY1216 9xMyc-TEV-
his -Elc1, 
Ela11-250 
MATa  ura3 leu2-3, 112 his3-11,15  trp1-1  ade2-1  
can1-100, 9xmyc-2xTEV-6xHis at N-terminus of 
Elc1::URA, Ela1 1-250::HIS 
MDW 
 
Strains were created for this study by: MDW = Marcus Wilson; MH = Michelle Harreman; 
Michael Taschner = MT. 
 
2.5.2 Generation of Yeast strains 
Yeast Deletions or C-terminal tags were created using a PCR technique. An 
auxotrophic marker gene was amplified, with homology to the start and end (gene 
knockout), or the end of the coding region of interest (Schneider et al., 1995). 1-3µg 
of PCR product was transformed into yeast cells and transformants were selected 
on SD media plates  (amino acid coded for by the auxotrophic marker). Correct 
integration was checked by PCR analysis and Western blotting. 
 
Def1 genomic truncations were created by homologous recombination of PCR 
products (5’- truncation sequence - HA tag - STOP codon – HIS3 selection marker 
- 3’ truncation sequence) into haploid or diploid yeast, and selection on SD plates 
lacking Histidine. The truncations were confirmed by genomic PCR and Western 
blot analysis. Heterozygous diploids were sporulated on sporulation media for 7 
days. Tetrads were partially digested with zymolase and dissected on a Singer 
msm micromanipulator. 
 
Inserting GFP at the N-terminus of Def1 via recombination, without altering the 
DEF1 promoter, created strain JSY1201. The PCR product (5’- homology to 
upstream DEF1 promoter – URA3 selection marker – DEF1 promoter – GFP in 
frame with the beginning of the Def1 coding sequence), created by two-step PCR, 
contained a URA3 resistance cassette 1 kb upstream of the GFP tag. 
 
Strains (JSY1191, 1193-1199 and 1208-1214) were created by inserting, via 
recombination, different versions of DEF1 into the genomic locus in the Δdef1::URA 
strain (JSY568). Strains in which the URA3 marker had been replaced by the 
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relevant version of DEF1 were selected on 5-Fluoroorotic acid. PCR analysis and 
Western blotting we used to check for correct integration. Growth of the strains was 
checked by dilution series growth assays. JSY1190 served as a control for 
experiments with these strains. As described above, the wild-type DEF1 gene was 
integrated into Δdef1::URA (recreating a wild-type DEF1 locus), creating Def1 WT. 
 
Strains JSY1203 1204, 1215 and 1216 were created by homologous recombination 
of PCR products (5’- truncation sequence - STOP codon – HIS3 selection marker - 
3’ truncation sequence) into haploid yeast. The JSY 1207 PCR product was 
created by two-step PCR (5’- truncation sequence -4xglycine-ubiquitin (G76V) - 
STOP codon – HIS3 selection marker - 3’ truncation sequence) and transformed as 
above. Correct integration was confirmed by PCR analysis, and expression by 
quantitative PCR of Ela1 transcript levels and Elc1 co-immunoprecipitation. 
 
2.5.3 Yeast Growth conditions 
Logarithmically growing yeast cells – 0.5x107-3x107 cells/ml - were used for all 
analyses. Typically cells were grown at 30oC, unless otherwise indicated, in YPD 
medium (2.1.2.1) or SD medium (2.1.2.2). Yeast cell density was assessed using a 
Z2 Coulter Particle Count and Size Analyzer (Beckman-Coulter), with particle 
gating from 2.5-7.5 µm. 
 
Table 2.3: Drugs used in Yeast liquid media in this study 
 
Drug Source Solvent used Final concentration 
4-Nitroquinoline 
1-oxide (4-NQO) 
Sigma Acetone 8µg/ml or 
10µg/ml (where indicated) 
Nocodazole Sigma DMSO 15µg/ml 
Leptomycin B Calbiochem Ethanol 100ng/ml 
MG132 Calbiochem DMSO 50µM 
Cycloheximide 
(CHX) 
Sigma DMSO 35µg/ml 
Rapamycin Calbiochem DMSO 200ng/ml 
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6-Azauracil (6-
AU) 
SIgma Water 250µg/ml 
Methotrexate 
(MTX) 
Sigma 100mM Tris 
pH9 
10 µM 
 
Drugs used in this study are listed in Table 2.3, Drugs were added to cells in liquid 
media, with the equivalent volume of solvent added as a minus treatment control.  
 
In the case of proteasome inhibitor MG132 and nuclear export inhibitor Leptomycin 
B, the drugs were added prior to the start of the experiment. MG132 was added 1 
hour prior to the start of the experiment; accumulation of poly-ubiquitylated proteins 
was used as a measure of activity (Figure 6.3 A). Leptomycin B was added 30 
minutes prior to the experiment, and assayed using the control construct NLS-NES-
GFP2 (pPS1372). 
 
2.5.4 UV treatment of cells 
Logarithmically growing yeast cells were harvested at 800g, washed once in saline 
solution (2.1.3.4), and resuspended in 1% of the initial volume (around 109cells/ml). 
The cell suspension was placed in large Pyrex dishes and distributed evenly. Cells 
were exposed to 300J/m2 of 254nm UV light, using a calibrated UV box. The Pyrex 
dishes were washed with saline to gather all yeast, spun down and resuspended in 
the original media. Timepoints were taken where indicated. 
 
2.5.5 Yeast cell transformations 
Yeast cells were grown overnight in the appropriate medium and diluted to early 
logarithmic phase (typically 2-5x106 cells/ml). Cells were allowed to grow until they 
reached a density between 1-2.5x107 cells/ml, harvested by centrifugation and 
washed once in sterile water, followed by a second wash in TE/LiOAc (see 2.1.2.4). 
Cells were resuspended at 109 cells/ml in TE/LiOAc. 50µl of this cell suspension 
was added to PCR product (1-3µg) or plasmid (100ng), 70µg of boiled salmon 
sperm carrier DNA, 35µl of DMSO and 300µl of PEG/TE/LiOAc (2.1.2.5) and 
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incubated for 30 minutes at 30oC. A negative control without PCR DNA was always 
performed. The cell mixture was heat shocked at 42oC for 15 minutes, washed 
once in water and plated. For auxotrophic selection SD plates lacking histidine, 
leucine, tryptophan and/or uracil were used and cells were plated directly. For 5-
FOA selection, cells were plated on YPD agar for 14 hours before replica plating 
onto SD 5-FOA plates. Plates were incubated at 25oC or 30oC until distinct colonies 
could be selected: typically 2-3 days. 
 
2.5.6 Yeast Dilution series growth assays 
Overnight yeast cultures were diluted to early logarithmic phase and allowed to 
grow. Equal numbers of cells were harvested and resuspended in an equal volume 
of sterile water. Ten fold serial dilutions were created, and dilution series from 106 
to 100 cells were spotted linearly on YPD agar or SD agar plates. Multiple plates 
were spotted concurrently with different sugar sources (glucose or galactose) or 
incubated at different temperatures. After growth, the plates were photographed 
using a GelDoc XR (BioRad). 
 
2.5.7 Galactose-induced overexpression in yeast cells. 
Typically the gene of interest was cloned into a vector containing the GAL1 
promoter and CYC1 terminator region (see Table 2.1), to promote galactose 
inducible expression. Cells were grown overnight in SD glucose media lacking the 
selecting amino acid. Cells were harvested and washed twice in sterile water 
before resuspension in SD raffinose media and incubated at 30oC for three hours. 
Galactose was added directly to a final concentration of 2% and the indicated time 
points were taken.  
 
2.5.8 Isolation of genomic DNA 
The MasterPure Yeast DNA purification kit was used to isolate total DNA from 108 
cells, following the manufacturers instructions, typically 0.5µL of resuspended DNA 
was used in subsequent PCR reactions. For quick genomic DNA extraction 107 
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cells were harvested and resuspended in 0.2% SDS and boiled for 10 minutes. 1 µl 
of the supernatant was used in PCR reactions. 
 
2.5.9 Whole cell extracts at sub-zero temperatures and chromatin 
enrichment 
Yeast cells were harvested at 800g and washed once in PBS. Cells were 
resuspended directly in 2 volumes of cold D-buffer (2.1.6.1) or cell lysis buffer 
(2.1.5.1) and drops were added to liquid nitrogen, to create yeast ‘popcorn’. The 
popcorn was either ground by hand using a liquid nitrogen cooled pestle and 
mortar, or disrupted using a freezer mill (Spex CertiPrep). Extent of cell disruption 
was assessed using optical microscopic measurements and grinding stopped when 
90% of cells were disrupted. 
 
Lysis via mechanical disruption at liquid nitrogen temperatures does not 
significantly solubilise chromatin (Kong and Svejstrup, 2002, Takagi et al., 2005a). 
As a result the above extract was spun at high speed (3900g for 10 minutes) and 
the pellet resuspended in D-buffer containing 4mM MgCl2. The extract was 
sonicated (output 30%, 3 cycles 10s), followed by the addition of 2 units of 
Benzonase (Novagen) per ml of extract and incubated at 25oC for 20 minutes. The 
extract was then spun at 3900g for 10 minutes, and the soluble fraction was taken. 
This fraction was now highly enriched for histone proteins. 
 
2.5.10 Alkaline quick whole cell extract preparation 
Whole cell extracts were created essentially as described (Kushnirov, 2000). Briefly, 
1-2x107 cells were pelleted and resuspended in 100mM Sodium Hydroxide for 5 
minutes at room temperature. Cells were pelleted and the supernatant discarded. 
The pellet was resuspended directly in 1.5x SDS loading buffer (2.1.3.9) and 
heated to 99oC for 5 minutes, before placing on ice. Samples were re-heated and 
spun at 14 000g for 1 minute before loading on SDS-PAGE gels. 
 
Chapter 2. Materials and Methods 
 
94 
2.5.11 Whole cell extract via glass bead beating 
3x108 Yeast cells were harvested by centrifugation and washed once in PBS before 
flash freezing in liquid nitrogen. Thawed pellets were resuspended in 700µl D-
buffer (2.1.6.1) and roughly 500µl 0.5mm diameter Glass beads (BioSpec 
Products) were added. The cells were disrupted using a FastPrep-24 cell 
homogenizer (MP Biosystems), using 6 rounds of beating at an intensity of 5.5, for 
30 seconds each. Samples were incubated on ice between disruptions, to reduce 
heating of the sample. The extracts were clarified twice at 20,000g for 10 minutes. 
Protein concentrations for extracts were estimated using the Bio-Rad protein assay 
or Nanodrop, using an extinction coefficient of 50.  
 
2.5.12 S-35 labelling of proteins 
Cells were grown to early logarithmic phase, and transferred to –methionine SD 
media for 30 minutes. Cycloheximide (25 µg/ml) was added at the indicated time 
points, before an S-35 chase was performed. 100nCi of S-35 labelled methionine 
(Perkin-Elmer) was added to the media for 10 minutes, to radioactively label any 
synthesised protein in this time period. 1x107 cells were harvested and washed 
extensively in media containing cycloheximide to remove unincorporated 
methionine and cell extracts created by alkaline quick whole cell extraction 
(Kushnirov, 2000). 
 
 
 
2.6 Protein Techniques 
2.6.1 SDS-PAGE 
Precast 4-12% Bis-Tris gradient polyacrylamide Criterion gels or 3-8% Tris-Acetate 
gradient Criterion gels (BioRad) were commonly used for protein separation. Gels 
were run in Criterion MES, MOPS or Tris-acetate buffer (BioRad) depending on 
protein size and separation required. Electrophoresis was carried out in Criterion 
gel tanks, typically at 180V. 
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Proteins were directly detected by staining the gel with InstantBlue (Expedion) or 
the SilverQuest silver staining kit (Invitrogen) following the manufacturers directions. 
Alternatively, proteins were transferred and subjected to Western blot (see below). 
2.6.2 Western blotting 
After electrophoresis, SDS polyacrylamide gels were incubated in transfer buffer 
(2.1.3.12). H-bond C-extra Nitrocellulose membrane (Amersham) was placed on 
top of the gel and sandwiched between Whatman 3MM paper in a Criterion Blotter 
(BioRad) filled with transfer buffer. Transfer was typically performed for 90 minutes 
at 500mA. After the transfer the membrane was washed briefly in water and then 
stained using Ponceau S solution (Sigma-Aldrich) and the image scanned, to 
confirm transfer and loading. The membrane was then washed in PBS and blocked 
in PBS TWEEN (2.1.3.3) containing 5% milk powder (Marvel) for 1-16 hours. 
 
Blotted proteins were detected using primary antibodies listed below (Table 2.4) at 
the stated dilutions in either 5% or 1% milk powder or 3% BSA, typically overnight 
at 4oC. After the initial incubation the membrane was washed three times, for 10 
minutes each, in PBS TWEEN. Membranes were incubated with the appropriate 
secondary antibody: anti-rabbit HRP (GE Healthcare), 1:10,000; anti-mouse HRP 
(GE Healthcare), 1:10,000; anti-mouse TrueBlot HRP (eBioscience), 1:1000; anti-
rabbit TrueBlot HRP (eBioscience), 1:1000. The secondary antibody was incubated 
for 1 hour at room temperature, followed by three 10-minute washes in PBS 
TWEEN. The membranes were then incubated with SuperSignal Pico or Dura ECL 
reagents (Thermo Scientific) for 5 minutes and exposed to Amersham Hyperfilm 
ECL. 
 
Figures were created using linear exposures - scanned using an Epson perfection 
V700 PHOTO scanner set at 720dpi at 24-bit colour. To quantify gel bands ImageJ 
v1.44 (W. Rasband, NIH) was used as per program specifications. 
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Table 2.2: Western blot antibodies used in this study 
 
Antibody Epitope Source Supplier Dilution 
4H8 Rpb1 CTD Mouse, m In house 1: 10,000 
8WG16 Rpb1 CTD Mouse, m In house 1: 1,000 
9E10 Myc tag Mouse, m In house 1: 5,000 
9E11 Myc tag Mouse, m In house 1: 5,000 
α-Pgk1 Pgk1 Mouse, m Invitrogen 1: 10,000 
α-His 6xHis Mouse, m Clonetech 1: 1,000 
12CA5 HA tag Mouse, m Abcam 1:1,000 
α-Ela1 Ela1 115-214 Mouse, p Abcam 1:1,000 
P4D1 ubiquitin Mouse, m Millipore 1:1,000 
1Y26 Rpb3 Mouse, m Abcam 1:1,000 
α-Def1 Def1388-738 Rabbit, p This study 1:1,000 
m=monoclonal 
p=polyclonal 
 
2.6.3 Analysis of pr-Def1 
pr-Def1 was visualised via Western blot using an anti-Def1 antibody or tag specific 
antibody, where indicated. The antibody exhibits increased specificity for this lower 
processed band. Def1 was always visualised immediately after the experiment, and 
using the quick whole cell extract method (2.5.10). 
 
2.6.4 Analysis of ubiquitylated proteins ex vivo 
Poly-ubiquitylated substrate enrichment assays were performed using multiDsk 
conjugated to GST beads (GE healthcare)(2.7.2). Typically, 2 mg of yeast protein 
extract in 750 µl was incubated with 15 µl of this resin (60µg protein) for 2 hours at 
4˚C before beads were extensively washed with D500-buffer (2.1.6.3), and with 
D50-buffer (2.1.6.4). Beads were resuspended in 1.5x SDS loading buffer and 
subjected to SDS-PAGE. In order to ascertain ubiquitin depletion, ubiquitin specific 
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antibodies were used (Table 2.4). In order to visualise individual ubiquitylated 
proteins, specific antibodies were used. 
 
For the protection assay, yeast extract was incubated with MultiDsk at 30˚C for the 
indicated times, and then resuspended directly in SDS loading buffer prior to SDS-
PAGE and Western blotting as above. 
 
2.6.5 Immunoprecipitations (IPs) 
Extract was prepared using either glass bead beating (2.5.11), or mechanical 
grinding at liquid nitrogen temperatures (2.5.9). Extracts were derived from strains 
JSY1199, 1198, 1116, 1202, 1206, 1215 and 1216, and UV-irradiated 1 hour prior 
to harvesting. Typically immunoprecipitations were performed with 15µl Protein A/G 
antibody cross-linked agarose beads (2.7.1). Typically 3.5mg of extract was used, 
in a total volume of 750µl (JSY1199, 1198 and 1206), and 20mg was used in a total 
volume of 13ml (JSY 1116, 1202, 1215 and 1216). IPs were incubated at 4oC for 
two hours and washed 3 times in D250-buffer (2.1.6.2) and once in D50-buffer 
(2.1.6.4.), before directly resuspending in 1.5x SDS loading buffer (2.1.3.9) and 
separated by SDS-PAGE. In order to remove the background signal from Antibody 
heavy and light chain upon Western blotting, TrueBlot secondary antibodies were 
used. 
 
 
 
2.7 Protein Purification 
2.7.1 Antibody cross linking to beads 
Cross-linking was performed as described (Harlow and Lane, 1999). Briefly, an 
equal mix of Protein A and Protein G Agarose beads (Pierce) were incubated with 
3-5mg of antibody/ml of resin overnight at 4oC. Beads were washed extensively 
with PBS and Borate buffer before coupling at room temperature for one hour using 
dimethylpimelidate. Incubating the beads with 1M Tris pH9 stopped the reaction, 
and beads were washed with PBS. The beads were stored as a 4x slurry in PBS 
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with 0.01% Sodium azide, at 4oC. Cross-linking was checked via detection of only 
the light antibody chain in SDS-PAGE. 
 
 
 
 
Figure 2.1: InstantBlue stained gel slices of Proteins purified in this study  
 
Asterisks indicate minor unidentified contaminants. Proteins in a complex are labelled. MultiDsk 
and Ela1 C-terminal deletions are included elsewhere (Figure 3.1 & Figure 7.5) 
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2.7.2 MultiDsk purification 
MultiDsk expression plasmid pGST-MD was propagated in BL-21 (DE3) cells, 
selected via ampicillin and expressed as above (2.4.3). Cells were lysed and 
protein solubilised essentially as described (Frangioni and Neel, 1993). Briefly, 
thawed pellets were resuspended in STE buffer with lysozyme (100µg/ml). After 15 
minutes on ice N-lauryl sarcosine was added to a final concentration of 1.5%, to 
denature all proteins. After brief sonication (20% output 4 cycles15s on) and 
centrifugation at 10 000g 5 minutes, Triton X-100 was added to the supernatant to 
a final concentration of 3%. The Triton (added at a w:w ratio of 1:8) masks the 
sarcosine by forming mixed micelles (Dekker et al., 2002). Pre-equilibrated 
glutathione agarose beads (GE healthcare) were added and the slurry incubated 
for 2-4 hours at 4˚C. The beads were washed thoroughly in MultiDsk wash buffer 1 
(2.1.4.2), followed by a low salt wash (2.1.4.3). For most purposes the protein was 
left bound to beads, stored as a 4x slurry in PBS +0.01% Sodium azide, at 4oC. 
The protein was eluted by incubating the resin overnight in GST elution buffer 
(2.1.4.7) (4 ml elution buffer per ml resin). The purified protein was then dialysed in 
Dialysis buffer 2 (2.1.4.15). 
 
2.7.3 Standard GST-Glutathione purifications 
Glutathione-S-Transferase (GST), GST-Ubiquitin, GST-Ubiquitin I44A, GST-
Ela1250-379 and GST-Dsk2 were all purified using the same protocol, after 
recombinant overexpression (2.4.3). Cells were lysed via sonication (30% output 6 
cycles 15s on) in GST lysis buffer (2.1.4.4) containing lysozyme (100µg/ml). The 
extract was clarified at high speed and pre-equilibrated glutathione agarose beads 
(GE healthcare) were added and incubated for 4 hours at 4˚C. The slurry was 
washed first in batch, and then on column with 100CV of GST wash buffer 
1(2.1.4.5) followed by 50CV of GST wash buffer 2 (2.1.4.6). SDS-PAGE gels 
stained with InstantBlue, using BSA as a standard, estimated purity and protein 
concentration. GST-Dsk2 protein was cleaved and eluted using overnight FactorXa 
cleavage (GE healthcare), and dialysed in Dialysis buffer 1 (2.1.4.14) 
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2.7.4 Rsp5 purifications 
GST-Rsp5 and GST-Rsp5 C777A were purified after recombinant overexpression 
(2.4.3). Cells were lysed in GST lysis buffer (2.1.4.4) containing lysozyme 
(100µg/ml), via sonication (30% output 6 cycles 15s on). The extract was clarified 
at high speed and pre-equilibrated glutathione agarose beads (GE healthcare) 
were added and incubated for 2-4 hours at 4˚C. The slurry was washed first in 
batch, then on column with 100CV of GST wash buffer 1(2.1.4.5) and then 50CV of 
GST wash buffer 2 (2.1.4.6) before elution overnight in GST elution buffer (2.1.4.7). 
 
2.7.5 RNAPII purification 
Rpb1-3xHA or Rpb3-FLAG RNAPII was purified essentially as described (Cramer 
et al., 2001). Briefly 100l of yeast cells (JSY919 or 951) were lysed via ball milling 
and clarified. Extract was passed over a heparin column, eluted with high salt and 
salted out using ammonium sulphate. The pellet was resuspended and bound to an 
Rpb1 CTD specific, 8WG16 column (2.7.1) for 4 hours at 4oC. RNAPII was eluted 
using high glycerol and the protein containing fractions were loaded onto an anion 
exchange, Mono Q (GE healthcare) column. 
2.7.6 Full-length Def1 purification 
Pure, full length Def1 was purified as a side fraction from the final Mono Q stage of 
RNAPII purification (2.7.5) 
 
2.7.7 Def1 1-500 purifications 
Def1 1-500 and 1-500/CUEm were purified after recombinant overexpression 
(2.4.3). Cells were lysed in Nickel lysis buffer (2.1.4.4) containing lysozyme 
(100µg/ml), via sonication (30% output 6 cycles 15s on). The extract was clarified 
at high speed and pre-equilibrated Nickel-NTA beads (Qiagen) were added and 
incubated for 4 hours at 4˚C. The slurry was washed first in batch, then on column 
with 150CV of Nickel wash buffer (2.1.4.10) before elution using imidazole, in 
Nickel elution buffer (2.1.4.11). Eluate was diluted by two to reduce salt and 
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imidazole levels and bound to pre-equilibrated glutathione agarose beads (GE 
healthcare) for 2-4 hours at 4˚C. The slurry was washed with 75CV of GST wash 
buffer 1(2.1.4.5) and then 10CV of GST wash buffer 2 (2.1.4.6) before proteolytic 
elution overnight using Turbo 3C protease (AG Scientific Inc.) (50ng/ml of resin) in 
HRV 3C buffer (2.1.4.8). Eluted protein was finally concentrated by Nickel affinity 
chromatography, as above. The resulting proteins were dialysed in Dialysis buffer 1 
(2.1.4.14). 
 
2.7.8 Ubc5 purification 
Yeast Ubc5 was purified after recombinant overexpression (2.4.3). Cells were lysed 
in Nickel lysis buffer (2.1.4.4) containing lysozyme (100µg/ml), via sonication (30% 
output 6 cycles 15s on). The extract was clarified at high speed and pre-
equilibrated Nickel-NTA beads (Qiagen) were added and incubated for 4 hours at 
4˚C. The slurry was washed first in batch, then on column with 150CV of Nickel 
wash buffer (2.1.4.10) before elution using Imidazole in Nickel elution buffer 
(2.1.4.11) 
 
2.7.9 Elc1-Ela1 purifications 
His-Elc1-Ela1 complex was induced in BL-21 DE3 E.coli cells, using 0.5mM IPTG 
at 25oC for 4 hours. Cells were lysed in Nickel lysis buffer (2.1.4.4) containing 
lysozyme (100µg/ml), via sonication (30% output 6 cycles 15s on). The extract was 
clarified at high speed and pre-equilibrated Nickel-NTA beads (Qiagen) were added 
and incubated for 4 hours at 4˚C. The slurry was washed first in batch, then on 
column with 150CV of Nickel wash buffer (2.1.4.10) before elution using Imidazole 
in Nickel elution buffer (2.1.4.11). The eluate was diluted by two – in order to 
reduce the Imidazole and salt concentration.  The proteins were then cleaned 
through a Mono Q (GE healthcare) column; Elc1-Ela1 complex does not bind to 
Mono Q resin. The flow through was loaded onto a cation exchange Mono S 
column, washed with 5CV of Mono S buffer A (2.1.4.12) and eluted using a salt 
gradient with Mono-S buffer B (2.1.4.13). Heterodimer containing fractions were 
dialysed in Dialysis buffer 1 (2.1.4.14). 
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Ela1 C-terminal deletions (Ela11-150, Ela11-250, Ela11-300, Ela11-350) were purified 
similarly to the full-length protein in a heterodimer with Elc1. The complexes eluted 
at a lower salt concentration on the Mono-S column to the full-length protein, but 
otherwise expressed and behaved identically. 
 
2.7.10 Ubp2 purification 
Ubp2 was purified from strain JSY1125, where Ubp2 and Rsp5 are tagged at their 
genomic locus. Cells were broken open in cell lysis buffer (2.1.5.1) by ball milling, 
followed by a clarification centrifugation. The supernatant was loaded onto 
9E10/9E11 conjugated antibody column (2.7.1), at a rate of 0.2ml/min. The column 
was washed thoroughly in 50CV of myc wash buffer (2.1.5.2) and 20CV of myc 
wash buffer 2 (2.1.5.3). Bound proteins were eluted by overnight TEV protease 
cleavage (produced by the Protein Production facility, London Research Institute) 
in TEV cleavage buffer (2.1.5.4) (50ng of TEV protease/ml of beads). Eluted Ubp2 
still contained a C-terminal 6xHis tag. Contaminating Rsp5 was removed by 
incubation of the cleaved supernatant with M2 agarose FLAG-beads (Sigma). Rup1 
bridging factor co-purified with Ubp2 at stoichiometric levels, as has been observed 
previously (Kee et al., 2005). 
 
2.7.11 Proteasome purifications 
26S and 20S proteasomes were purified essential as described (Verma et al., 
2000), using a FLAG-HIS tagged Pre1 strain (RJD1144). Briefly, 20l of yeast cells 
were grown and lysed in the freezer mill. Clarified supernatant was mixed with anti-
Flag M2 agarose (Sigma) for 4 hours at 4oC. Beads were washed extensively in 
physiological salt and 5mM MgCl2 containing buffer, and eluted in 4CV of the same 
buffer with 200µg/ml 3xFLAG peptide. Critically to ensure intact 26S proteasome 
5mM ATP was used in all buffers, in the 20S purification this was omitted. 
Proteasome activity was checked via an immunogenic peptide assay. 
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2.7.12 Protein concentrations 
Protein concentration estimations were performed using a Bradford assay (Bio-Rad 
protein assay), whereby 20µl of protein added to 1ml of diluted Bradford reagent 
and incubated for 5 minutes. The reaction was visualised on an ultraspec 110 pro 
spectrophotometer at A595, if the reading was in the linear range (0.1-0.7), this was 
taken as the approximate concentration of protein in mg/ml. More accurate 
estimates were then performed by running the pure protein on SDS-PAGE and 
InstantBlue staining; the stained protein band was compared with known BSA 
standard. 
 
For proteins with unusual Bradford reactions and InstantBlue stain (i.e Def1), 
concentration measurements were further performed with NanoDrop 
measurements using a calculated extinction coefficient (Protparam 
http://web.expasy.org/protparam/). 
 
2.7.13 Dialysis 
Purified proteins were dialysed in Slide-a-lyzer Dialysis cassettes (Pierce) with a 
molecular cut off of 10,000 Da, into either Dialysis buffer 1(2.1.4.14) or 2 (2.1.4.15). 
Cassettes were resuspended in a volume equal to 300 times the cassette volume. 
The buffer was replaced three times and dialysed for 2 hours each. 
 
 
 
2.8 In vitro Biochemistry 
2.8.1 Ubiquitylation assays 
Def1 and RNAPII Ubiquitylation assays were performed essentially as described 
for RNAPII ubiquitylation (Somesh et al., 2005) using purified components. Briefly, 
all components (below) were added to U-buffer at a final volume of 40µl (2.1.6.8) 
and incubated at 30oC for 90 minutes. The reaction was stopped upon addition of 
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5x SDS-PAGE running buffer (2.1.3.10) to the reaction, and proteins resolved via 
SDS-PAGE and detected by Western blotting. 
 
 
E1 rUba1 0.3 pmol Boston Biochem 
E2 yUbc5 2 pmol 2.7.8 
E3 GST-Rsp5 50 nmol 2.7.4 
Ubi yUbiquitin 250 pmol Boston Biochem 
 hUbiquitin No lysines 250pmol  
DUB Ubp2 5 pmol 2.7.10 
Substrate Def1 20 pmol 2.7.6 
 RNAPII 20 pmol 2.7.5 
 
Mono-ubiquitylated RNAPII was purified away from the ubiquitylation components 
by first depleting GST-Rsp5 using glutathione beads. This was followed by 
separation from non-ubiquitylated RNAPII using anion exchange mini Q column 
chromatography (GE Healthcare) 
 
2.8.2 Proteasome processing assays 
In vitro proteasome assays were performed in P-buffer (2.1.6.5) at 30oC or 4oC, 
where stated. Purified yeast 26S and 20S proteasome (10nM) were added to 
reactions with Def1 or ubiquitylated Def1 (2.8.1) (1.5 µM). MG132 was used to 
inhibit the proteasome at concentrations of 10 µM or 100 µM and lactacystin at 50 
µM, where indicated. Pure RNAPII (2.7.5) or mono-ubiquitylated RNAPII (2.8.1) 
was added at ten-fold molar excess to Def1 (150 µM). The reaction was initiated 
upon the addition of Def1 and stopped by addition of 5xSDS page loading buffer 
(2.1.3.10) at the indicated times. Proteins were then resolved via SDS-PAGE and 
detected by Western blotting. The proportion of Def1 converted to processed bands 
was assessed as the amount of upper band remaining, quantified by ImageJ (see 
2.6.2). 
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2.8.3 Ubiquitin chain binding assay 
The poly-ubiquitin chain-binding assay was performed essentially as described in 
(Anindya et al., 2010). 20µl of GST, GST-Dsk2 or GST-multiDsk (200µg total each) 
were washed in Binding buffer (2.1.6.6). 400µl of B-buffer with 50µg/ml of either 
Lys-48 or Lys-63 linked ubiquitin chains (Enzo) were incubated with the beads for 2 
hours at 4oC. The beads were washed three times in B-buffer and resuspended 
directly in 1.5x SDS-PAGE loading buffer (2.1.3.9) 
 
2.8.4 Ubiquitin binding assay 
15µl of GST, GST-Ubiquitin, GST-ubiquitin I44A or GST-Ela1250-379 (2.7.3)(100µg 
total each) were washed in B-buffer (2.1.6.6). 700µl of B-buffer with 55µg/ml of 
either recombinant Def1 1-500 or recombinant Def1 1-500/CUEm (2.7.7) were 
incubated with the beads for 2 hours at 4oC. The beads were washed three times in 
B-buffer and resuspended directly in 1.5x SDS-PAGE loading buffer (2.1.3.9). 
 
2.8.5 Elc1-Ela1 binding assays 
Def1 1-500, Def1 1-500/CUEm (2.7.7) and Dsk2 (2.7.3) were immobilised on 
Affigel-15 as per the manufacturers instructions, at a concentration of 2 µg/µl. The 
UBDs of RAP80 and Ataxin-3 (Boston Biochem) were similarly cross-linked to 
Agarose beads, and diluted using empty quenched Affigel-15 beads to 2µg/µl. 
Empty Affigel-15 beads - with cross-linker blocked by ethyl-ethanolamine - were 
used as empty bead controls. 
 
Pure recombinant His-Elc1-Ela1 proteins (2.7.9) were incubated with 15µl of pre-
blocked Affigel-protein beads, in 700µl of BP-buffer (2.1.6.7) with 55µg/ml of 
recombinant heterodimer complexes. After a two-hour incubation, beads were 
washed three times in BP-buffer and directly resuspended in 1.5x SDS-PAGE 
loading buffer (2.1.3.9). 
 
For the ex vivo ubiquitin binding assay (Figure 7.4 B) extracts were prepared from 
chromatin (2.5.9) from strain JSY1116, one hour after UV damage. 8mg of extract 
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was incubated in 700µl of D-buffer (2.1.6.1), at 4oC for two hours and washed 3 
times in D250-buffer (2.1.6.2) and once in D50-buffer (2.1.6.4.), before directly 
resuspending in 1.5x SDS loading buffer (2.1.3.9) and separated by SDS-PAGE. 
 
2.8.6 RNAPII binding assays 
Mono-ubiquitylated RNAPII-3HA was created as described (2.8.1). Control RNAPII-
3HA was not ubiquitylated, by omitting ubiquitin in the reaction. 20 pmol of RNAPII 
in U-buffer (2.1.6.8) was bound to 15µl of anti-HA affinity matrix (Roche) for 1 hour 
at 4oC, before washing once in U-buffer and twice in BP-buffer (2.1.6.7). Pure 
recombinant His-Elc1-Ela1 (30µg/ml) (2.7.9), Def1 1-500 and Def1 1-500/CUEm 
(35µg/ml) (2.7.7) were added to a total volume of 700µl in BP-buffer. Proteins were 
incubated with the beads at a 20 molar excess to RNAPII, for 2 hours at 4oC. 
Bound complexes were washed three times in BP-buffer, before directly 
resuspending in 1.5x SDS loading buffer (2.1.3.9). 
 
 
2.9 Fluorescence microscopy 
Cells were grown to logarithmic phase and, where appropriate, treated with drugs 
(2.5.3) or UV irradiated (2.5.4) as described previously. Where indicated (Figure 
6.8 & Figure 6.7) cells were fixed for 30 minutes at their reaction temperature, 
using 3.75% Formaldehyde. 10mM Tris pH 8 was added to media 1 hour prior to 
visualisation, to enhance GFP fluorescence. 
 
Typically 5x106 cells were harvested at no greater than 800g, and washed once in 
sterile water. Cell pellets were incubated with 20µl of Vectashield containing 4',6-
diamidino-2-phenylindole (DAPI) (Vector laboratories) for five minutes before 1µl 
was added to 1% Agar on microscope slides (for technique see yeast resource 
centre http://depts.washington.edu/yeastrc/pages/plasmids_protocols.html). 
Coverslips were immediately applied and sealed using Nail varnish (Revlon). 
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Cells were visualized on a DeltaVision workstation (Image Solutions), using an 
X100 UplanSApo 1.40 NA oil objective lens on an Olympus inverted microscope 
(IX71). Images were acquired and deconvolved using SoftwoRX software (Applied 
Precision), using 5 iterations with low noise reduction. 
 
Assessment of Def1 nuclear localisation was scored by eye, when there was 
convincing overlap between green GFP signal and Blue nuclear DAPI stain. Only 
cells with positive nuclear DAPI stain were counted. Quantification was performed 
in Excel (Microsoft) and Prism (GraphPad Software). 
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Chapter 3. Results I 
MultiDsks: A Ubiquitin Specific Affinity Resin 
 
3.1 Aims 
 
Post-translational modification by ubiquitin has emerged as an extremely common 
event resulting in multiple cellular fates (see Introduction 1.1). Studying protein 
ubiquitylation ex vivo has been hampered by two key technical limitations: the 
difficulty in achieving high affinity enrichment of native ubiquitylated proteins and 
the transient nature of the modification in extracts. 
 
Ubiquitylated proteins are subject to rapid proteasomal degradation and aberrant 
de-conjugation of ubiquitin by intracellular de-ubiquitylating enzymes (DUBs), 
exposed upon cell lysis (Finley et al., 2012). To counteract this problem, chemical 
inhibitors of ubiquitin proteases have commonly been used in cell lysis buffers, to 
reduce unwanted, non-targeted, loss of ubiquitin from target proteins. These 
inhibitors are non-specific, short-lived in aqueous solutions, only partially inhibit 
ubiquitin proteases, and can cause aberrant covalent modifications. One inhibitor, 
Iodoacetamide, has been reported to create covalent modifications on protein 
substrates that could be confused with ubiquitin remnants on digested peptides 
(Nielsen et al., 2008). Whilst the majority of DUBs are cysteine proteases, the 
Rpn11 subunit of the proteasome is a Zinc-metalloprotease (Verma et al., 2002), 
not inactivated by the majority of inhibitors used. Alternatively, lysates can be 
prepared under denaturing conditions, thereby inactivating any protease activity. 
However, this renders these proteins unusable for further extracellular assays. 
 
Enrichment of ubiquitylated proteins from cells has been performed using a number 
of different methods, each with problematic technical caveats. N-terminal tagging of 
ubiquitin and using a tag-specific affinity resin allows efficient depletion of tagged 
ubiquitin and any conjugated proteins. However, this requires the tricky 
replacement of all ubiquitin in the cell with the tagged version (for example, yeast 
have several genes encoding ubiquitin precursors), or risk competition from the 
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abundant endogenous form of the protein (Ziv et al., 2011). It is also conceivable - 
considering the small size and many possible modifications of ubiquitin - that the 
addition of any tag may perturb the function of the molecule in vivo. Nevertheless 
multiple proteomic and targeted studies have utilised N-terminally His-tagged 
ubiquitin (Peng et al., 2003, Kirkpatrick et al., 2005, Jeon et al., 2007), a small tag 
with the benefit of allowing the experiments to be carried out under denaturing 
conditions. High background and concerns over artefactual effects of ubiquitin 
overexpression has resulted in an increased use of strategies that utilise 
endogenous ubiquitin. 
 
As an alternative to ubiquitin-tagging, ubiquitin specific antibodies may be used to 
deplete ubiquitin from extracts. However, such antibodies have proven to be of low 
affinity and show specificity for certain chain subtypes (Newton et al., 2008). 
Recent studies have made use of GG-peptide antibodies (Wagner et al., 2011, Kim 
et al., 2011), which have proven useful to identify ubiquitylated proteins after trypsin 
digestion. 
 
Isolation of native, un-modified ubiquitylated proteins has relied upon using 
ubiquitin-binding domain (UBD) containing proteins, typically fused to GST (Layfield 
et al., 2001). Using a complete UBD protein can bias the recruitment to mono- or 
linkage-specific ubiquitylated proteins (Raasi et al., 2005, Funakoshi et al., 2002) 
and has been shown to exhibit high background – due to interaction with non-
ubiquitylated proteins (Kang et al., 2007). Moreover, the affinity of ubiquitylated 
substrates for UBDs is low (Kd ≈ 15-500µM) (Hurley et al., 2006). Furthermore, 
immobilised GST-Dsk2 protein, for example, is unstable, degrading entirely - even 
in its purified form - within two weeks at 4oC. 
 
In a recent paper (Hjerpe et al., 2009), the authors produced a recombinant protein 
comprised of 4 ubiquitin binding domains in tandem (termed TUBEs). Not only did 
the TUBE-1 protein bind ubiquitin with high avidity, but it could also be used to 
protect ubiquitylated proteins from ubiquitin-specific proteases in cell extracts. 
Unfortunately, TUBEs are only available commercially, limiting their usefulness. 
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Inspired by the TUBEs paper we decided to create a higher affinity, freely available 
tool to help study protein ubiquitylation, namely a high-avidity, ubiquitin-specific 
affinity resin, hereafter called MultiDsk. 
 
 
3.2 Results 
 
3.2.1 Creation and purification of the MultiDsk resin 
 
The artificial MultiDsk protein relies on the ubiquitin affinity of multiple UBDs. The 
UBA domain, from the C-terminus of the ubiquitin-binding protein Dsk2, was 
chosen. Dsk2 helps to target poly-ubiquitylated proteins to the proteasome for 
degradation (Saeki et al., 2002); through binding ubiquitylated substrates via its 
UBA domain, and to the proteasome via an N-terminal ubiquitin homology domain 
(Elsasser et al., 2002). The UBA UBD of Dsk2 has been well characterised (Raasi 
et al., 2005, Ohno et al., 2005), and exhibits relatively high affinity, of approximately 
15µM to mono-ubiquitin (Ohno et al., 2005). Our laboratory has previously used the 
GST tagged full-length Dsk2 protein to enrich ubiquitylated proteins from extracts 
(Anindya et al., 2007, Harreman et al., 2009). The engineered MultiDsk protein 
instead consists of five Dsk2 UBA domains in tandem, each separated by a 7-
amino acid flexible linker. An N-terminal GST tag and a C-terminal 6xHis tag were 
included to ease purification and allow the protein to be immobilised (Figure 3.1A). 
By obtaining a codon-optimised version of the sequence (GenScript USA, Inc.), we 
hoped to achieve higher levels of bacterial expression, aiding purification. 
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Figure 3.1: Schematic and purification of MultiDsk 
 
A. Schematic representation of the MultiDsk protein, including primary sequence of one 
Ubiquitin binding repeat, including the 7-amino acid spacer section (lower case). 
B. MultiDsk protein is insoluble under native cell lysis conditions. E.coli post-induction cell 
pellets were resuspended in STE buffer supplemented with the indicated chemicals. A sample 
was taken before and after the cells were lysed using extensive sonication and lysozyme 
treatment. Gel was stained with InstantBlue. WCL- whole cell lysate; Sup- supernatant after cell 
lysis. 
C. MultiDsks were purified as described in Materials and Methods (2.7.2). Gel was stained with 
InstantBlue. Molecular weight marker positions on the left are in kDa. In-Input; FT- flow-through. 
 
 
MultiDsk expression studies were performed to maximise protein yields (data not 
shown). Under a wide range of temperatures, induction times, and IPTG 
concentration, the protein was expressed extremely well. However, the expressed 
protein was consistently found to be insoluble under native cell lysis conditions 
(Figure 3.1 B). We therefore used mild denaturing conditions to solubilise the 
protein, found almost exclusively in inclusion bodies. Instead of harsh, urea-based 
denaturation - which cannot be rapidly reversed - the bacterial cells were first 
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solubilised with sarcosyl. Sarcosyl coats the hydrophobic core of proteins in a 
similar manner to SDS (Frangioni and Neel, 1993, Dekker et al., 2002). The extract 
- including MultiDsk protein - was then refolded by removing the denaturant, by 
forming mixed triton-sarcosyl micelles (Frangioni and Neel, 1993). Using this 
approach, both the Dsk2 binding domains (as tested by the ability to bind 
ubiquitylated proteins) and the N-terminal GST protein (as judged by its ability to 
bind to glutathione resin) refolded properly. Despite denaturation-renaturation 
process leading to a 50% loss of starting MultiDsk protein (Figure 3.1 C, Flow-
through), yields of around ~15 mg of active, pure protein per litre of bacteria culture 
were routinely obtained (Figure 3.1 C). Where appropriate, MultiDsk protein was 
eluted using reduced glutathione from the resin and dialysed before use. However, 
MultiDsk protein, immobilised on glutathione beads, was highly pure and stable, 
retaining activity for at least 6 months upon storage at 4oC. 
 
 
3.2.2 MultiDsks can deplete all ubiquitylated proteins from extract 
 
We next tested the ability of pure immobilised MultiDsk protein to enrich 
ubiquitylated proteins from yeast extracts. In order to ease visualisation, and to 
prevent any chain linkage specificity imparted from a ubiquitin antibody, we 
commonly utilised a yeast strain where the only copy of ubiquitin is His-Myc tagged 
(SUB592, from Spence et al., 2000). To ensure that the tag was not affecting 
ubiquitylation or MultiDsk association wild-type extracts were also used, where 
indicated. 
 
Upon GST pull-down, a strong signal was observed for poly-ubiquitylated - low to 
high molecular weight - ubiquitin conjugates when MultiDsk was coupled to beads, 
but not when using GST alone (Figure 3.2 A, compare lane 2 to lanes 4,6,8,10,12). 
The amounts of total immobilised protein and bead volume were kept constant 
throughout this experiment, by supplementing GST protein for MultiDsk protein, to 
yield the final MultiDsk concentration stated. Depletion of ubiquitylated proteins by 
MultiDsk exhibited a clear concentration dependence; only relatively modest 
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amounts of MultiDsk protein was required to remove ubiquitylated proteins from the 
extract. At a concentration of 1.6-3.2 µM, virtually all ubiquitylated proteins were 
depleted from the extract (Figure 3.2 A compare input, lane 1, with the flow 
throughs in lane 3, lane 11, and lane 13). The MultiDsk resin binds efficiently to 
ubiquitylated proteins in extracts from a number of different organisms (Wilson et 
al., 2012 and Marco Saponaro and Gabriele Piergiovanni, personal 
communication): a testament to the high conservation of ubiquitin between species. 
Fascinatingly, the resin exhibits high avidity, specifically towards ubiquitin. 
Immunoblots using antibodies raised against NEDD8 and SUMO, which are 
Ubiquitin-like proteins, did not show any appreciable enrichment from extracts (data 
not shown). These experiments were performed using yeast extracts; it remains to 
be seen whether this would also be case in more complex organisms with a greater 
number of ubiquitin-like proteins. 
 
Each ubiquitin in a chain can be modified on 7 internal lysine residues and its N-
terminal methionine, creating a vast array of different possible chain linkages. 
Different ubiquitin-binding proteins can bind different ubiquitin chain conformations 
(see introduction, 1.1.3). This specificity permits the different fates of different 
ubiquitylated proteins to be read through a ‘ubiquitin code’ (Komander and Rape, 
2012). Importantly, MultiDsk resin can deplete all ubiquitylated proteins from 
extracts (Figure 3.2 A lane 13 Flow through), regardless of chain linkage. It was 
imperative to investigate whether MultiDsk was capable of enriching all 
ubiquitylated species more or less equally, to ensure that specific linkages were not 
over-represented in the final pull-down. Full-length Dsk2 protein has previously 
been shown to have some specificity for Lys-48 linked poly-ubiquitin chains 
(Funakoshi et al., 2002). In contrast, MultiDsk does not appear to discriminate 
between chain topologies, at least for pure Lys-48 and Lys-63 poly-ubiquitin chains 
(Figure 3.2 B). Compared to the inputs, the enrichment of the isolated chains 
appears to be equal. The apparent discrepancy of levels between Lys-48 and Lys-
63 chains observed is due to the ubiquitin-blotting antibody used displaying a far 
higher affinity for Lys-63 linked chains than for Lys-48 chains. This is clear from the 
difference between the Ponceau-S detected protein loading and the Western blot 
inputs shown and has already been documented by the manufacturers (Enzo). 
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Figure 3.2: MultiDsk binds efficiently to ubiquitylated proteins 
 
A. 2 mg of yeast whole cell lysate from strain SUB592 expressing Myc-His-tagged ubiquitin was 
incubated with glutathione affinity beads. Differing amounts of GST protein, alone or as a 
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mixture with GST-MultiDsk protein were mixed with agarose beads so that equal amounts of 
total protein and bead bed volumes were used in each experiment. The flow-through not bound 
to the beads was retained and loaded at equivalent levels to the Input (Lane 1). After 
electrotransfer, the membrane was stained with Ponceau S to reveal total protein in samples 
(lower panel), and Western blot was performed using anti-Myc antibodies to detect ubiquitylated 
species (upper panel). 
B. GST alone, full length GST-Dsk2 protein, or MultiDsk, bound to beads, were incubated with 
20 µg of synthetic Lys-48 or Lys-63 linked ubiquitin chains for 2 hours. After Western transfer, 
the membrane was stained with Ponceau S to reveal total protein in samples (lower panel), and 
Western blot was performed using anti-ubiquitin antibody (P4D1) to detect ubiquitylated species 
(upper panel). 
 
 
Similarly, MultiDsk does not show obvious preference for mono-ubiquitin over short 
poly-ubiquitin chains. The ubiquitin chains purchased are of variable length, due to 
the inefficiency of coupling. Roughly equal levels of free single ubiquitin are 
enriched in vitro compared to chains of 5-6 ubiquitin moieties (Figure 3.2 B 
compare lanes 1 and 4, 5 and 8). This is in stark contrast to the immobilised full-
length Dsk2 protein, which does not interact very well with free unconjugated 
ubiquitin (Figure 3.2 B compare lanes 5 and 7), and has previously been shown to 
underestimate mono-ubiquitylated protein levels in extracts (Zhang et al., 2009). 
 
 
3.2.3 MultiDsks can protect ubiquitin chains 
 
The MultiDsk resin is able to isolate virtually all ubiquitylated proteins from a cell 
extract. Relatively little protein was required, suggesting MultiDsk displays a high 
avidity for ubiquitin chains. The binding of ubiquitylated protein by MultiDsk is 
stable in both high salt and detergent (Figure 3.3 C), and is almost as stable as the 
GST-glutathione interaction. As a principally hydrophobic binding (Ohno et al., 
2005, Lowe et al., 2006), the binding surface of Dsk2 UBA domain and ubiquitin is 
large. This, coupled with the high affinity of interaction between MultiDsk and 
ubiquitin, led us to postulate that the resin might help to sterically block, and 
prevent the action of, yeast DUBs in the extract. To assess the ability of MultiDsk to 
protect poly-ubiquitin chains from de-ubiquitylation and degradation we incubated 
protein in crude extracts at physiological 30oC temperature (Figure 3.3 A).  
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Figure 3.3: Protection of poly-ubiquitin chains in extract 
 
A. Extract from strain SUB592 was incubated with equivalent amounts of GST, GST-Dsk2, 
commercially available TUBE-1, and MultiDsk (1.6 µM) and incubated at 30˚C for the indicated 
time. Total protein extracts were subject to Western blot and probed using anti-myc antibody. 
B. As (A), except using wild-type cells and probing using a ubiquitin antibody. Different 
concentrations of MultiDsk proteins were used in the extract. 
C. MultiDsk beads were incubated for 2 hours with 2mg of yeast extract and spun down. They 
were then washed three times under the stated conditions, before elution in sample loading 
buffer. Western blot was performed using anti-ubiquitin antibody (P4D1) to detect ubiquitylated 
species. 
 
 
Over a 6-hour time-course, there is a loss of high molecular weight ubiquitin 
conjugates when yeast extract is incubated with GST control protein only (Figure 
3.3, lanes1-6). In contrast, MultiDsk protein offered significant protection, despite 
use at a relatively low concentration (1.6 µM, or 0.4 µg MultiDsk per mg crude 
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yeast extract [lanes 19-24]), with a large retention of ubiquitylated species in 
solution. Whilst MultiDsk was not as effective as using a combination of GST-Dsk2 
and a high concentration of chemical inhibitor (5 mM NEM [lanes 7-12]), it was 
significantly more potent than the commercially available alternative TUBE-1 
(LifeSensors [lanes 13-18]). The chemical inhibitor, NEM, was the principal 
protecting agent in the GST-Dsk2–NEM mixture, as NEM on its own was sufficient 
to protect ubiquitylated proteins (Figure 3.3 B), whereas Dsk2 in isolation was not. 
Varying the concentration of MultiDsk protein used in extract affected the extent of 
protection, suggesting a direct stoichiometric affect of binding. Near complete 
ubiquitin-protein protection was observed by using a concentration of 3.2 µM or 0.8 
µg MultiDsk per mg of crude yeast extract, over the 6-hour time course (Figure 3.3 
B). In support of the direct stoichiometry hypothesis, this was also the estimated 
concentration required to completely deplete ubiquitylated proteins from the extract. 
When ubiquitylated proteins from extracts were pre-bound to the MultiDsk resin 
they were also protected from a broad range of purified DUBs (purchased from 
Boston Biochem), added in vitro (data not shown). These data show that the 
MultiDsk protein can be used not only as an affinity resin, but also as a protecting 
agent after cell lysis. 
 
 
3.2.4 MultiDsks can be used to assess the changing ubiquitylation state of a 
protein 
 
By using a resin that specifically enriches all ubiquitylated proteins we can assess 
how protein ubiquitylation changes under different conditions. When only a very 
small sub-fraction of the total cellular pool of a particular protein is ubiquitylated this 
cannot normally be visualised, as the signal from the unmodified version of the 
protein is typically much stronger and obstructs the signal from the modified form. It 
is also worth noting that all molecular weight shifts of 5-10 kDa should not be 
automatically assigned to ubiquitin, as many other post translational modifications 
can similarly alter electrophoretic mobility. Furthermore, for large proteins it is often 
impossible to observe the shift in molecular weight brought about by addition of the 
relatively small ubiquitin protein.  
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By using the MultiDsk resin to pull-out all ubiquitylated proteins - and wash away 
non-ubiquitylated contaminants - it is then possible to probe via Western blotting for 
the protein(s) of interest. To ensure that this is not due to contamination of non-
ubiquitylated protein, an electrophoretic mobility shift - due to the addition of the 
extra molecular weight of ubiquitin or poly-ubiquitin - can often be observed by 
comparing to the migration of the input protein in the crude extract. 
 
 
 
 
Figure 3.4: MultiDsks can be used to characterise the kinetics of ubiquitylation of 
a specific protein species 
 
A. Cells were either treated with 4-NQO for one hour, or left untreated, as indicated. Equal 
amounts of extracts were incubated with MultiDsk resin. Dilute input extract (1%) and washes 
from the beads were also loaded. Proteins were analysed by Western blotting using anti-Rpb1 
antibody, 4H8.  
B. Exponentially growing yeast cells were either treated with 4-NQO for one hour, or left 
untreated, as indicated. Equal amounts of the extracts were incubated with agarose beads 
loaded with GST alone, GST-Dsk2 protein, commercial TUBE1, or MultiDsk. Proteins were 
eluted via boiling in sample buffer and subjected to Western blot analysis using the anti-Rpb1 
antibody, 4H8 (upper panel). Ponceau S staining (lower panel) shows relative amounts of 
affinity proteins used.  
C. Yeast cells were harvested at the indicated time after treatment with 4-NQO, incubated with 
MultiDsk resin, and isolated proteins were analysed by Western blotting using either 4H8, or an 
anti-Def1 antibody, as indicated. 
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This method was used for the 215kDa largest subunit of RNAPII, Rpb1, which 
becomes poly-ubiquitylated in response to DNA damage (Svejstrup, 2007 and see 
Introduction section 1.5.3). This is hypothesised to occur as RNAPII becomes 
persistently stalled at DNA lesions and needs to be removed. Importantly, this 
protein is also subject to numerous other post-translational modifications that have 
sometimes previously been misinterpreted as ubiquitylation events (Starita et al., 
2005). To inflict consistent and reproducible DNA damage, 4-nitroquinoline 1-
oxdide (4-NQO) was used. 4-NQO is commonly called a UV mimetic drug, which 
upon metabolism readily forms bulky DNA adducts on purines in DNA (Tanooka 
and Tada, 1975). These lesions are repaired by the nucleotide excision repair 
pathway, and promote the degradation of Rpb1 (Beaudenon et al., 1999). Using an 
Rpb1 CTD specific antibody, a signal in the MultiDsk pull-downs was observed, 
with a notable electrophoretic mobility shift compared to the Input (Figure 3.4A, 
compare lane 1 with lane 6 and 7 [stippled line]), corresponding to specific 
enrichment of ubiquitylated forms of Rpb1. Mono-ubiquitylation of Rpb1 appears to 
be relatively constitutive, as has been reported previously (Woudstra et al., 2002, 
Sigurdsson et al., 2010). The slower migrating, poly-ubiquitylated forms of Rpb1 
resulting from DNA damage can also be detected (Figure 3.4 A, compare lanes 6 
and 7). 
 
Previously, GST-Dsk2 protein has been used to follow the ubiquitylation status of 
Rpb1 (Anindya et al., 2007, Harreman et al., 2009, Verma et al., 2011). To 
compare the MultiDsk to GST-Dsk2 and the commercially available TUBE-1 protein, 
roughly equal amounts of these proteins were immobilised on glutathione beads 
(Figure 3.4B, lower panel) and incubated with equal amounts of yeast extract. A 
weak ubiquitylated signal for Rpb1 was observed after DNA damage, when using 
the GST-Dsk2 protein (Figure 3.4B lanes 2 and 3). This correlated with overall 
reduced enrichment of ubiquitin conjugated proteins. A similarly weak Rpb1 signal 
was obtained when using the commercially available ‘TUBE- 1’ protein for ubiquitin 
enrichment (Figure 3.4B, lane 4). Only extract treated with 4-NQO was used in this 
case, and the TUBE-1 was more efficient than the single UBD GST-Dsk2 resin, 
though more TUBE-1 was also used (compare lanes 3 and 4). In both cases, a 
single band, corresponding to mono-ubiquitylated Rpb1, was observed with little or 
no higher molecular weight poly-ubiquitylation signal observed at the exposure 
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shown. In contrast, MultiDsk is much more efficient at enriching ubiquitylated Rpb1, 
so that both the constitutive, mono-ubiquitylated form (Figure 3.4B, lane 5), and the 
increased signal from induced Rpb1 mono-ubiquitylation and poly-ubiquitylation - 
stimulated by DNA damage - can be more readily observed (lane 6). 
 
One of the benefits of using a resin that enriches only ubiquitylated proteins is that 
novel ubiquitylation targets can be identified. Any protein bound to the MultiDsk 
resin should be ubiquitylated; therefore using an antibody to the protein of interest 
will reveal if, and to what extent, it is ubiquitylated. Poly-ubiquitylation of Rpb1 has 
been shown to be reliant on Def1 (Woudstra et al., 2002), though little mechanistic 
detail, or information on how it is activated, has been reported (see subsequent 
Results chapters). By using a Def1-specific antibody we could use the MultiDsk 
ubiquitin pull-downs to assess if Def1 was modified. The Def1 antibody used 
throughout this thesis is a polyclonal rabbit antibody, raised against the C-terminal 
350 amino acids of Def1. Unexpectedly, we observed the appearance of a band 
that cross-reacted with the Def1 antibody in MultiDsk extract pull-downs (Figure 
3.4C), which increased with time upon exposure to 4-NQO. This band migrates at a 
slightly higher position than would be expected for unmodified Def1, suggesting 
that this is a new, DNA damage-inducible, mono-ubiquitylated form. This was Def1 
specific band, no such band was observed upon enrichment of ubiquitylated 
proteins from Δdef1 cells. There is a low basal level of Def1 mono-ubiquitylation, 
and possible higher molecular weight Def1 ubiquitin conjugates observable using 
this technique. Whether this is related to RNAPII ubiquitylation or part of the normal 
cellular degradation of Def1 is unclear. Indeed, previously ubiquitylation has been 
misinterpreted as having important functional consequences, when instead its role 
was in normal cellular recycling (Davies et al., 2010). However, the formation of 
mono-ubiquitylated Def1 has similar kinetics to that of the poly-ubiquitylation of 
Rpb1 and these events are indeed inherently interlinked. Furthermore, the mono-
ubiquitylation of Def1 appears to be crucial for its function (see results presented in 
section 6.2.1). The MultiDsk resin can be used on any protein of interest under a 
wide variety of conditions, to identify dynamic changes in their ubiquitin post-
translational modification state. 
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3.2.5 MultiDsks can be used to help purify ubiquitylated proteins to 
homogeneity 
 
The MultiDsk resin allows the specific isolation of ubiquitylated proteins from cell 
extracts. As the MultiDsk protein can be eluted from glutathione beads by adding 
reduced glutathione, a second purification step can be introduced to specifically 
isolate the ubiquitylated form of a chosen protein. 
 
 
 
 
Figure 3.5: MultiDsks can be used to purify a specific ubiquitylated protein 
 
A. A schematic of purification of ubiquitylated RNAPII from 4-NQO treated Rpb3-FLAG tagged 
cells. Cells were treated with 10µg/ml 4-NQO for one hour before extract was created.  
B. Western blot of two-step purification, probed with anti-Rpb1 antibody (4H8) and anti-ubiquitin 
antibody (P4D1). MD-MultiDsk; In-input; FT-flow-through; IP-Immunoprecipitation.  
C. Silver stain comparing FLAG immunoprecipitate post-MultiDsk enrichment (lane 6 from B) to 
pure Rpb3-FLAG tagged RNAPII. Different concentrations of pure RNAPII are loaded for 
comparison. Bands at corresponding heights are labelled, non-specific background bands from 
residual MultiDsk proteins are indicated by asterisks. 
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The validity of this approach was illustrated by the specific purification of 
ubiquitylated RNAPII from extracts prepared from an Rpb3-FLAG strain (Figure 3.5 
A). Cells were treated with 4-NQO 1 hour prior to harvesting and cell lysis. 
Stringent washing allows the removal of non-modified forms of RNAPII from the 
MultiDsk beads (Figure 3.5 B lane 3). After glutathione elution, the ubiquitylated, 
FLAG-tagged, RNAPII can be purified using an anti-FLAG M2 affinity resin (Figure 
3.5 B, lane 6). The high affinity antibody-epitope interaction allowed stringent (1M 
NaCl) washing that removes not only all the other ubiquitylated proteins, but also 
the majority of the MultiDsk protein that initially bound ubiquitylated-RNAPII. In a 
silver stain of the FLAG Immunoprecipitate, bands corresponding to Rpb2 and a 
shifted Rpb1 band can be observed (Figure 3.5 C), compared to RNAPII purified by 
conventional means (Cramer et al., 2001). 
 
 
3.3 Conclusions 
The MultiDsk protein is a novel protein tool useful for depletion and protection of 
ubiquitylated proteins ex vivo. MultiDsk binds strongly and specifically to 
ubiquitylated protein species and allows the unbiased enrichment of a small, often 
unstable pool of proteins. The resin provides a useful tool for the analysis of protein 
ubiquitylation and will be used extensively elsewhere in this thesis. 
 
Chapter 4. Discussion I 
 
123 
Chapter 4. Discussion I  
MultiDsks: A Ubiquitin Specific Affinity Resin 
 
The data presented here indicate that the MultiDsk protein offers an excellent 
alternative to the previously used methods for studying protein ubiquitylation. The 
MultiDsk can be used to obtain pure, native, non-tagged ubiquitylated proteins from 
cell extracts, as well as to ensure the maintenance of the their ubiquitylation state, 
via a strong protective function, which blocks cellular de-ubiquitylating enzymes 
(DUBs). 
 
 
 
4.1 The High Avidity Interaction of MultiDsk 
 
By combining multiple ubiquitin binding domains (UBDs) from the yeast Dsk2 
protein, a dramatic synergistic increase of affinity for ubiquitylated proteins was 
achieved. The amount of ubiquitylated protein isolated with MultiDsk was far 
greater than that obtained with the single UBD containing GST-Dsk2 and 
significantly greater than the commercially available TUBE-1 protein.  
 
In all likelihood, the interaction of the MultiDsk is imparted through the synergistic 
action of the multiple UBDs engaging with the same ubiquitin chain. Whilst only 4 
ubiquitin moieties are sufficient to target proteins to the proteasome (Thrower et al., 
2000), in vivo chains of all topologies often extend much further Kim and 
Huibregtse, 2009. The TUBE-1 protein displays approximately 1,000 times greater 
avidity to poly-ubiquitin chains compared to a single UBD (Hjerpe et al., 2009). 
Whilst the affinity for each UBD to ubiquitin is thought to remain constant, the co-
operative action of multiple binding surfaces, engaging simultaneously, increases 
the overall avidity. Indeed, the relationship is probably non-linear for the interaction 
of subsequent UBDs, due to the reduced entropic penalty after the initial UBD 
binding. 
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The increased avidity of the MultiDsk protein over the TUBE-1 protein is likely due 
to the increased individual affinity of each UBD and the presence of a fifth, 
additional UBD. The UBA domain from HR23A, which is used in the TUBE-1 
protein, has a Kd of 40-60µM (Hjerpe et al., 2009, Withers-Ward et al., 2000), whilst 
the Dsk2 UBA domain has a much higher individual affinity, with a Kd of around 
15µM (Ohno et al., 2005). Whilst the MultiDsk resin appears to be more efficient at 
enriching ubiquitylated proteins than all other alternatives, the exact biophysical 
data to substantiate this case is lacking. Further work to provide quantitative values 
of affinity - using a technique such as surface plasmon resonance - is required to 
confirm the observed comparative, qualitative high avidity. 
 
 
 
4.2 Specificity of MultiDsk 
 
Importantly, the MultiDsk resin does not appear to discriminate between different 
kinds of ubiquitin chains. This is at least the case for the two most prevalent 
ubiquitin chains present in the cell, Lys-48 and Lys-63. Similarly, the binding to 
single free ubiquitin and mono-ubiquitylated proteins is better for MultiDsk than the 
single UBD protein, GST-Dsk2. The full-length Dsk2 protein is known to interact 
specifically with Lys-48 chains (Funakoshi et al., 2002), whilst the isolated UBA 
domain alone does not show such preference (Raasi et al., 2005, Ohno et al., 
2005). Some isolated UBA domains do exhibit Lys-48 specificity (Varadan et al., 
2005, Trempe et al., 2005), through dual ubiquitin interaction surfaces, the second 
of which contains a conserved phenylalanine residue. This is not present in Dsk2’s 
UBA (Ohno et al., 2005, Zhang et al., 2008). Therefore, the chain topology 
preference of the Dsk2 protein may be due to the exact spatial orientation of its 
UBA domain within the full-length protein, or its oligomerisation state (Lowe et al., 
2006, Sasaki et al., 2005). 
 
The MultiDsk construct was deliberately designed with a flexible linker between 
UBA domains, possibly allowing the free rotation of these domains to 
accommodate multiple chain topologies. Lys-48 and Lys-63 chain linkages only 
Chapter 4. Discussion I 
 
125 
account for roughly half of all chain linkages in yeast cells (Xu et al., 2009a). 
Unfortunately, synthetic poly-ubiquitin chains of the untested linkages are not 
currently available, preventing in vitro interaction studies with MultiDsk. However, 
all ubiquitylated proteins were depleted from cell extracts, suggesting that MultiDsk 
can also interact with the other, minor chain linkages. Future biochemical 
experiments are required to assess whether MultiDsk exhibits any chain preference. 
 
The ubiquitin field is increasingly recognising the importance of Ubiquitin-like (Ubl) 
proteins, which can also covalently mark proteins post-translationally (van der Veen 
and Ploegh, 2012). The exact prevalence of these modifications is unclear, but for 
Smt3 (yeast SUMO) targeting appears to be restricted (Hannich et al., 2005). 
These Ubl modifications tend to utilise their own conjugation apparatus (Johnson 
and Gupta, 2001), recognition apparatus (Pfander et al., 2005) and deconjugation 
enzymes (Cope et al., 2002). However, recent work has suggested that the highly 
ubiquitin-homologous Rub1 - or human Nedd8 - can be utilised by ubiquitin ligases, 
integrated into ubiquitin chains and recognised by UBDs (Hjerpe et al., 2012, 
Leidecker et al., 2012, Singh et al., 2012). Critically, Rub1 interacts, with a similar 
affinity as Ubiquitin, with the UBA domain from the human homologue of Dsk2 
(Singh et al., 2012). In our experiments, MultiDsk pull-downs did not appear to 
appreciably enrich Rub1 or Smt3 conjugates. However, these proteins were 
identified using human isoform specific antibodies with poor Ubl detection in crude 
extracts. Direct in vitro evidence and better - yeast specific - antibodies are 
required to further substantiate these conclusions. 
 
 
 
4.3 Using MultiDsk as a Protein Reagent 
 
The MultiDsk protein also acts to preserve poly-ubiquitylated proteins in extracts, 
avoiding the need for hazardous chemical DUB inhibition. The MultiDsk protein 
provides a significant protective role at concentrations as low as 0.2 µM (Figure 3.3 
B), making it suitable for use in even large-scale extract-based experiments. It is 
interesting to note that the protective role of both the MultiDsks and commercial 
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TUBE- 1 was not complete at the concentrations used in this study. A previous 
report (Hjerpe et al., 2009) suggested that a TUBE- 1 concentration of 1.6 µM was 
sufficient for complete protection from cellular DUBs. However, these protection 
assays were performed using human extracts, rather than S. cerevisiae extracts, 
suggesting that the problem posed by non-specific DUBs is greater in yeast. It is 
likely that the MultiDsk protein protects poly-ubiquitin chains through direct steric 
occlusion of DUB enzymes from their substrates.  
 
One of the expected problems of working with proteins as reagents is their inherent 
low stability (Taverna and Goldstein, 2002). Proteins unfold and degrade under 
non-physiological temperatures, pHs and salt concentrations. However, the 
MultiDsk protein can withstand complete unfolding and refolding (Figure 3.1 C). 
Furthermore, the interaction of MultiDsk with ubiquitylated proteins is stable under 
a range of pHs and <1M sodium chloride (Figure 3.3 C). In the Svejstrup lab, GST-
Dsk2 was previously used to enrich ubiquitylated proteins. This protein is unstable 
in its purified state (see Figure 3.4 B, lower panel lanes 2 and 3), and unusable 
within 2 weeks after storage at 4oC. The MultiDsk protein appears to be far more 
stable; MultiDsk resin retains activity for upwards of 6 months and can be stored 
pure at -20oC for up to a year. 
 
Unfortunately, as a tool for assessing the whole ubiquitome, the large amount of 
MultiDsk protein required, coupled with the inability to easily release bound 
ubiquitylated proteins, somewhat limits MultiDsk use in mass spectrometry. 
However, as a tool for assessing the ubiquitylation state of an individual protein, 
MultiDsk is a uniquely specialised reagent. The resin was used to follow the 
ubiquitylation status of two proteins, Rpb1 and Def1, after treatment with DNA 
damage. It is important to note that by pulling out the ubiquitylated protein in its 
native state, the molecular weight shifts could be due to numerous post-
translational modifications, one of which is probably ubiquitylation. Some post-
translational modifications occur concurrently; Rpb1 SUMOylation and 
ubiquitylation occurs under the same transcription stall conditions (Chen et al., 
2009) and SUMO directed ubiquitin E3 ligases have been identified (Uzunova et al., 
2007). Care must be taken not to over-interpret MultiDsk pull-down data. 
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We have shown that it is possible to purify in vivo ubiquitylated proteins using the 
MultiDsk resin coupled to traditional protein purification techniques. As the majority 
of the MultiDsk protein can be removed using high salt washes, a native 
ubiquitylated form of a protein can be isolated and used for further biochemistry, 
eliminating the need for in vitro ubiquitylation reactions. However, as only a sub-
fraction of cellular proteins tend to be ubiquitylated; a larger amount of extract 
starting material is required to enrich proteins to the same extent. 
 
Since publication (Wilson et al., 2012), the plasmid expressing the MultiDsk protein 
has been requested by multiple laboratories worldwide and is proving to be a 
valuable research tool for the isolation of ubiquitylated proteins in a number of 
different systems. 
 
 
 
4.4 Implications for the Rpb1 Poly-ubiquitylation Pathway 
 
The MultiDsk resin was used to assess the ubiquitylation status of two proteins 
involved in the ‘last-resort’ Rpb1 poly-ubiquitylation pathway (see 1.5.3). The high 
avidity of MultiDsk enabled the total depletion of the ubiquitylated forms of the 
proteins from extracts and allowed the ubiquitin status of Rpb1 and Def1 to be 
evaluated, after treatment with DNA damaging agents. RNAPII mono- and poly-
ubiquitylation are separate steps that are catalysed by different E3 ligases. Whilst 
initial mono-ubiquitylation is required for the subsequent poly-ubiquitylation of Rpb1 
(Harreman et al., 2009), there is a basal level of mono-ubiquitylation under normal, 
unstressed, conditions. The extent of this mono-ubiquitylation has been unclear, 
partially due to the preference of the GST-Dsk2 resin, which was used previously, 
for poly-ubiquitin chains (Funakoshi et al., 2002, Zhang et al., 2009). MultiDsk does 
not seem to display such a preference (Figure 3.2 B). Illuminatingly, the levels of 
Rpb1 between the input (loaded with 1% of protein used in the assay) and pull-
downs were roughly equivalent; suggesting that at least 1% of all total RNAPII is 
modified by mono-ubiquitin, in the absence of induced transcription stress (Figure 
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3.4 A). Whether this mono-ubiquitylation has a functional relevance, outside of its 
role as an intermediate in degradation, is currently unclear.  
 
Def1 has not been previously shown to be ubiquitylated from whole genome 
approaches, or from more tailored, directed investigations (Peng et al., 2003) 
attesting to the high sensitivity of the MultiDsk. resin. However, since this project 
was initiated, a number of studies have identified three separate ubiquitylated Def1 
peptides (Starita et al., 2012, Beltrao et al., 2012). Further work in this thesis has 
identified four additional lysine residues of Def1 that are ubiquitylated in response 
to DNA damage (see section 6.2.1). Interestingly, it appears that Def1 is inducibly 
mono-ubiquitylated with a similar kinetic to that of Rpb1 poly-ubiquitylation. Since 
we know that Def1 is required for this Rpb1 poly-ubiquitylation, it is tempting to 
speculate that Def1 mono-ubiquitylation plays a role in the activation of this protein. 
Evidence for a role for Def1 ubiquitylation is covered later (see section 6.2.1). 
 
In order to explain the substantial Rpb1 degradation that is observed after DNA 
damage, the minor fraction of poly-ubiquitylated Rpb1 must be very short lived, and 
under constant turnover. However, it is interesting to note that RNAPII poly-
ubiquitylation can be separated from degradation (Verma et al., 2011). We have 
tended to interpret the two events as inherently linked, due to the rapid 
proteasomal degradation of poly-ubiquitylated Rpb1 (Luo et al., 2001, Beaudenon 
et al., 1999). For all the experiments shown in this thesis both Rpb1 ubiquitylation 
and degradation were observed under the same conditions, even if not shown. 
RNAPII can also be modified with non-degradable, Lys-63 chains (Harreman et al., 
2009). In future studies it would be critical to ascertain the nature of the 
ubiquitylation status of Rpb1 and whether this leads to proteasomal degradation. 
 
Notably, Rpb1 levels do not appear to reduce in the inputs of Figure 3.4 C, despite 
robust poly-ubiquitylation. This may be due to the Rpb1 antibody used, which is 
specific towards hyper-phosphorylated Rpb1, known to be induced upon DNA 
damage (Rockx et al., 2000, Mitsui and Sharp, 1999). The phosphorylation state of 
Rpb1 helps to distinguish it for poly-ubiquitylation (see introduction, 1.5.3.5). As a 
result, whilst the overall levels of Rpb1 may be decreasing, the phosphorylated 
levels detected with this antibody may be higher, leading to the apparent lack of 
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Rpb1 degradation. This phospho-specific antibody was not used to measure Rpb1 
degradation elsewhere in the rest of this thesis. 
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Chapter 5. Results II 
Def1 Partial Proteolytic Processing 
 
5.1 Aims 
 
Def1 protein - from the yeast Saccharomyces cerevisiae - was originally identified 
by the Svejstrup lab as an interacting partner of Rad26p in chromatin (Woudstra et 
al., 2002). Whilst Rad26 is the key yeast protein mediating transcription coupled-
nucleotide excision repair (TC-NER), Def1 does not appear to function directly in 
this pathway. Instead, Def1 is a critical player in the alternate, back-up pathway to 
TC-NER, namely the poly-ubiquitylation and degradation of Rpb1. Cells that lack 
Def1 exhibit normal TC-NER and are not UV sensitive, but do not poly-ubiquitylate 
and degrade Rpb1 after DNA damage. This effect is direct: poly-ubiquitylation of 
RNAPII can be reconstituted in an extract based in vitro assay and is entirely reliant 
upon Def1 (Reid and Svejstrup, 2004). 
 
Def1 has also been implicated directly in telomere maintenance and mitochondrial 
retention (Chen et al., 2005). Genetic studies have revealed a number of cellular 
deficiencies in def1Δ cells (Jordan et al., 2007, Manogaran et al., 2011, Cai et al., 
2006, Suzuki et al., 2011). Despite a clear role in ubiquitylation of chromatin-
associated RNAPII, localization studies assigned Def1 to the cytoplasm (Huh et al., 
2003, Tkach et al., 2012). 
 
In spite of years of extensive research on Def1 the molecular role of the protein in 
the mechanism of Rpb1 poly-ubiquitylation was still unknown. Intriguingly, prior to 
work presented here, Western blots of extracts from DNA damaged cells - with 
antibodies raised against Def1 - showed a faster migrating, cross-reacting, band 
that was not present in the untreated controls. This band was also reproducibly 
observed under other conditions of transcription stress. The aim of my project was 
to further investigate the nature of this inducible, smaller form of Def1. Some of this 
work overlapped with the efforts of Michelle Harreman, a postdoctoral fellow in the 
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Svejstrup lab. Therefore, some of the figures presented below were the product of 
Michelle Harreman’s experiments. These are clearly labelled as such. 
 
5.2 Results 
 
5.2.1 The faster migrating band corresponds to a N-terminal fragment of 
Def1 
 
Def1p is a 738 amino acid protein with a predicted molecular weight of 86 kDa. The 
protein contains only one identified functional domain; a CUE domain identified in 
silico (Ponting, 2002; Figure 5.1 A). Strikingly, greater than 40% of the C-terminal 
half of the protein sequence is composed of glutamines, possibly explaining the 
unusual mobility of Def1 on SDS-PAGE: Def1 runs at around 120 kDa (Figure 5.1 
B). As observed previously (see above), a collection of similar, faster-migrating, 
protein bands, cross-reacting with the Def1 antibody, appear after 4-NQO 
treatment (Figure 5.1 B), or after exposure of cells to 254 nm UV-B light (Figure 5.1 
C). These conditions are known to cause bulky, helix-perturbing DNA damage (Kim 
et al., 1995, Tanooka and Tada, 1975) and block the path of RNAPII along a 
transcribed gene (Svejstrup, 2007). Long RNAPII pauses are signals for DNA 
repair, or eventually RNAPII poly-ubiquitylation. Intriguingly, the faster-migrating 
Def1 bands appear at a similar kinetic to that of Rpb1 poly-ubiquitylation (Figure 
5.1 C) and subsequent degradation (Figure 5.1 B). The faster-migrating Def1 
bands runs at a molecular weight of around 90kDa, commonly as a doublet. These 
bands are only observed if the processed samples are run immediately after cell 
lysis. The bands are not stable in extracts even in the presence of SDS-PAGE 
loading buffer, possibly due to the action of uninhibited vacuolar proteases. It 
should be noted that the Def1 antibody shows some preference for the lower form 
of Def1 over the full-length protein. As a result, the lower, p90, bands are often 
clearly seen in Western blots, with no appreciable reduction in the full-length p120 
Def1 signal. 
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Figure 5.1: A faster migrating Def1 band appears after transcription stress 
 
A. Schematic representation of Def1 indicating the CUE domain, approximate area of 
processing site (arrow), and glutamine rich region. 
B. Quick extracts (2.5.10) from 4-NQO exposed cells, Immunoblotted using antibodies against 
Rpb1 (8WG16), Def1, and Pgk1 (loading control). 
C. Extracts from UV-irradiated cells analysed by Western blotting at the indicated times as in 
(B). Ubiquitylated Rpb1 isolated from the extract using MultiDsk pull-down (PD) and probing for 
Rpb1 (4H8) (as Figure 3.4). Ubiquitin pull-down loading confirmed by probing for ubiquitin 
(P4D1). 
 
 
In order to assess the conditions under which the faster migrating band was 
observed, cells were subjected to a number of cellular stresses (Figure 5.2). The 
lower band (hereafter referred to as processed-Def1 or pr-Def1) might be formed 
as a general response to DNA damage in a separable, independent pathway to 
Rpb1 degradation. Alternatively, these processes may be inherently interlinked. 
Rpb1 degradation occurs as a consequence of persistent transcription stall. This is 
commonly induced using DNA damaging agents, which chemically alters the read 
DNA so it can no longer be transcribed. RNA synthesis can also be blocked by the 
depletion of rNTP pools, leading to RNAPII stalling in the absence of DNA damage 
(Archambault et al., 1992). 6-azauracil (6-AU) inhibits IMP dehydrogenase, the 
rate-limiting enzyme in biosynthesis of GTP. 6-AU treatment rapidly leads to the 
depletion of cellular GTP pools (Exinger and Lacroute, 1992) and the stalling of 
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RNAPII. After inducing stalling by treatment with 6-AU, the processed form of Def1 
also appears (Figure 5.2 A). The appearance of pr-Def1 after 6-AU treatment is 
slow, compared to treatment with DNA damaging agents. Similarly treating cells 
with 6-AU leads to slower RNAPII poly-ubiquitylation, compared to treatments that 
cause DNA damage (Somesh et al., 2005). 
 
 
 
 
Figure 5.2: pr-Def1 occurs after cellular stress 
 
A. Cells were incubated in the absence (control) or presence of 6-azauracil (6-AU), and extracts 
analysed by Western blot using the Def1 antibody. Michael Taschner performed this 
experiment.  
B. Cells were G2 arrested using nocodazole; by the final time point all cells in nocodazole 
treated sample were double-budded, whilst the control cells showed a normal asynchronous 
budding pattern. Quick extracts were run on SDS-PAGE and Western blotted using the anti-
Def1 antibody. 
C. Extracts from cells grown at below (25oC) and above (37oC) optimal growth conditions. Cells 
were shifted from 30oC and samples taken at the indicated timepoints. Western blotting was 
performed with the anti-Def1 antibody. 
D. Quick extracts from equal cell numbers were created from the same culture as it proceeded 
through logarithmic growth. Cells were counted every 90 minutes and 1.5x107 cells extracted. 
Western blot using anti-Def1 antibody. 
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E. Stable logarithmic-phase growing cells were harvested and resuspended in pre-warmed YPD 
(2.1.2.1). Either fresh YPD (lanes 8-10), YPD supernatant taken from stationary phase cells 
(lanes 5-7) or YPD taken from stationary phase culture supplemented with 2% glucose and 40 
µg/ml amino acids was used.  Lane 1 corresponds to equivalent cell numbers from the 
stationary phase culture (SC). Quick extracts were analysed by Western blot using the Def1 
antibody. Asterisk corresponds to non-specific band occasionally observed with the Def1 
antibody. 
F. Cells were incubated with YPD supplemented with or without 3% ethanol, for the indicated 
time periods. Quick extracts were analysed by Western blot using anti-Pgk1 and anti-Def1 
antibodies. 
 
 
The treatment of cells with DNA damaging agents or transcription inhibitors not 
only blocks RNAPII, but also perturbs normal yeast cell cycle progression. To 
discount the possibility that the faster migrating pr-Def1 band is formed in a cell 
cycle-specific manner, cells were treated with a microtubule depolymerisation 
agent, nocodazole, blocking cells in G2 phase (Figure 5.2 B). No processed band 
was formed as the cells became synchronised, confirmed by the observation of 
cells in a dual-budded state. Treatment of MATa cells with α-factor arrests them in 
the G1 phase of the cell cycle (Bucking-Throm et al., 1973). Similarly to nocodazole 
treatment, α-factor treatment did not result in the processing of Def1 (data not 
shown). This data suggests that pr-Def1 forms as the direct result of transcription 
stress, rather than due to any off-target or downstream signalling effects of the 
agents used. 
 
Interestingly, Def1 also becomes processed under a wide variety of other cellular 
stresses. Cells shifted to a permissive, but higher than optimal, growth temperature 
also produce pr-Def1 (Figure 5.2 C). As cells entered late logarithmic growth 
phases, and cell density increased, Def1 was also processed (Figure 5.2 D). 
Puzzlingly, this occurred at middle-to-late log growth phase, when growth 
conditions are not limiting. This was not due to direct overcrowding; cells at a low 
cell density incubated with old media - taken from cells at high cell density - also 
exhibited Def1 processing (Figure 5.2 E lanes 5-8). Supplementing the old, pre-
used media with essential amino acids and glucose did not prevent the formation of 
pr-Def1 (Figure 5.2 E, lanes 2-4), suggesting that the processing stimulus in this 
case is an accumulating waste product, rather than a declining nutrient source. 
Despite growth in aerobic conditions, S. cerevisiae commonly respires 
anaerobically in the presence of excess glucose (Crabtree, 1928). This produces 
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ethanol as a by-product, which becomes toxic at high concentrations. Addition of 
3% ethanol - a concentration that the strain used in this study could tolerate (Dinh 
et al., 2008) - was sufficient to induce some Def1 processing (Figure 5.2 F). This 
suggests the Def1 processing seen at high cell density may, at least in part, be due 
to the accumulation of toxic metabolic by-products.  
 
In conclusion, pr-Def1 formation occurs not only in response to transcription stress, 
but also more widely as a response to a variety of cellular stresses. Whether these 
stress conditions trigger Def1 processing by affecting transcript elongation through 
RNAPII is presently unclear and requires further study. The remainder of the 
current work will focus completely on the robust induction of pr-Def1 observed upon 
DNA damage, and on its effect on Rpb1 ubiquitylation and degradation. 
 
 
5.2.2 The N-terminal fragment is not a new protein product of Def1 
 
To investigate the identity of the faster-migrating pr-Def1 band, the genomic 
version of Def1 was tagged at either the N- or C-terminus (JSY 1198 and 642, 
respectively). After treating the tagged strains with agents that cause DNA damage, 
extracts were subjected to Western blotting to detect the proteins, using polyclonal 
antibodies raised against Def1. When tagging the protein at its N-terminus, the 
migration of both the full-length Def1 protein and pr-Def1 was shifted upwards in 
the gel, compared to the wild-type protein (Figure 5.3 A, left). This suggests both 
forms of Def1 contain the N-terminal tag and consequently both are of higher 
molecular weight than their wild-type equivalents. In contrast, whilst the full-length 
protein - tagged at the C-terminus - was shifted upwards in the gel, the pr-Def1 
band was not (Figure 5.3 A, right), strongly indicating that pr-Def1 does not contain 
the C-terminal tag. Indeed, pr-Def1 could not be detected when using an antibody 
against the C-terminal tag (data obtained by Michelle Harreman, not shown). These 
results suggest that pr-Def1 corresponds to an N-terminal product of Def1.  
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Figure 5.3: Full length Def1 protein is processed to an N-terminal fragment 
 
A. Western blot showing WT or tagged Def1, after incubation of cells with 4-NQO for 1 hour. 
(Left panel) The WT strain was compared to a N-terminally Myc tagged strain (JSY1198). (Right 
panel) as above, but with cells expressing C-terminally 6xHA-tagged Def1 (JSY642), performed 
by Michael Taschner. 
B. Quantification of relative mRNA levels of Def1 after 4-NQO treatment. Quantification 
normalised to β-actin levels in each sample, then against untreated conditions (time0). Primers 
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were used from the start (white), middle (grey) and end (black) of the Def1 gene. Error bars 
correspond to the standard deviation across three biological replicates. 
C. Def1 processing occurs post-translationally. (Left) Autoradiogram of SDS-PAGE gel, showing 
cellular proteins, radioactively labelled in vivo. Protein synthesis was inhibited by the addition of 
25 µg/ml cycloheximide to mid-log cells at time 0, and new protein synthesis measured by 
incorporation of radioactive label in proteins (S35-methionine pulse initiated at the times 
indicated after cycloheximide inhibition). Time point 0’ was transferred to grow in radioactive 
methionine immediately after addition of cycloheximide. 
D. Cells were pre-treated with cycloheximide (CHX) – to block protein translation – 5 minutes 
prior to the addition of 4-NQO. Quick extracts were collected for analysis by Western blot using 
anti-Def1 antibody. 
 
 
The N-terminal pr-Def1 fragment could arise through three possible mechanisms. 
Firstly, upon cellular stress and transcription stall, a different mRNA product might 
be transcribed from the DEF1 gene that encodes only the N-terminal section of 
Def1. This could occur through alternate stop-site usage or splicing removing the 3’ 
end of the gene. To assess these possibilities, the level of Def1 mRNA was 
measured under pr-Def1-inducing conditions by treating cells with 4-NQO (Figure 
5.3 B). Three separate primer sets were used that amplified the start, middle, or 
end of the coding region, respectively (Figure 5.3 B lower). Def1 mRNA levels did 
not change significantly across the body of the gene, including the 3’ coding end of 
the gene (Figure 5.3 B, black bars), suggesting that the mRNA product was not 
altered by DNA damage. It is worth noting that overall DEF1 mRNA levels did 
decrease after damage induction; however, this was not significantly reduced when 
compared with total mRNA (the data presented here has been normalised to the 
mRNA from the housekeeping gene β-actin). The half-life of DEF1 mRNA produced 
from the GAL promoter is around 5 minutes (data not shown). Assuming that this is 
also true for DEF1 mRNA produced from its own promoter, the mRNA detected at 
the time-points used here should be predominantly synthesised after DNA damage. 
 
A second possible explanation for the formation of the shorter pr-Def1 band is that 
Def1 is being alternately translated after DNA damage, or co-translationally cleaved, 
forming the N-terminal, pr-Def1 fragment. A direct, metabolic labelling, pulse-chase 
approach to detect the formation of pr-Def1 from full-length Def1 was not 
successful. The pr-Def1 band formed is a minor proportion of the total cellular Def1 
and was below the detection limit of the experiment performed.  
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Instead, the relationship between pr-Def1 formation and translation was assayed 
by blocking protein synthesis. In these experiments, cells were first pre-incubated 
with cycloheximide, an inhibitor of the translocation step of translation, before DNA 
damage was induced. In order to assay the effectiveness of cycloheximide, cells 
were treated with a pulse of S-35-Methionine before or after the addition of 
cycloheximide (Figure 5.3 C). Addition of cycloheximide almost immediately shut-
off protein synthesis. Indeed, even the earliest time point (0’, corresponding to the 
time taken between addition of cycloheximide and the addition of S-35-Methionine) 
showed little to no radioactive methionine incorporation. As a result cells were pre-
treated with cycloheximide for only 5 minutes, to shut-off all protein production, 
prior to the addition of damage inducing 4-NQO. As can be seen in Figure 5.3 D, 
even in the absence of new protein synthesis, pr-Def1 still forms after transcription 
stress, suggesting that pr-Def1 formation is not dependent on active translation. 
 
The pr-Def1 band was not formed as a result of altered transcription or translation. 
Therefore, only one option remains: pr-Def1 protein must be formed from the full-
length protein post-translationally, in all likelihood as the result of a proteolytic 
cleavage event. All subsequent experiments presented in this thesis are consistent 
with this hypothesis; pr-Def1 appears to be the proteolytically cleaved product 
formed from full-length Def1. We have not been able to detect the C-terminal 
fragment of the protein, despite using multiple different detection methods (data not 
shown). We, therefore, assume that the C-terminus is degraded during the 
proteolytic cleavage or immediately thereafter. 
 
 
5.2.3 Mapping the site of processing: activity of truncation mutants 
 
The data above suggest, but do not prove, that the pr-Def1 (p90) fragment is 
created post-translationally, by proteolysis, from full-length Def1 (p120). This 
suggests there is a direct site of proteolytic cleavage, which consistently produces 
two similar molecular weight N-terminal fragments. Unfortunately, due to the 
unusual electrophoretic mobility of Def1, the molecular weight of the supposed p90 
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pr-Def1 fragment was unclear. In order to map the processing site of Def1, a library 
of C-terminal genomic truncations of the DEF1 gene were created (JSY 1176-
1181), for comparison to the processed band on Western blot. 
 
When the endogenous DEF1 gene is truncated by recombination, small C-terminal 
deletions had little or no effect on the growth of cells, whilst large C-terminal 
truncations resulted in a similar slow-growth phenotype as the null strain (Figure 
5.4 A). Interestingly, a former Svejstrup lab postdoc, Jim Reid, had previously 
obtained preliminary evidence that Def11-400 and Def11-500 could not be generated 
using this method, a result confirmed by Michelle Harreman. This was not an 
artefact of the method used: a diploid strain expressing both Def11-500 and a wild-
type copy of Def1 could be created (JSY 1182). This strain grew normally and 
could be sporulated and tetrad dissected into haploid spores. However, only two of 
the four spores were ever viable and these contained the wild-type, full-length 
version of Def1 (Figure 5.4 B), as confirmed by PCR. We therefore surmised that 
expressing the shorter Def1-400 or Def11-500 was extremely detrimental to the cell. As 
pr-Def1 is also an N-terminal product, we hypothesised that genomically deleting 
the C-terminus artificially mimicked constitutive processing of Def1. 
 
When GAL-regulated Def1 was expressed on plates containing galactose, this 
rescued the slow growth phenotype of Δdef1 cells. In contrast, and in support of the 
above hypothesis, galactose driven expression of Def11-500, prevented the growth 
of Δdef1 cells (Figure 5.4 C), exacerbating the slow growth phenotype. As the over-
expression of Def11-500 is toxic to the cell, it seems reasonable to hypothesise that 
the formation of pr-Def1 - induced by DNA damage and transcription stress – is 
harmful if not tightly controlled. Over-expression of the Def1 C-terminal fragment 
(Def1 500-738) concomitantly with Def11-500 did not overcome the toxicity of the N-
terminal fragment (data not shown). 
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Figure 5.4: Def1 C-terminal deletions can be toxic to the cells 
 
A. Dilution growth series (2.5.6) of cells expressing Def1 N-terminal fragments, grown on YPD-
agar. No viable clones could be acquired for def11-400 or def11-500. Michelle Harreman performed 
this experiment. 
B. Spores (A-D) from 4 different tetrads (1 through 4) from a heterozygous DEF1/def11-500 
diploid, with haploid spore genotype indicated.  
C. Dilution series of Δdef1 yeast cells (carrying the GAL-driven plasmid indicated on the left), 
grown on SD -Uracil Agar glucose or galactose as indicated. 
 
 
The data above suggest that the toxic Def1-400 or Def11-500 polypeptides may 
artificially mimic the processed form of Def1 observed after DNA damage. In order 
to test this hypothesis, it was necessary to fine map the exact site. Smaller C-
terminal genomic truncations were created, with the aim of comparing these 
against the processed band on Western blot. As the deletion of the last 138 amino 
acids of Def1 (Def11-600) was viable whilst Def11-500 was lethal we surmised that 
genomic truncations in the region of 500-600 would be very informative. No 
transformants were obtained for Def1 truncations between 1-500 and 1-520, 
suggesting expression of these proteins was also toxic to cells. Truncations over 
540 amino acids in length were viable with no obvious phenotype. A strain with the 
N-terminal 530 amino acids of Def1 expressed was viable but found to be 
temperature sensitive (Figure 5.5 A, JSY 1183). The Def11-530 protein migrated at a 
marginally higher position in gel than the endogenously induced pr-Def1 band 
(Figure 5.52 B). Assuming that pr-Def1 is not post-translationally modified in a 
Chapter 5. Results II 
 
141 
different manner to Def11-530, this suggests that the exact site of processing lies 
somewhere in the region encompassed by residues 520-530. 
 
 
 
 
Figure 5.5: Expression of Def11-530 is tolerated in cells 
 
A. Dilution growth series of Wild-type cells compared to cells with a C-terminal HA tag (JSY 
1181), and cells lacking the last 208 amino acids of Def1 with a C-terminal HA tag (JSY1183). 
Cells were plated on YPD-agar and grown at the indicated temperatures. Michelle Harreman 
created these strains. 
B. Western blot showing Def1 from def11-530-HA and 4-NQO treated Def1-HA cells, respectively. 
C. Western blots of extracts from Def1-HA and def11-530-HA cells grown at permissive (25°C) or 
restrictive temperature (37°C) for the indicated times. Anti-Rpb1 (8WG16) and anti-Pgk1 
antibodies were used for the Western blot. Michelle Harreman performed this experiment. 
 
 
In order to assess what was causing the slower growth of the def11-530 strain, 
various cellular proteins were examined after shifting to the non-permissive 
temperature, 37oC. The total protein content of the samples was not altered, as 
measured by Ponceau-S stain and the Pgk1 loading control (Figure 5.52 C lower 
panel). The protein levels of Def11-530 were also not detectably altered. Growth was 
retarded at higher temperatures for the Def11-530 strain, but protein concentration 
was normalised by loading equal amounts of whole cell extract. Def1 has a critical 
role in the degradation of Rpb1 (Woudstra et al., 2002). The slow growth of the 
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Def11-530 strain may be, at least partly, due to the reduction in the levels of the 
essential Rpb1 protein. In fact, Rpb1 levels decreased steadily, the longer the 
Def11-530 strain was incubated at 37oC, to just 25% of the original starting levels 
after 2 hours (Figure 5.52 C, upper panel). The cognate wild-type strain did not 
exhibit a reduction in Rpb1 levels at 37oC under the same conditions, despite some 
pr-Def1 formation (Figure 5.2C). This suggests that elevated temperature activates 
the Def11-530 protein to promote the aberrant degradation of Rpb1, even in the 
absence of damage-induced transcription stalling. 
 
 
5.2.4 Mapping the site of processing: inactivation of proteolytic cleavage 
 
In a further attempt to map the site of processing, and attempt to disrupt it, we 
decided to create a form of Def1 that was insensitive to damage-induced 
proteolysis. Strains with small internal deletions in Def1 were made, with the aim of 
removing the protease cleavage and/or recognition site. As proposed earlier, the 
pr-Def1 processing site probably lies in the region near residues 520-530. We first 
created mutations in this region, which did not affect the processing of Def1 
appreciably (data not shown). Therefore, larger internal deletions of 40-70 amino 
acids between residues 400 and 575 were created (JSY1208-1211). These internal 
deletions changed the electrophoretic mobility of the full-length protein, but not in 
proportion to the size of the deletion (Figure 5.6 A). The amino acid composition 
radically alters Def1 electrophoretic mobility, and unsurprisingly this is also the 
case for these small internal deletions. Importantly, none of the deletions - even 
those spanning the proposed processing site – blocked the processing of Def1 
after DNA damage (Figure 5.6 A) or at high cell density (data not shown). The 
deletions did, however, shift the site of processing; the faster migrating, processed 
band also changed electrophoretic mobility compared to the wild-type protein. This 
suggests that the processing site is not a fixed short amino acid sequence. Rpb1 
degradation was not altered in any of the internal deletion strains (Figure 5.6 A, 
upper panel). As Def1 has an unusual electrophoretic mobility, the distance 
between processed and full-length bands cannot be directly inferred. One 
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possibility is that the proteolytic cleavage of Def1 occurs at a fixed length from the 
C-terminus of Def1. However, tagging Def1 at the C-terminus did not affect the site 
of processing (Figure 5.3 A), suggesting that if there is some kind of ‘molecular 
ruler’ marking the site of cleavage, it must be reliant on Def1’s primary sequence 
rather than other domains added to the protein. 
 
 
 
 
Figure 5.6: Def internal deletions shift the site of processing 
 
A.Quick alkaline extracts from WT Def1 (JSY1190) and Def1 small (40-70 residue) internal 
deletion strains indicated, before and after treatment with 4-NQO for 30 and 60 minutes. 
Western blot using anti-Rpb1 (8WG16), anti-Def1, and anti-Pgk1 antibodies. 
B. As (A) with larger (100-200 residue) internal deletions of Def1. 
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Larger internal deletions removing hundreds of amino acids were created around 
the proposed processing site of Def1, and the strains expressing these were found 
to be viable (JSY1212-1214). 4-NQO treatment of cells with Def1 residues 400-500 
deleted resulted in the shifted mobility of both full-length and processed band, 
suggesting alternate processing site usage (Figure 5.6 B), as above. However, 
Def1 proteins with internal deletions from 400-600 and 500-600 no longer appeared 
to be processed after DNA damage. Interestingly, whilst the 506-575 deleted strain 
did exhibit Def1 processing, albeit at a different position, the 500-600 deletion did 
not. Surprisingly, the Def1Δ 400-600 and Def1Δ 500-600 strains exhibited normal Rpb1 
degradation after DNA damage, suggesting that Def1 was still functional in these 
cells, without any detectable proteolytic processing. Both these strains exhibit a 
slight growth defect at 30oC. Similar to the Def1 protein expressed by the def11-530 
strain, Def1Δ 400-600 and Def1Δ 500-600 might, under certain conditions, behave like the 
processed band without the need for proteolytic processing. Additional experiments 
are required to investigate these intriguing strains further. 
 
 
5.2.5 The N-terminal processed product of Def1 is the biologically active 
fragment 
 
pr-Def1 is an N-terminal proteolytic fragment formed in response to transcription 
stress. pr-Def1 appears to be the active form of the protein: the pr-Def1-like, def11-
530 can degrade Rpb1 spontaneously upon heat stress (Figure 5.5 C). However, a 
more direct link between the formation of the shorter activated version of Def1 and 
Rpb1 poly-ubiquitylation was still lacking. 
 
In order to help answer this question, a TEV cleavable form of Def1 was created 
(JSY 1191). TEV protease is the catalytic domain from the highly specific N1a 
protease from Tobacco Etch Virus (Dougherty et al., 1989, Parks et al., 1995). The 
N1a protease fragment helps to cleave the Tobacco etch virus polyprotein, at the 
consensus ExxYxQG peptide motif. TEV protease’s high specificity has been 
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utilised previously to create the specific, induced, cleavage of a modified cohesion 
subunit, outside of its normal cellular context (Uhlmann et al., 2000). 
 
 
 
Figure 5.7: Def1-TEV poly-ubiquitylates Rpb1 in the absence of damage 
 
A. Western blot of extracts from cells expressing WT Def1, or Def1 containing a TEV protease 
cleavage site. Both cell types contained galactose inducible Myc-tagged TEV protease. Western 
immunoblot of cell extracts of Def1 and TEV protease induction (anti-myc), and Pgk1 are shown 
(left panel). MultiDsk ubiquitin enrichment was performed on the extracts and immunoblotted for 
Rpb1 (4H8) and ubiquitin (P4D1) (right panel). 
B. Yeast dilution growth assay of the indicated strains transformed with galactose inducible 
Myc-tagged TEV protease plasmid. Cells grown on SD –Leucine Agar containing glucose and 
galactose as indicated. 
 
To mimic the generation of pr-Def1, without induced transcription stress, we placed 
a consensus TEV protease cleavage site into the approximate region that is 
normally subject to proteolytic cleavage (between residue 522 and 523 of Def1; 
Chapter 5. Results II 
 
146 
Figure 5.7 A, upper panel). Inserting the TEV cleavage site does not measurably 
affect the normal function of the Def1-TEV protein: the TEV site does not affect 
normal proteolytic processing or Rpb1 degradation (data not shown), or normal 
growth (Figure 5.7 B, glucose). GAL-regulated TEV protease - containing a Myc tag 
and nuclear localisation signalling (NLS) - was expressed from a transformed 
plasmid in these strains. Upon galactose induction of TEV protease Def1-TEV was 
proteolytically cleaved (Figure 5.7 A, left panel). This induced cleavage is at a 
similar position to that observed in the wild-type Def1 protein upon transcription 
stress, as estimated by comparing the electrophoretic mobility of the two bands. As 
expected, Def1 lacking a TEV cleavage site was not cleaved in the presence of 
TEV protease (Figure 5.7 A, left panel lanes 1-5). Importantly, concurrent with the 
emergence of the TEV-cut Def1 form, Rpb1 became poly-ubiquitylated, 
independently of induced transcription stalling (Figure 5.7 A right panel). No poly-
ubiquitylation of Rpb1 was observed when the TEV protease is expressed with a 
non-cleavable wild-type version of Def1. This suggests that the proteolytic nicking 
of Def1 is sufficient to induce the aberrant poly-ubiquitylation of Rpb1, and partially 
reconstitute the proteolytic processing, even in the absence of damage-induced 
transcription stalling. 
 
It is important to note that the extent of Rpb1 poly-ubiquitylation is lower compared 
to irradiation of cells with UV (Figure 5.1 C), despite roughly equal levels of cleaved 
Def1. Indeed, a noticeable reduction in the total cellular levels of Rpb1 could not be 
detected after expression of TEV protease in the Def1-TEV strain. Furthermore, 
there was only a slight growth defect of the Def1-TEV strain, compared to the wild-
type Def1 strain, on galactose plates (Figure 5.7 B), suggesting that constant Def1-
TEV cleavage was not overly detrimental to cell growth. Whether this was because 
the TEV-cleaved form of Def1 does not truly mimic pr-Def1, or if Rpb1 degradation 
requires other signalling events, is presently unclear. There is no induced 
transcription stall in this experiment. As Def1 is thought to promote the poly-
ubiquitylation of stalled mono-ubiquitylated RNAPII, this is likely the limiting factor 
in these conditions. The ubiquitylation observed is possibly the aberrant poly-
ubiquitylation of RNAPII that is temporarily paused or arrested, a natural 
consequence of all on-going transcription (Sigurdsson et al., 2010). 
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Figure 5.8: Def1 acts as an oligomer 
 
A. Dilution series of Wild-type yeast cells (carrying the GAL-driven plasmid indicated on the left), 
grown on SD -Uracil Agar glucose or galactose as indicated. 
B. Western blot showing Def1-HA and Rpb1 retained on immobilized Myc-Def1 beads after anti-
myc immunoprecipitation (IP, see 2.6.5). IP from cells expressing both Myc-Def1 and Def1-HA 
(JSY642 with pRS414-MTH-DEF1) 
C. Western blot of extracts from the above strain, immunoprecipitated for Myc epitopes and 
probed using anti-Def1 antibody. 
D. Coiled-coil domain prediction plot of Def1 created using COILs server (http://embnet.vital-
it.ch/software/COILS_form.html). 
 
 
It was surprising that Def11-400 or Def11-500 was extremely toxic to haploid cells, but 
not to diploid cells expressing a normal wild-type copy of DEF1 (Figure 5.4 B). The 
absence of a dominant negative effect of Def1 truncations was also observed when 
overexpressing Def11-400 and Def11-500 in wild-type cells, where a normal version of 
Def1 was expressed (Figure 5.8 A). This suggests that the wild-type version of 
Def1 is helping to sequester the toxic fragment, possibly via direct interaction. To 
ascertain if Def1 oligomerises, cells expressing a C-terminally HA-tagged form of 
Def1 (JSY 642) were transformed with a plasmid expressing an N-terminal Myc 
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tagged form of DEF1, from its own promoter. In these cells both forms of Def1 
protein were expressed roughly equally. Immunoprecipitation of the Myc-tagged 
form of Def1 co-precipitated the other Def1-HA form (Figure 5.8 B), suggesting that 
the protein exists as a multimer in vivo. Myc-tagged Def1 could still interact with 
Rpb1, but whether this was at the same time as interacting with another copy of 
Def1 requires further investigation. The association of Def1 with a partner appears 
to be somewhat inducible by DNA damage (Figure 5.8 C); increased levels of 
higher molecular weight Def1-HA appeared to associate with Myc-Def1 after 4-
NQO treatment for one hour. 
 
Whilst the exact stoichiometry of the Def1 self-interaction is unclear, it seems 
probable that Def1 forms as multimers rather than just as a dimer. Presumably, 
under constant galactose induction of Def11-400 or Def11-500, the amount of these 
proteins would exceed that of the endogenous wild-type Def1. However, despite 
the higher protein level, such expression is not toxic in wild-type strains, suggesting 
that the full-length protein can sequester multiple copies of the toxic Def11-500 or 
Def11-400. Def1 is predicted, with high probability, to have multiple coiled-coil 
regions (Woudstra et al., 2002, Figure 5.8 D). Coiled-coil domains typically consist 
of multiple α-helical-like secondary structures wound around each other in a rope-
like manner (Yu, 2002). Coiled-coils are a common structural motif associated with 
oligomerisation of proteins, either as dimers (such as leucine zippers), trimers (in 
keratin) or pentamers (Malashkevich et al., 1996). Whether the identified coiled-coil 
domains in Def1 associate inter- or intra-molecularly is unclear.  It is interesting to 
note that the most C-terminal predicted coiled-coil domain ends at around residue 
481, before the proposed proteolytic processing site. Def1 also contains a CUE 
domain at its N-terminus. Whilst principally described as a ubiquitin binding domain 
(UBD), CUE domains in solution can dimerise (Kang et al., 2003). The oligomeric 
state of Def1 is clearly important for its function and deserves further study. 
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5.3 Conclusions 
 
The faster migrating protein doublet that cross-reacts with a Def1 antibody on 
Western blots is a product of the Def1 protein. Full-length Def1 is post-
translationally processed, by proteolytic processing, creating an N-terminal 
fragment, termed pr-Def1. The exact site of proteolytic processing is unknown, but 
appears to be in the range of 520-530 amino acids from the N-terminus of Def1. 
 
Def1 is processed in response to RNAPII stalling and this processed protein - if 
expressed at high enough levels - is dangerous to the cell. The results presented 
here suggest pr-Def1 is the active form of Def1 and that it is toxic if aberrantly 
expressed and/or expressed at too high abundance. This toxicity is mediated, at 
least in part, through the degradation of Rpb1. Interestingly, we have found that the 
pr-Def1 protein is extremely short lived in protein extracts, and in vivo, suggesting 
that it is rapidly removed, as would be expected for such a toxic protein. 
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Chapter 6. Results III 
Def1 Protein Control 
 
6.1 Aims 
 
The data presented in the previous results chapter indicate that Def1 is 
proteolytically processed to an active fragment. However, the identity and control of 
the protease responsible for this cleavage was unknown. When Def1 processing 
was artificially mimicked - creating active fragments of Def1 – it promoted the 
aberrant poly-ubiquitylated of Rpb1. Confining the removal of the C-terminus, to 
occur only after transcription stress, appears to be crucial in order to prevent the 
inappropriate degradation of Rpb1. 
 
Furthermore, the mechanism by which removal of Def1’s C-terminus activates the 
protein was still unclear. Expression of a C-terminus fragment of Def1 did not 
prevent the toxicity of over-expressing Def11-500. Previous experiments have shown 
that full-length Def1 protein can interact with RNAPII and Rad26 (Reid and 
Svejstrup, 2004, Woudstra et al., 2002). Furthermore, pure Def1 can promote the 
formation of - albeit non-physiological - Rsp5-catalysed Lys-63 linked ubiquitin 
chains on RNAPII in vitro (Somesh et al., 2005). This would suggest that full-length 
Def1 is still biochemically functional. If this is the case, why is it necessary to 
proteolytically activate Def1 and why is this fragment toxic?  
 
One intriguing possibility is that the C-terminus might control Def1 through altering 
its sub-cellular localisation. Despite Def1’s primary role in chromatin, previous 
studies have shown that the protein primarily localises to the cytoplasm (Huh et al., 
2003, Tkach et al., 2012). The second of these studies observed no change in the 
steady state localisation of Def1 after the induction DNA damage. Importantly, in 
both studies, the authors used a C-terminal GFP tagged form of Def1. They, 
therefore, did not visualise the active N-terminal fragment of interest under 
investigation here. The molecular mechanism of Def1 proteolytic processing, its 
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control and effect on sub-cellular localisation were investigated and the results are 
presented in this chapter. 
 
 
6.2 Results 
 
6.2.1 Def1 processing is ubiquitin-dependent and requires Rsp5 
 
One of the benefits of working in S. cerevisiae is the large number of strains with 
gene disruptions available. Assaying the formation of pr-Def1 in many different 
genetic backgrounds was therefore possible, using the Def1 antibody. We 
undertook a candidate approach to assess Def1 processing in strains that had 
already been implicated in Def1 interaction, or involved in the Rpb1 degradation 
pathway. In most cases processing was not affected, however, this was not the 
case when the ubiquitin ligase Rsp5 was inactivated (Figure 6.1 A).  
 
Rsp5 is a HECT domain Ubiquitin ligase responsible for many processes in vivo, 
including the mono-ubiquitylation of Rpb1 (Kaliszewski and Zoladek, 2008). As 
Rsp5 is an essential protein in yeast (Wang et al., 1999), a temperature sensitive 
allele, termed rsp5-1, was used. At the permissive temperature, 25oC, Rsp5 
function is not impaired: Def1 processing and Rpb1 degradation occurs as normal 
(Figure 6.1 B). Shifting cells to the non-permissive temperature, 37oC, for 90 
minutes inactivates the protein (Harreman et al., 2009, Beaudenon et al., 1999). 
Rsp5-inactivated cells, treated with 4-NQO, exhibit greatly reduced pr-Def1 
formation, and no Rpb1 degradation (Figure 6.1 A). Whilst total Def1 levels appear 
to be reduced in the rsp5-1 strain, this is a loading artefact (Figure 6.1 A, compare 
Pgk1 loading to Def1 blots). Def1 is not processed, and therefore stabilised when 
Rsp5 is inactivated. Def1 processing, and subsequent Rpb1 degradation, can be 
observed in the wild-type control (Figure 6.1 B, left panel). Some Def1 processing 
is even observed without 4-NQO treatment; possibly due to the increased 
temperature, used during the assay, causing some transcription stress (see Figure 
5.2 C). 
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Figure 6.1: Def1 processing requires ubiquitylation by Rsp5 
 
A. Western blot of extract from WT and rsp5-1 cells, grown at 37°C (non-permissive 
temperature) for 2 hours before addition of 4-NQO for the indicated times. Asterisk denotes an 
unrelated or non-specific band, occasionally observed with the anti-Def1 antibody. 
B. Quick extracts from WT and Rsp5-1 strains treated with 4-NQO at the permissive 
temperature, 25oC. Western blot probed using anti-Rpb1 (8WG16), anti-Def1 and anti-Pgk1 
antibodies. 
C. Western blots of Def1 ubiquitylation, reconstituted in vitro using highly purified proteins (Def1, 
ubiquitin, Uba1, Ubc5, Rsp5 and Ubp2; see 2.8.1). An Rsp5 catalytic site mutant (C777A) and 
the de-ubiquitylating enzyme Ubp2 were used as specificity controls. Western immunoblot using 
anti-Def1 antibody. 
 
 
It was important to show a direct role for Rsp5 in the processing of Def1. Rsp5 is a 
promiscuous enzyme in vivo and also mono-ubiquitylates Rpb1, which might 
conceivably act as the signal for Def1 processing. As we have previously shown 
that Def1 becomes mono-ubiquitylated upon DNA damage (Figure 3.4 C), we 
therefore hypothesised that Rsp5 might be the ligase catalysing this ubiquitylation. 
Def1 ubiquitylation was reconstituted in vitro, using highly purified Uba1 (E1), Ubc5 
(E2), Rsp5 and ubiquitin. Two bands of reduced electrophoretic mobility were 
observed, corresponding to the oligo mono-ubiquitylated forms of Def1. These 
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were only present upon addition of pure active Rsp5 (Figure 6.1 lane 5); when an 
active site mutant form of Rsp5 was used (Rsp5 C777A, lane 4) ubiquitylation was 
absent. This mono-ubiquitylation can be trimmed back by Ubp2 (lane 6), a ubiquitin 
protease commonly associated with Rsp5 (Kee et al., 2005). Furthermore, pure 
recombinant Def11-500, mimicking pr-Def1, can associate with immobilised pure 
recombinant Rsp5 (data not shown). Def1 contains two degenerate PY motifs, 
possibly the recognition sites for the WW-domains of Rsp5 (Sudol, 1996, Chang et 
al., 2000). However, the binding to Rsp5 requires further investigation. 
 
 
 
 
Figure 6.2: Mutation of Def1 ubiquitylation sites reduces processing and Rpb1 
degradation 
 
A. Comparison of extracts from Def1 KI (WT) and a strain with 4 identified ubiquitin sites 
mutated from lysine to arginine (4xUbm, JSY1193), before and after treatment with 4-NQO for 
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30 minutes. Schematic with the position of mutated lysine residues indicated (top left). Cells 
were treated with and without 4-NQO for 1 hour. Western blot of extracts probed using anti-
Rpb1 (8WG16), anti-Def1 and anti-Pgk1 antibodies (left panel). MultiDsk pull-down from 
extracts, immunoblotted for Rpb1 (4H8), Def1 and ubiquitin (P4D1) (right panel). 
B. Western blot showing time course of cells from the above strains after UV irradiation. 
Western blot of extracts probed using anti-Def1 and anti-Pgk1 antibodies and MultiDsk pull-
down probed with anti-Rpb1 (4H8). 
 
 
From the in vitro ubiquitylation reaction described above, two ubiquitylated Def1 
peptides were identified by mass spectrometry. Both these peptides contained two 
lysines; it was not possible to identify which of these was ubiquitylated. A strain 
was created where these four lysines (K281, K288, K328 and K329) were all 
mutated to the closely related - but non-ubiquitylatable – arginines (4xUbm, 
JSY1193; Figure 6.2 A schematic). Mutation of these sites greatly reduced DNA 
damage-inducible mono-ubiquitylation of Def1 (Figure 6.2 A, right panel). The 
under-ubiquitylated Def1 was processed far less efficiently after transcription stress 
(Figure 6.2 A, left panel & B). Damage induced poly-ubiquitylation (Figure 6.2 A 
and B) and degradation of Rpb1 (Figure 6.2 A, left panel) was also markedly 
reduced in the 4xUbm strain. This suggests that ubiquitylation of Def1 is important 
for efficient pr-Def1 formation and again suggests a link between the processing of 
Def1 and Rpb1 degradation.  
 
Def1 is probably only ubiquitylated at just one or two sites on each molecule, as is 
implied from both the in vivo and in vitro molecular weight shifts. Interestingly, 
despite mutating four ubiquitylated lysines, Def1 mono-ubiquitylation and 
processing was not fully abrogated, suggesting that ubiquitylation can occur at 
alternative sites, with reduced efficiency. Ubiquitylation is often a promiscuous 
reaction that can target lysines in a local, conformational area (Danielsen et al., 
2011). Def1 is lysine-rich between residues 200-335 (14% of all residues in this 
area are lysines): these residues may lie close to each other in both primary and 
tertiary structure. Other ubiquitylation sites on Def1 have been reported using 
whole ubiquitome profiling (Starita et al., 2012, Beltrao et al., 2012). Therefore, 
additional lysines might also need to be mutated in order to totally ablate Def1 
ubiquitylation and processing. Another possibility (discussed below) is that 
ubiquitylation is not absolutely required for processing, but significantly enhances 
its efficiency.  
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6.2.2 Def1 processing requires the proteasome 
 
Whilst Def1 ubiquitylation greatly enhances its processing, the identity of the 
protease responsible for the proteolytic cleavage was still unclear. Surprising 
results, presented here, point to a role of the proteasome in this process.  
 
 
 
 
Figure 6.3: Rpb1 poly-ubiquitylation and def1 processing is reduced when the 
proteasome is inhibited 
 
A. Time-course of treatment of the proteasome inhibitor sensitive strain (GAC202) after addition 
of 4-NQO (10 µg/ml). Cells were pre-treated for an hour with or without the proteasome inhibitor 
MG132. Western blot of total cellular ubiquitylated proteins (P4D1) and anti-Pgk1 (lower) and 
MultiDsk pull-down probed for Rpb1 (4H8). 
B. Western blot of extracts from GAC202 cells treated (or not) with the proteasome inhibitor 
MG132, prior to incubation with 4-NQO for the indicated times. 
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MG132 is a potent, specific inhibitor of the chymotryptic activity of the proteasome 
(Lee and Goldberg, 1998b). MG132’s use in yeast has been limited due to its low 
efficiency inhibition of the yeast proteasome and its effective export by the multi-
drug resistance pump, Pdr5 (Lee and Goldberg, 1998a). A strain, deleted for the 
gene encoding this pump, and with active site mutations in trypsin and caspase-like 
subunits of the proteasome core particle, is highly sensitive to MG132 (Collins et al., 
2010, GAC202). When treating GAC202 cells with MG132, high molecular weight 
ubiquitin conjugates accumulate (Figure 6.3 A, middle panel), signifying the 
inhibition of proteasome-mediated protein degradation. As shown previously, DNA 
damage induces the poly-ubiquitylation of Rpb1 (Figure 3.3 C and 5.1 C), which 
under normal conditions is cleared by proteasomal degradation (Beaudenon et al., 
1999, Verma et al., 2011). Combining pre-treatment of MG132 and DNA damage 
would, thus, be expected to result in increased levels of Rpb1 poly-ubiquitylation: 
as Rpb1 is both becoming ubiquitylated and prevented from being degraded. 
Unexpectedly, however, the opposite was observed under these conditions: there 
was a reduction in the poly-ubiquitylated form of Rpb1 in response to both 4-NQO 
and MG132 compared to 4-NQO treatment alone (Figure 6.3 compare lanes 1-6 
and 7-12). Whilst it has been observed that poly-ubiquitin conjugation is somewhat 
limited during proteasome inhibition – as free ubiquitin concentration becomes 
limiting (Hjerpe et al., 2012) - the result is still striking. This suggests that the 
proteasome has a role upstream of its function in degrading Rpb1, possibly in 
promoting the poly-ubiquitylation of Rpb1.  
 
The mono-ubiquitylated form of Rpb1 was not affected by proteasome inhibition. 
Cells lacking Def1 also exhibit normal Rpb1 mono-ubiquitylation, but no poly-
ubiquitylation, after DNA damage (Woudstra et al., 2002). As pr-Def1 is believed to 
be the active form of Def1, it is conceivable that the proteasome plays a role in the 
proteolytic processing step of Def1. The formation of pr-Def1 was therefore 
assessed under the same conditions as Rpb1 poly-ubiquitylation. Pre-inhibiting the 
proteasome before 4-NQO treatment greatly reduced the formation of pr-Def1 
(Figure 6.3 B). Def1 processing was normal without MG132 treatment and in the 
congenic wild-type strain to GAC202, even when treated with MG132 (data not 
shown). 
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There are multiple possible explanations for the role of the proteasome in Def1 
processing. Processing may be mediated directly, via the proteolytic action of the 
proteasome. Alternatively, the proteasome might act indirectly, by degrading an 
inhibitor of pr-Def1 formation, after transcription stress. Finally, despite the high 
specificity of MG132, this compound could also be inhibiting other cellular 
proteases, which process Def1. MG132 is not widely used in yeast cells so 
possible off-target effects have not been investigated fully. 
 
In order to ascertain whether the proteasome can directly proteolytically process 
Def1, the reaction was reconstituted in vitro. Adding highly purified yeast 
proteasome to purified Def1 protein led to the rapid appearance of a faster 
migrating band, reminiscent of pr-Def1 (Figure 6.4 A). Indeed, the lower, 
proteasome-generated, Def1 band is of equivalent size to the pr-Def1 band 
observed in vivo after DNA damage (Figure 6.4 B, compare lanes 2 and 3). No 
further Def1 degradation products were observed, suggesting that only partial 
proteasomal processing - rather than total Def1 degradation - is occurring in this 
reaction. The conversion of the full-length protein to the smaller processed version 
occurs in a time-dependent manner. These data suggest that Def1 is partially 
proteolytically processed directly by the proteasome. 
 
As expected, inhibiting the pure 26S proteasome protein with MG132 drastically 
reduces the formation of the processed product in vitro (Figure 6.4 A left panel). In 
order to ascertain whether processing can occur independently of the purified 
proteasome, or if MG132 is not completely inhibiting the proteasome, the 
experiment was performed in the presence of excess MG132 and another 
proteasome inhibitor, lactacystin, which inhibits all protease activity of the 
proteasome (Fenteany et al., 1995) (Figure 6.4 C).  
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Figure 6.4: Def1 is directly processed by the proteasome 
 
A. Reconstitution of Def1 processing with purified Def1 and 26S proteasome at 30oC (2.8.2), in 
the absence or presence of MG132. An immunoblot using anti-Def1 antibody showed no other 
bands than presented here. 
B. Comparison of quick extracts from cells treated with or without 4-NQO for 30 minutes, with in 
vitro processed Def1 (lane 3). 
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C. In vitro proteasome proteolytic reaction performed at 30oC: without Drug control (+DMSO, 
lanes 13-18); large excess of MG132 (100µM) and lactacystin (50µM) (lanes 7-12); and without 
the addition of proteasome (lanes 1-6). Quick extracts with and without 4-NQO treatment are 
loaded as a control for the processed band(s) (lane 19 & 20). 
D. In vitro proteasome assay performed at 4oC, with MG132 inhibitor (lanes 1-3), or with 26S 
proteasome (lanes 4-6), or 20S proteasome (lanes 13-15). The assay was also performed with 
26S proteasome and pure RNAPII (lanes 7-9) and 26S proteasome and pure, mono-
ubiquitylated RNAPII (lanes 13-15). 
E. Proteolysis of full-length, ubiquitylated Def1 (ubi-Def1), or un-modified Def1 (Def1) over time 
in response to incubation with proteasome in the absence (-) or presence (+) of MG132. Def1 
was ubiquitylated in vitro prior to the assay (see Figure 6.1 C). Western blot quantifications 
(ImageJ) of the disappearance of full-length or ubiquitylated Def1 were normalised to 100% at 
starting time point 0. 
F. Western blot of quick extracts of wild-type and Def1 with mouse Dihydrofolate reductase 
(DHFR) attached to the C-terminus. Cells were grown for 3 hours in media containing 
methotrexate (Piwko and Jentsch, 2006) before treatment with 4-NQO. 
 
 
Intriguingly, even with the very high amounts of inhibitor used, some residual in 
vitro processing of Def1 still occurred (lanes 7-12). Whilst processing is far slower 
than without inhibitor (lanes 13-18), no observable pr-Def1 formation occurs - over 
the time course of the experiment - when proteasome is not added (lanes1-6). This 
observation is not unprecedented: reconstituted NF-κB p105 processing in extracts 
shows a reduction of only around 50% of processing in the presence of great 
excess of MG132 (Kravtsova-Ivantsiv et al., 2009). Further study of this effect has 
been hampered due to the inherent instability of the Def1 protein, which appears to 
spontaneously ‘self-cleave’ during longer incubations at 30oC (see lower band in 
ubiquitylation reaction in Figure 6.1 C). Intriguingly, this spontaneous cleavage 
appears to occur at the same site as normal in vivo processing. Further work is 
required to investigate this finding. A fascinating possibility is that the proteasome 
is inhibited in the in vitro reaction presented in Figure 6.4 C, but that it is the binding 
of Def1 to the proteasome that then induces breakage at an inherently unstable site 
in Def1. 
 
Performing the proteasome-processing assay at 4oC still permits production of the 
active processed fragment, albeit at a slower rate (Figure 6.4 D). Partial processing 
has been re-constituted previously for the p105 subunit of NF-κB1, using pure 
components with 20S proteasome (Moorthy et al., 2006). We could also observe 
partial processing by the 20S proteasome particle (Figure 6.4 D, lanes 13-15) that 
lacked the 19S caps, normally critical for the unwinding and feeding of substrates 
into the proteasome (Lee et al., 2001a). However, the efficiency of processing was 
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reduced compared to the reaction with complete 26S proteasome (compare lanes 
4-6 and 13-15). 
 
Both the in vivo and the in vitro data points to a direct role for the proteasome in the 
partial proteolytic processing of Def1, which cleaves and degrades Def1’s C-
terminus, allowing the active N-terminal pr-Def1 fragment to escape. Proteolytic 
cleavage is commonly used to produce active proteins from their inactive 
precursors (Hengartner, 2000, Berg et al., 2002). Partial proteolytic processing has 
been reported previously in a number of different studies (see introduction, 1.1.6). 
Not all proteasome-mediated protein degradation requires ubiquitylation of the 
target protein (Jariel-Encontre et al., 2008). However, previous cases of partial 
proteolytic processing have required ubiquitylation of the processed protein, at 
least in vivo, in order to target the protein to the proteasome (Palombella et al., 
1994, Hoppe et al., 2000). 
 
However, in the in vitro system outlined above, ubiquitylation is not absolutely 
required for proteasomal processing. This appears to be at odds with the previous 
observations of Def1 DNA damage-inducible ubiquitylation, and subsequent 
processing (section 6.2.1). In order to investigate the role of ubiquitylation in pr-
Def1 formation in vitro, ubiquitylated Def1 was created as described previously 
(Figure 6.1 C). Ubiquitylated Def1 is more rapidly proteasomally processed in vitro 
than its non-ubiquitylated counterpart; quantification of the upper, full-length bands 
show more rapid loss in overall signal of the ubiquitylated Def1 band, compared to 
the non-ubiquitylated Def1 band (Figure 6.4 E). These observations, whilst not in 
strict agreement with the requirement for Rsp5 and its identified ubiquitylation sites 
observed in vivo, are not unprecedented. In other reconstituted systems 
ubiquitylation seems to play an accessory - but stimulatory - role in processing, 
however, the same proteins in vivo require ubiquitylation (Moorthy et al., 2006, 
Kravtsova-Ivantsiv et al., 2009, Kraut and Matouschek, 2011). It is interesting to 
note that the ubiquitylation sites identified are in the N-terminal section of Def1; 
however, the pr-Def1 bands do not appear to be ubiquitylated. 
 
Further study into the ubiquitin-dependent processing of Def1 has been hampered 
due to the inherent instability of the Def1 protein, which spontaneously cleaves 
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during the lengthy ubiquitylation-reaction incubation in vitro (Figure 6.1 C). One 
potential possibility is that direct Def1 ubiquitylation is not required for processing 
in vivo: instead it is the association with mono-ubiquitylated RNAPII that triggers 
Def1 proteasomal cleavage. According to this model, the requirement of Rsp5 for 
Def1 processing would be indirect. Rsp5 would be necessary for RNAPII mono-
ubiquitylation, instead of Def1 ubiquitylation, by the same enzyme. If this were the 
case, one would expect to see an increase in the formation of pr-Def1 when 
excess, purified, mono-ubiquitylated RNAPII is added to the in vitro processing 
reaction, but this was not observed (Figure 6.4 D, lanes 10-12).  
 
The exact mechanism of proteasomal degradation is still unclear. In the case of 
partial proteasomal processing, the proteasome might act as an exo-peptidase; 
chewing up the substrate from the C-terminus, until it is blocked or reaches a stop 
signal in the processed protein (Orian et al., 1999). Alternatively, the proteasome 
may act at an internal initiation site and process the fragment bi-directionally (Piwko 
and Jentsch, 2006). In order to test these two possibilities, we created a strain 
expressing Def1 protein with mouse Dihydrofolate reductase (DHFR) and a HA tag 
at its C-terminus (JSY1218). Previous studies have used DHFR to block the 
proteasome (Piwko and Jentsch, 2006, Prakash et al., 2004, Kraut and 
Matouschek, 2011). DHFR, when bound to methotrexate, is refractive to 19S 
unwinding and is extremely stable in vivo (Johnston et al., 1995). When cells 
expressing the Def1-DHFR fusion protein were pre-incubated with methotrexate, 
and then treated with 4-NQO, Def1 was still processed. This suggests that the 
DHFR tag did not block the processing reaction, and argues against the processing 
reaction occurring from the C-terminus. Instead, processing by the proteasome 
may be initiating from an internal Def1 site. This preliminary experiment requires 
further optimisation to assert this conclusion. Unfortunately, the ‘stable’ Def1-DHFR 
C-terminus could not be visualised using either a mouse DHFR antibody or HA 
antibody, suggesting it may still have been degraded by the proteasome as an exo-
peptidase. This may be because Def1 can be processed independently of the 19S 
subunit (Figure 6.4 D), possibly bypassing the inhibitory role otherwise observed for 
mouse DHFR. 
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6.2.3 Def1 changes steady state subcellular localisation after UV irradiation 
 
 
 
Figure 6.5: GFP-Def1 changes subcellular localisation after DNA damage 
 
Localisation of N-terminally GFP-tagged Def1 in untreated and UV-irradiated cells. Live cells 
were visualised 1 hour after irradiation, the nucleus is marked by DAPI staining. (Upper panels) 
A typical field of cells. (Lower panels) Enlargement of the yeast cell, indicated by white box, in 
the top panels. Please note that although the number and size of vacuoles differed from 
experiment to experiment, it had no influence on the nuclear accumulation observed. 
 
 
Previous studies have shown that Def1 is localised to the cytoplasm (Huh et al., 
2003, Tkach et al., 2012), despite its involvement in RNAPII poly-ubiquitylation on 
chromatin. These studies relied on a C-terminally GFP-tagged Def1, allowing 
visualisation of the full-length protein, but not pr-Def1. By engineering DNA 
encoding an N-terminal enhanced green fluorescent protein (eGFP) tag into the 
DEF1 genomic locus (JSY1194), the localisation of both full-length and processed 
forms of Def1 could be ascertained. As eGFP fluoresces in live cells, intact non-
fixed cells could be visualised. Without UV treatment, Def1 localises predominantly 
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to the cytosol. Def1 is largely absent from two patches in the cell, one of which is 
attributable to the nucleus, identified by the blue nuclear DAPI staining (Figure 6.5, 
panel c and zoom in on one cell panel i). The other, typically larger, GFP signal 
exclusion zone is the yeast vacuole. The vacuole changes in size during cell cycle 
progression and due to different nutrient conditions. As a result, the size of the 
vacuole varies between different experiments, which did not alter the results 
obtained. Cells were also imaged 1 hour after UV irradiation and under these 
conditions the eGFP signal was distributed across the whole cell. Notably, there is 
considerable overlap between the blue, DAPI-stained genetic material and the 
green, GFP Def1 signal (Figure 6.5, panel f and l). This indicates that, after UV 
treatment, Def1 can change its subcellular localisation, and partially redistribute to 
the nucleus. 
 
 
6.2.4 pr-Def1 changes subcellular localisation after UV irradiation 
 
It was important to ascertain whether it is specifically pr-Def1 that is capable of 
changing its subcellular localisation, rather than the whole cellular pool of Def1. 
Moreover, it was unclear whether the apparent change in sub-cellular distribution of 
Def1 was just an artefact of exposing cells to UV radiation. This remained a 
possibility as the GFP signal became visible across the whole cell, including the 
vacuole, after UV irradiation. Hence, UV treatment might theoretically destroy these 
intracellular compartments, allowing free diffusion of GFP-Def1.  
 
Cells expressing a C-terminally GFP-tagged form of Def1 exhibited normal cellular 
morphology after UV treatment.  Furthermore, these cells did not show appreciable 
relocalisation of GFP signal after treatment with UV, suggesting that the cellular 
compartments remained intact (Figure 6.6 A, panel e). Moreover, the lack of Def1-
GFP in the nucleus suggests that it is only the N-terminal fragment that changes 
sub-cellular distribution after UV treatment (compare Figure 6.6 A, panel f with 
Figure 6.5 panel f). Upon quantification, only the N-terminally, GFP-tagged Def1 
strain exhibited significant overlap of nuclear DAPI stain with GFP signal after 
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irradiation (Figure 6.6 A, right). Around 20% of cells in both strains exhibited some 
overlap of DAPI with GFP signal, in the absence of DNA damage, which may 
reflect the lower sensitivity threshold of the experimental system. 
 
Def1 was also N-terminally eGFP-tagged in the MG132 sensitive yeast strain 
(eGFP-Def1 GAC202, JSY1195) and pre-treated with MG132 prior to irradiation. 
This allowed the role of the proteasome - and thus the processing of Def1- in the 
sub-cellular re-distribution of Def1 to be investigated. As shown above, inhibition of 
proteasomal activity ablates the DNA damage-dependent processing of Def1 
(Figure 6.3 B). Without inhibition of the proteasome, the GFP-Def1 signal was 
observed across the whole cell after UV treatment (Figure 6.6 B, panel f), as seen 
previously. When the proteasome was inhibited, however, the cellular localisation 
of Def1 was not appreciably altered by DNA damage. After UV irradiation the 
majority of cells still displayed predominantly cytosolic localisation of Def1 (Figure 
6.6 B, compare panel f with l; see also quantification on the right), suggesting that 
proteasome-dependent generation of pr-Def1 is required for Def1 accumulation in 
the nucleus. 
 
Proteasome inhibition does not completely block GFP-Def1 spreading in all the 
cells. From the quantification of two biological replicates, approximately 40% of 
cells exhibit overlap of the nuclear and Def1 signal after DNA damage and MG132 
treatment, compared to approximately 80% of cells after only DNA damage (Figure 
6.6 B, right). This partial effect may be due to incomplete inhibition of the 
proteasome, which allows some residual Def1 processing (see Figure 6.3 B, 
+MG132). It should be noted that MG132 treatment of cells affected their 
morphology: there was a decrease in the number of budded cells, consistent with a 
reduction in cell growth. MG132 treatment also resulted in the emergence of 
cytosolic Def1 foci, which were more pronounced after DNA damage (Figure 6.6 B, 
panels h and k). Human cells exhibit cytosolic foci of unfolded ubiquitylated 
proteins, termed aggresomes, upon proteasome inhibition (Johnston et al., 1998). 
Whether the yeast foci observed upon proteasome inhibition are aggresomes, 
containing Def1, is unclear and requires further study. 
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Figure 6.6: accumulation of pr-Def1 in the nucleus after DNA damage mediates 
its toxicity 
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A. A typical field of cells showing localisation of C-terminally GFP-tagged Def1 in untreated and 
UV-irradiated cells as Figure 6.5 (left panel). Quantification of Def1 nuclear accumulation in 
cells expressing N-terminally tagged GFP-Def1 or C-terminally tagged Def1-GFP, respectively, 
with or without UV-irradiation as indicated (right panel). Error bars indicate standard deviation of 
three biological replicates, counting a total of 200-300 cells for each condition.  
B. Localisation of GFP-Def1 in proteasome-sensitive GAC202 cells incubated in the absence or 
presence of MG132 for 1 hour prior to UV irradiation and visualised one hour hence. (Left 
panel) A typical field of cells. (Right panel) Quantification of Def1 nuclear accumulation in 
proteasome active and inhibited cells, with and without UV treatment. Data obtained from 
around 200 cells from two biological replicates. 
C. Yeast growth analysis of Δdef1 cells with (right panel) or without (left panel) galactose 
induction of 1-500 Def1 or 1-500 Def1 with a consensus Nuclear Export Signal (NES) at the N-
terminus. 
 
 
Over-expression of the first 500 amino acids of Def1 is toxic to cells (Figure 5.4 C). 
As the active pr-Def1 form is localised to the nucleus, we considered the possibility 
that the forced export of Def11-500 from the nucleus might suppress its toxicity. 
Indeed, appending a nuclear export signal (NES; Wen et al., 1995) to the N-
terminus of Def11-500 partially rescues the toxic phenotype (Figure 6.6 C, compare 
vector to NES-Def11-500). This suggests that the toxicity mediated by the Def11-500 is 
at least partially dependent upon its nuclear localisation. This is not a complete 
rescue; possibly because Def11-500 is still imported to the nucleus before it is 
shuttled out again, and thus allowed access to RNAPII. Def11-500 is also under 
constant galactose expression, resulting in very high levels of expression; this 
might overload the NES-dependent export pathway, resulting in some growth 
retardation. 
 
 
6.2.5 The C-terminus of Def1 promotes its steady state cytoplasmic 
localisation 
The data above indicate that Def1 can accumulate in the nucleus upon partial 
proteasomal processing. Under normal, non-stressed, steady state conditions the 
protein appears to be largely cytoplasmic, spatially excluded from its substrate in 
the nucleus. As a result, Def1 processing and dynamic compartmentalisation may 
help to control Def1 function, by restricting access to stalled RNAPII on chromatin. 
Def1 may be actively excluded from the nucleus by its C-terminus, whereby the 
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removal of this section – after transcription stress - allows active import into the 
nucleus. 
 
There are several shortcomings of this hypothesis. First, this model does not 
explain how the signal of persistently stalled RNAPII is transduced to the cytosol, 
leading to the processing of Def1. Second, previous data indicated that full-length 
Def1 can be extracted from chromatin (Woudstra et al., 2002) and can associate 
with nuclear RNAPII (Reid and Svejstrup, 2004). Finally, the Svejstrup lab has 
shown that some poly-ubiquitylation and degradation of Rpb1 is required to deal 
with ‘everyday’ transcription stalling (Sigurdsson et al., 2010, Hobson et al., 2012). 
As a result, some Def1 might be required, even in the absence of DNA damage, 
due to some basal transcription-stress. 
 
An alternative possibility is that full-length Def1 can be present both in the nucleus 
and cytoplasm, but appears to be mainly steady state cytosolic because it is 
actively pumped out of the nuclear compartment. In this model, Def1 constantly 
samples the nucleus for RNAPII stalling, and may become proteolytically 
processed, on chromatin in situ, when stalling occurs, allowing its nuclear retention. 
The two models - nuclear exclusion versus nuclear export - differ in their prediction 
for the function of the C-terminus of Def1: in the former it inhibits nuclear import, 
and in the latter it directs nuclear export. 
 
In order to distinguish between these models, the relative distribution of control 
proteins in the strains used in this study was first required. A protein with both a 
nuclear localisation signal (NLS) and a NES was distributed around the whole cell, 
indicating a dynamic balance between the NLS targeting the protein to the nucleus 
and the NES directing it to the cytoplasm (Figure 6.7, panels a-c), as has been 
observed previously by others (Taura et al., 1998). A construct with a NLS, GFP 
protein and β-galactosidase (β-gal) was used as a positive control for nuclear 
localisation (Figure 6.7, panels d-f). The β-galactosidase acts as a control protein-
tag that does not affect the localisation of the hybrid protein, which is directed to the 
nucleus by the N-terminal NLS (Lee et al., 1996). 
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Figure 6.7: The C-terminus of Def1 promotes the nuclear export of Def1 
 
Localisation of NLS-GFP proteins in fixed cells. Wild-type (upper panel) or rat7-1 (lower panel) 
cells expressing NLS-NES-GFP2 (pPS1372), NLS-GFP-β-galactosidase (pPS815), or NLS-
GFP-Def1500-738 were grown at 23oC and shifted to 30oC for 2 hours before fixing in 
formaldehyde. 
 
 
To test the role of the C-terminus of Def1, the β-gal control tag was substituted with 
the last 238 amino acids of Def1 (NLS-GFP-Def1500-738). If the C-terminal 
polypeptide of Def1 - removed by proteolysis in processing - normally prevents 
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entry to the nucleus, then the NLS-GFP-Def1500-738 construct would only appear in 
the cytosol. In contrast, if this domain promoted nuclear export, then the fusion 
protein would be able to move into the nucleus, before being pumped out. 
Interestingly, the C-terminus of Def1 radically altered the localisation of NLS-GFP, 
mirroring the pattern observed for the NLS-GFP2-NES (Figure 6.7, panels g-i): the 
GFP signal was distributed equally over the entire cell. This suggests that the C-
terminus of Def1 does not interfere with nuclear import and may actively promote 
nuclear export. 
 
To further test this hypothesis, a temperature-sensitive rat7-1 strain was used. 
Rat7/Nup159 is a core component of the nuclear pore complex. In the rat7-1 strain 
most nuclear export is inhibited at the non-permissive temperature (Gorsch et al., 
1995). Analysing the same constructs described above in the rat7-1 strain showed 
marked nuclear accumulation of both the NLS-GFP2-NES and NLS-GFP-Def1500-738 
proteins (Figure 6.7, panels j-l, p-r), indicating these were captured in the nucleus, 
unable to be re-exported after NLS-directed import. Interestingly, this marked effect 
was observed even at the semi-permissive temperature of 30oC. These 
observations suggest that the C-terminus of Def1 is acting like a NES, to promote 
the export of Def1 from the nucleus, rather than preventing its entry. Whilst the 
artificial test proteins used here are distributed throughout the whole cell, this is not 
the case for the full-length Def1 protein. This is possibly due to the relative strength 
of any NLS found within Def1 compared to the SV40 NLS sequence used in the 
constructs tested here. The SV40 NLS is near to the ideal consensus sequence 
recognised by Kap60 (importin-α) (Lange et al., 2007). Def1 contains a predicted, 
but weak, lysine-rich NLS encompassed by the CUE domain (residues 74-80). A 
high level of NLS sequence conservation promotes improved nuclear import (Hodel 
et al., 2006). Furthermore, the positioning of the NLS in Def1 might alter its ability 
to bind Kap60. Thus, the import activity of this NLS may normally be overwhelmed 
by the activity of the - so far poorly defined – Def1 C-terminal nuclear export signal. 
 
The C-terminus of Def1 is sufficient to promote nuclear export of another protein. 
The majority of proteins actively exported from the nucleus contain a short leucine 
rich NES, which is bound directly by the Crm1/Xpo1 exportin (Hutten and 
Kehlenbach, 2007). No clear leucine rich region could be identified in Def1, either 
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manually or by using NES prediction tools (http://www.cbs.dtu.dk/services/ 
NetNES/). In agreement with the lack of a NES-like sequence, the export of Def1 
does not seem to rely on Crm1. This was visualised using a strain carrying a CRM1 
mutation, sensitising the protein to Leptomycin B (LMB) inhibition (MNY8; Neville 
and Rosbash, 1999). LMB inhibits Crm1 in Schizosaccharomyces pombe and its 
homologue in mammalian cells, Exportin-1, by covalently binding to a conserved 
cysteine residue in the proteins’ NES-binding domain. The S. cerevisiae MNY8 
strain has this sensitising cysteine mutation, making it possible to rapidly block 
NES-directed export by addition of LMB to the media (Neville and Rosbash, 1999). 
 
Addition of LMB to MNY8 cells transformed with the NLS-GFP2-NES protein rapidly 
led to the accumulation of the protein in the nucleus, as nuclear export for this 
NES-containing protein was blocked (Figure 6.8 A, panels j-l). Movement of Def1 in 
the same strain background was observed by N-terminally eGFP tagging Def1 
genomically (JSY1201). This strain did not accumulate eGFP-Def1 in the nucleus 
after extensive LMB treatment (Figure 6.8 A, panels d-f), suggesting the dynamic 
shuttling of Def1 was not appreciably affected. Therefore, Def1 nuclear export is 
probably not mediated via the classical Crm1/NES pathway. Instead, export may 
be mediated through one of the other, poorly characterised, nuclear export 
pathways identified in yeast (Strom and Weis, 2001). 
 
Remembering the striking range of phenotypes observed by making Def1 C-
terminal genomic deletions (Def11-500, was lethal, Def11-530 was viable but 
temperature sensitive and Def11-540 had no discernable phenotype) (Figure 5.5), we 
hypothesised that the region encompassing amino acids 500-540 might contain a 
sequence required for nuclear export. However, appending Def1 residues 500-540 
to a protein with an N-terminal NLS-and two GFPs was not sufficient to alter its 
subcellular localisation, suggesting that this region is not sufficient, by itself, to 
promote nuclear export (Figure 6.8 B, compare panels c and f). The export signal 
may be a large conformational element, which cannot be described by short, 
simple tracts of primary sequence. No export sequences have been identified for 
the other, non-Crm1 dependent, export pathways found in yeast. It is more likely 
that recognition is mediated through tertiary structure (Xu et al., 2010) and 
therefore the entire C-terminus of Def1 may be required for export. In connection, it 
Chapter 6. Results III 
 
171 
is interesting to note that the C-terminal region of Def1 is glutamine rich, and poly-
glutamine expansions have been shown to promote nuclear export (Chan et al., 
2011). In this paper, a large poly-glutamine section was sufficient to ensure nuclear 
export. However, this was mediated via the Exportin-1-NES pathway. In contrast, if 
the glutamine rich region of Def1 helps to promote nuclear export in yeast, it is 
probably not dependent upon the Crm1-NES pathway. 
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Figure 6.8: Def1 is exported in a Xpo1 independent manner 
 
A. Localisation of GFP proteins in fixed Leptomycin B (LMB) sensitive MNY8 cells. MNY8 cells 
with the T539C LMB sensitising mutation in Crm1 were incubated with or without LMB for 30 
minutes before fixing in formaldehyde and visualising. MNY8 cells, with eGFP-Def1, were 
generated by Michelle Harreman. 
B. A typical field of cells showing the localisation of NLS-GFP proteins under steady state 
conditions. Cells were transformed with vectors promoting the expression of NLS-GFP2-Def1500-
540 and NLS-NES-GFP2. 
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6.2.6 Conclusions 
 
In this chapter, evidence has been provided for the manner in which Def1 is 
processed to an active N-terminal fragment, how this is controlled, and why it is 
necessary to control the protein. Def1 is ubiquitylated by the HECT E3 ligase Rsp5 
and blocking this ubiquitylation ablates partial proteolytic processing. Ubiquitylation 
may target Def1 to the proteasome, where instead of being totally degraded it is 
partially processed, releasing an active N-terminal fragment. This active, pr-Def1 
fragment appears to be no more active biochemically than the full-length protein. 
Instead, Def1 is controlled at a cellular level, through dynamic 
compartmentalisation. The pr-Def1 fragment accumulates in the nucleus, as the C-
terminus normally promotes the nuclear export of full-length Def1. The partial 
proteasomal processing of Def1 creates an elegant, irreversible control step, in 
order to mediate Def1 access to its substrate. Exactly how the C-terminus of Def1 
facilitates nuclear export remains unclear, but it is not mediated through the 
canonical NES-Crm1 pathway 
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Chapter 7. Results IV 
The Role of Def1 in the Nucleus 
 
7.1 Aims 
 
The previous results chapter outlined that pr-Def1 accumulates in the nucleus after 
its C-terminus has been proteolytically removed. Up to this point the protein has 
been termed as ‘active’ and ‘toxic’, but what mediates this toxicity is not known. 
Aberrant expression of pr-Def1-like molecules leads to the poly-ubiquitylation and 
degradation of Rpb1. The manner in which nuclear pr-Def1 mediates this process 
was investigated and the results are presented in this chapter.  
 
Def1 lacks any clear enzymatic activity domains, so instead, may act as a scaffold 
for binding components of the RNAPII poly-ubiquitylation pathway. We set out to 
find what pr-Def1 was binding to in the nucleus and how this leads to the 
degradation of Rpb1. Previous studies have found that full-length Def1 can interact 
with Rad26 (Woudstra et al., 2002) and RNAPII (Reid and Svejstrup, 2004). 
RNAPII poly-ubiquitylation is a multi-step process involving many protein factors 
(see 1.5.3), all of which could be potential pr-Def1 interactors. We also wanted to 
investigate which part of Def1 was responsible for any binding and whether this 
was also responsible for mediating RNAPII poly-ubiquitylation.  
 
 
7.2 Results 
 
7.2.1 Def1 requires its N-terminal CUE domain for activity 
 
Def1 has a putative N-terminal CUE (coupling of ubiquitin conjugation to 
endoplasmic reticulum degradation) ubiquitin-binding domain (UBD), identified via 
loose sequence homology (Ponting, 2002). CUE domains have been reported to 
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bind ubiquitin; structural and mutational data has revealed that this interaction is 
mediated via hydrophobic interactions (Shih et al., 2003, Kang et al., 2003). A 
hydrophobic pocket within the CUE domain fold accommodates the Leu8-Ile44-
Val70 patch of ubiquitin. The mutation of four key residues in the CUE domain 
pocket ablates ubiquitin-binding activity (Shih et al., 2003). In Def1 these residues 
were predicted to correspond to Phe32-Pro33 and Ile54-Ile55. We mutated these 
residues to alanine, hereafter termed CUE mutant (CUEm Figure 7.1 A, left). Over-
expression of wild-type Def1 in Δdef1 cells, leads to a rescue of the slow growth 
phenotype of these cells. Such rescue was also observed for over-expression of 
the mutant protein (Figure 7.1 A, right), suggesting that the full-length CUEm 
protein can be both expressed and is not detrimental to growth. However, over-
expression of the CUE mutated 1-500 Def1 (Def11-500/CUEm) was not toxic, unlike the 
expression of the cognate non-mutant Def11-500 (Figure 7.1 A, right). This dramatic 
rescue suggests that the CUE domain is critical to the function of pr-Def1.  
 
Mutating the CUE domain at the genomic locus of Def1 (def1CUEm, JSY 1196) does 
not affect the formation of pr-Def1, in response to UV irradiation (Figure 7.1 B). 
Furthermore, the mutations do not prevent the induced accumulation of pr-Def1 in 
the nucleus after UV damage (Figure 7.1 C, compare panels f to l), suggesting that 
the function of the CUE domain lies downstream of Def1 activation. Indeed, 
def1CUEm displays reduced poly-ubiquitylation of Rpb1 after UV irradiation (Figure 
7.1 B, upper). Despite the correct processing of Def1 and relocalisation to the 
nucleus, a functional CUE domain is thus required to induce poly-ubiquitylation of 
Rpb1. 
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Figure 7.1: The CUE domain of Def1 is essential for Def1-dependent poly- 
ubiquitylation of Rpb1 
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A. (Left) Schematic of Def1 showing the 4 key residues of the CUE domain, which were 
mutated (F33A, P34A. I54A, I55A). (Right) Yeast growth assay of Δdef1 cells (carrying the GAL-
driven plasmid indicated on the left) on glucose or galactose, as indicated. 
B. Western blot of extracts from KI def1 (WT), def1CUEm (JSY1196) or Δdef1 strains. Cells were 
UV-irradiated and extracts taken at the indicated time-points taken. Western immunoblot for 
Def1 and Pgk1 in cell extracts is shown. MultiDsk ubiquitin enrichment was performed on the 
extracts and immunoblotted for Rpb1 (4H8). Asterisk indicates a non-specific antibody band. 
C. A typical field of live cells showing localisation of Def1 in GFP-Def1 wild-type and GFP-
Def1CUEm cells, in untreated and UV-irradiated conditions. DNA was stained by DAPI. 
 
 
The primary hypothesis investigated was that nuclear CUEm pr-Def1 was deficient 
in a binding event, required for Rpb1 poly-ubiquitylation. The CUE domain of Def1 
was predicted to bind mono-ubiquitin (Shih et al., 2003). To assess this in vitro we 
purified the first 500 amino acids of Def1, with a C-terminal His tag (Def11-500-His), 
from E.coli. It was assumed that this protein would mimic the functions of pr-Def1. 
The CUE domain mutations were also incorporated in this protein, creating Def11-
500/CUEm-His. Def11-500-His binds to immobilised GST-ubiquitin, but not to GST alone, or 
to GST-ubiquitin with a mutation in the hydrophobic patch (GST-Ubi I44A) (Figure 
7.2 A, left). In contrast, Def11-500/CUEm-His interacts very poorly with GST-Ubiquitin, 
despite roughly equal protein amounts added to the assay (Figure 7.2 A, right). The 
bound Def1 runs at a lower position to the Input due to a loss of the C-terminal 
6xHis tag during the experiment. Intriguingly, Def11-500 appears to bind 
preferentially without the C-terminal tag, suggesting that either this form is enriched 
from the Def11-500 population, or binding to ubiquitin induces the loss of the 6xHis 
tag. These results confirm that Def1 does contain a UBD and that this is the N-
terminal CUE domain identified bioinformatically. 
 
The def1CUEm strain cannot promote efficient poly-ubiquitylation of Rpb1. Moreover, 
the CUE domain of Def1 can bind to immobilised ubiquitin. As RNAPII requires 
mono-ubiquitylation before a subsequent poly-ubiquitylation step (Harreman et al., 
2009) - which involves Def1 (Woudstra et al., 2002) – the most obvious target of 
Def1’s CUE domain would be mono-ubiquitylated RNAPII. In order to test this 
hypothesis directly, mono-ubiquitylated RNAPII-HA was created using pure E1, E2 
(Ubc5), E3 (Rsp5) and NoK ubiquitin - where all internal lysine residues are 
mutated, to prevent the formation of poly-ubiquitin chains. The reaction is robust 
and results in a molecular weight shift and slight smear of multiple mono-ubiquitins 
added to Rpb1 (Figure 7.2 B, compare lanes 3&4). As a control, RNAPII-HA was 
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left un-ubiquitylated by omitting ubiquitin in the reaction. The ubiquitylation 
reactions were then incubated with a HA-affinity resin and washed extensively 
before incubation with recombinant Def11-500-His proteins. Surprisingly, Def11-500-His 
bound well to immobilised RNAPII, but not to mono-ubiquitylated RNAPII (Figure 
7.2 B, lanes 3 & 4). Furthermore, when the CUE domain of Def1 was mutated this 
did not affect the observed binding pattern (Figure 7.2 B, lanes 6 & 7). Def11-
500/CUEm-His bound poorly to mono-ubiquitylated RNAPII, but equally as well to 
unmodified RNAPII as Def11-500-His. These results suggest that, unexpectedly, Def1 
interaction with RNAPII is neither dependent on its CUE domain, nor is it stimulated 
by the ubiquitylation of RNAPII. It is, of course, impossible to rule out that the in 
vitro ubiquitylated RNAPII is not the proper substrate for Def1s CUE domain, or 
recombinant Def1 is not competent for RNAPII-Ubi binding. While the above 
experiment was performed using artificial reaction conditions and substrates, 
multiple other attempts to test the CUE domain dependence of Def1 binding to 
mono-ubiquitylated RNAPII were also unsuccessful (data not shown).  
 
 
 
Figure 7.2: The CUE domain of Def1 binds ubiquitin but not RNAPII. 
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A. Binding of purified, recombinant Def11-500-His, or Def11-500/CUEm-His to immobilized GST, GST-
ubiquitin or GST-ubiquitin with a hydrophobic patch mutation I44A. 5% of input and bound 
proteins were loaded onto an SDS-PAGE gel, followed by anti-Def1 immunoblotting. Ponceau S 
is shown as a loading control for the immobilized proteins. 
B. Binding of purified Def11-500-His, or Def11-500/CUEm-His to HA antibody immobilized RNAPII or 
mono-ubiquitylated RNAPII. Western blot analysis was performed with Rpb1 (4H8), Def1 (anti-
Def1) and Rpb3 (1Y26), after extensive washing and SDS-PAGE.  
 
 
In order to find the correct substrate for the CUE domain - taking a less biased 
approach - Def11-500-His and Def11-500/CUEm-His were immobilised on cross-linkable, 
Affigel beads (BioRad) and incubated with irradiated crude cell extract. After 
washing, the bound proteins were resolved by SDS-PAGE and identified by mass 
spectrometry. Overall, there was a significant enrichment for RNAPII subunits, but 
no difference between the CUEm and wild-type protein resins. Ubp3, another 
confirmed Def1 interactor (Kvint et al., 2008), was also significantly enriched in both 
mutant and wild type pull-downs.  Immunoprecipitations (IPs) of Def1, with and 
without the CUE mutation, displayed no difference in Rpb1 association (Figure 
7.7A). Whilst Def1’s CUE domain is essential for its function, its exact target 
remained elusive.  
 
 
7.2.2 Def1 interacts with Ela1-Elc1 via its CUE domain 
 
As the first, most obvious, theory for Def1’s role in promoting RNAPII poly-
ubiquitylation had been ruled out, an alternate possibility was investigated. Def1 - 
and, critically, its CUE domain - may be involved in the binding and recruitment of 
the E3 ligase required for the poly-ubiquitylation of RNAPII. The Elongin-Cullin 
complex is required for the sequential poly-ubiquitylation of pre-mono-ubiquitylated 
Rpb1 (Ribar et al., 2006, Ribar et al., 2007, Harreman et al., 2009). This Elongin-
Cullin complex co-purifies as four identified subunits: Elc1 and Ela1 form a Skp1-F-
box-like complex, usually implicated in selecting substrate; whereas Cul3 and Rbx1 
form the structural and catalytic centre of the ubiquitin ligase, promoting the 
ubiquitin transfer to substrate. Indeed, null strains lacking components of the 
proposed ligase cannot poly-ubiquitylate Rpb1 (Ribar et al., 2006, Ribar et al., 
2007). 
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Figure 7.3: pr-Def1 binds Ela1-Elc1 via the CUE domain 
 
A. Immunoprecipitation of N and C-terminally Myc tagged forms of Def1. Tagged strains 
(JSY1198 & JSY1207) were UV irradiated and allowed to recover for 1 hour before harvest for 
lysis. Immunoblot for Def1 and Ela1. 
B. Silver stain gel of in vitro interaction between immobilised Def1 bait protein (covalently 
immobilised on Affigel beads) and recombinant Elc1-Ela1 heterodimer. 1% input for Elc1-Ela1 is 
shown. 
 
 
N-terminally tagged Def1 interacts with the Ela1 subunit of the Elongin-Cullin ligase 
via co-immunoprecipitation (Figure 7.3 A, left panel). IP studies were performed 
using extracts derived from cells, irradiated with UV 1 hour prior to harvesting. 
When Def1 is tagged via its C-terminus, Ela1 association is dramatically reduced 
(Figure 7.3 A, right panel). This suggests that the active pr-Def1 form - not pulled 
out when the protein is C-terminally tagged - preferentially interacts with Ela1. Note 
that Ela1 could not be detected in the input extracts: both Ela1 and Elc1 are 
believed to be expressed at very low levels cells (Ghaemmaghami et al., 2003), 
and could not be visualised in extracts in this study. Co-immunoprecipitation of 
Def1 and Ela1 does not rule out the possibility that this interaction is indirect, via a 
common interacting partner. Indeed, as both proteins are thought to bind to stalled 
RNAPII after DNA damage, this co-precipitation might conceivably be mediated 
through polymerase association. 
 
In order to ascertain whether the interaction between Ela1 and Def1 is direct, 
recombinant forms of the proteins were used. Ela1-Elc1 forms a hetero-dimer (Koth 
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et al., 2000). Elc1 contains a region with high homology to Skp1 and Ela1 is an F-
box protein (Botuyan et al., 1999, Figure 7.5 A). The proteins have been proposed 
to interact via the C-terminus of Elc1 and N-terminus of Ela1 and, intriguingly, 
share opposite and extreme protein isoelectric points. We co-expressed His-tagged 
Elc1 and Ela1 in E.coli, and the complex co-purified at a 1:1 ratio. E.coli does not 
contain an identified ubiquitin system, so any proteins produced in this system 
would not be ubiquitylated. The recombinant proteins ran at the same molecular 
weight as the proteins purified from yeast (Figure 7.7 A and data not shown). After 
chemically cross-linking Def11-500-His and Def11-500/CUEm-His to beads, Ela1-Elc1 
association could be tested. Both Elc1 and Ela1 associate with Def11-500-His beads, 
but not with control beads or beads containing cross-linked Def11-500/CUEm-His (Figure 
7.3 B). The Def1 CUEm, which prevents Def1 toxicity and ubiquitin interaction, also 
prevents association with the Elongin-Cullin substrate adaptor. Notably, 
immobilising Def11-500-His protein via its N-terminus reduced the association with the 
Ela1-Elc1 dimer (data not shown), suggesting the N-terminus of Def1 may 
somehow be involved in this interaction. As Def11-500-His can associate with RNAPII 
and an Elc1-Ela1 dimer, we propose that pr-Def1 helps to target the Elongin-Cullin 
ligase to RNAPII (see further evidence in section 7.2.4). 
 
7.2.3 Ela1 contains a C-terminal ubiquitin homology domain, with specificity 
for Def1 
 
The CUE dependency of the Def1 interaction with Elc1-Ela1 raises an intriguing 
possibility; does Elc1 or Ela1 contain a ubiquitin homology (UbH) domain? As 
Def11-500-His has been shown to interact with ubiquitin in a CUE-dependent manner 
(Figure 7.2 B), the binding to this domain is probably through a ubiquitin-like fold. 
Domains with homology to ubiquitin have been found via sequence annotation in 
32 proteins in S. cerevisiae (SMART database), however due to low sequence 
conservation many other proteins have been predicted to contain UbH domains 
(Kiel and Serrano, 2006), based on the ubiquitin-domain superfold. The lack of 
biochemical and structural evidence to back-up the in silico identifications has left 
the list of proposed UbH domain proteins largely uncurated. Using the simplest 
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biochemical definition, one would assume that a UbH domain would bind to a UBD. 
Hence, the presence of a UbH domain can be tested through the binding of the 
proposed UbH-protein to a panel of UBDs. We found that the purified Ela1-Elc1 
heterodimer complex not only specifically interacts with the CUE UBD of Def1, but 
also with all other UBD-containing polypeptides tested (Figure 7.4 A). Pure, 
recombinant Ela1-Elc1 binds to cross-linked resins containing full-length UBA 
domain-containing Dsk2, the UIM domains of Ataxin-3 and the tandem UIM 
domains of RAP80. This interaction is more or less equal, with the exception of 
some increased association with RAP80 and Ataxin-3 UIMs, possibly due to the 
presence of multiple UBDs, and hence a higher avidity for Ubiquitin or UbH 
domains. 
 
 
 
 
Figure 7.4: Ela1-Elc1 interacts with other UBD containing proteins in vitro. 
 
A. Western blot displaying the interaction of Ela1 and His-Elc1 heterodimer with immobilized 
UBD containing proteins: Def11-500, Dsk2 and the tandem UIMS from RAP80 and Ataxin-3. 
Immunoblotted using antibodies raised against Ela1 and His tag (Elc1). 
B. Western blot of ex vivo Myc-Elc1 (JSY1116) extract incubated with the UBD resins listed 
above, immunoblotted for ubiquitin (P4D1), Ela1 and Elc1 (myc). As expected, Ela1 cannot be 
detected in the crude extract. 
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Whilst this in vitro experiment with pure proteins further indicates that the Ela1-Elc1 
complex contains a UbH domain, it raises an important question: If any UBD 
containing protein can bind to Ela1-Elc1, how is specificity for Def1’s CUE domain 
imparted? The in vitro experiments were performed with large excesses of pure 
protein and BSA, to prevent background binding and simulate protein crowding. 
The read-out does not provide much quantitative information on the affinities of 
these interactions, or how these interactions would fare in their proper cellular 
milieu. 
 
In order to better simulate the in vivo environment, the same UBD-containing resins 
were incubated with UV-irradiated chromatin-enriched extracts taken from a Myc-
tagged Elc1 strain (JSY1116). Whilst the Dsk2, RAP80 and Ataxin-3 polypeptides 
bound to a wide variety of ubiquitylated proteins - as indicated by the smear of 
proteins pulled-down that cross-react with a ubiquitin antibody (Figure 7.4 B, upper 
panel) - Def11-500-His did not. Longer exposures revealed that immobilised Def11-500-
His could enrich ubiquitin-conjugated proteins, but far less efficiently than the other 
UBD resins tested. The immobilised Def11-500-His, however, did bind well to both 
Ela1 and Elc1 from the extract (Figure 7.4 B, lower panels). The other UBD 
containing proteins did not bind to Ela1 or Elc1 in the presence of extracted 
ubiquitylated proteins. Under these conditions, the proposed UbH domain 
contained within Ela1-Elc1 likely outcompeted the more abundant ubiquitin for Def1, 
to mediate specificity. Dsk2, RAP80 and Ataxin-3 exhibit chain specificities and can 
bind multiple ubiquitylated substrates (Funakoshi et al., 2002, Sobhian et al., 2007, 
Chai et al., 2004) leading to the promiscuity of binding observed. There was no 
detectable Ela1-Elc1 association with Dsk2, RAP80 or Ataxin-3, probably because 
protein enrichment was too low, and/or because the UbH domain is outcompeted 
by bona fide ubiquitin interactions with these proteins. 
 
UbH domains typically have low sequence, but high structural homology to 
ubiquitin. As a result, direct alignment of sequences is often poor. Elc1 is a small 
protein, almost entirely assigned as a Skp1-like protein (Figure 7.5 A, upper), and 
the solution structure does not resemble ubiquitin (Botuyan et al., 2001). In contrast, 
Ela1 has an N-terminal F-box domain and no other identified downstream features. 
We aligned the C-terminus of Ela1 and found that it has remarkable homology to 
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ubiquitin (Figure 7.5 A, lower). Despite three large insertions in Ela1, many key 
ubiquitin residues were, if not conserved, then highly similar. The hydrophobic 
patch, Ile-44 in ubiquitin, appears to be conserved with residue Leu-289 of Ela1. 
Despite a high number of lysine residues in the C-terminus of Ela1, only Lys-27 
and Lys-63 align near Ela1’s lysines, and ubiquitin chains on Ela1 have not been 
reported. This same aligned section contains conserved residues at the appropriate 
positions postulated by Kiel and Serrano to predict a three-dimensional ubiquitin-
like superfold (Kiel and Serrano, 2006). 
 
Independent of the above sequence alignment, expression constructs were created 
with sections of Ela1 removed from the C-terminus, in an unbiased attempt to 
determine which part of Ela1 was required for the interaction with Def1. The N-
terminal 143 residues of Ela1 contain the F-box motif and are sufficient to bind to 
Elc1 (Koth et al., 2000). Constructs expressing truncated proteins were generated, 
with 50 amino acids removed at intervals, between residues 150-379 of Ela1 
(Figure 7.5 B, right). The proteins co-expressed and formed a complex with Elc1 
(Figure 7.5 B, lanes1, 4 and 7), much like the full-length Ela1 protein (lane 10). 
When incubated with Def11-500-His cross-linked beads, both Ela1 1-250 and 1-300 
showed no appreciable binding (Figure 7.5 B, lane 3 and 6), as would be expected 
if the UbH fold was disrupted. Ela1 1-350 - lacking only the last 29 residues of Ela1 
- did bind to immobilised Def11-500, but not as efficiently as the full-length protein 
(Figure 7.5 B, compare lanes 9 and 12). These data, partnered with the earlier 
findings (Figure 7.3 B), indicate that the UbH domain of Ela1 is directly recognised 
by Def1’s CUE domain. It is probable that artificial removal of even a few residues 
at the C-terminus of Ela1 is enough to disrupt the UbH fold, but do not lead to Ela1 
protein instability. The very C-terminal region of Ela1 may be important for this 
interaction; since strains with a tag added to the C-terminal of Ela1 show reduced 
ability to degrade Rpb1 after DNA damage (data not shown). 
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Figure 7.5: Ela1 contains a Ubiquitin-like domain 
 
A. (Upper) schematic representation of Elc1 and Ela1 proteins, indicating the proposed 
domains, including the C-terminal UbH domain (yellow) in Ela1. (Lower) sequence alignment of 
the C-terminus of Ela1 with yeast ubiquitin. Similarly conserved residues are highlighted in grey 
and totally conserved residues highlighted in red. Alignment created using ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
B. (Left) Silver stain gel of in vitro interaction between immobilised Def11-500 and Ela1-Elc1 
heterodimers with C-terminal deletions in Ela1. B=empty beads control, D=Def11-500-beads. 
Asterisk corresponds to a degradation product of Ela1 observed in this experiment. (Right) 
schematic of Ela1 proteins used in this assay.  
C. Binding of purified, recombinant Def11-500 to immobilised GST, GST-ubiquitin, GST-ubiquitin 
I44A or GST-Ela1 250-379. 2.5% of input and bound proteins were loaded onto an SDS-PAGE 
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gel, followed by anti-Def1 immunoblotting. Ponceau-S is shown as a loading control for the 
immobilized proteins. 
 
 
The C-terminal UbH domain of Ela1 is necessary for the interaction with Def11-500-
His, but is the UbH domain sufficient to mediate this interaction? In order to test this 
possibility the last 129 residues of Ela1 were cloned into a GST expression vector 
and expressed. The resulting recombinant protein, GST-Ela1250-379, was 
immobilised on glutathione beads in parallel with GST-Ubiquitin (positive control), 
GST-Ubiquitin I44A and GST alone (negative controls) (Figure 7.5 C, lower panel 
for loading). Pure, recombinant Def11-500-His bound to GST-Ubiquitin, as described 
previously (Figure 7.2 B), and, importantly, also bound to GST-Ela1250-379 (Figure 
7.5 C). Whilst the interaction was weaker than for Def1 binding to ubiquitin, this 
suggests the C-terminus of Ela1 is sufficient to promote Def1 interaction in vitro. As 
immobilised Def11-500-His exhibits specificity for Ela1-Elc1 over ubiquitylated proteins 
ex vivo, other regions of the Ela1-Elc1 complex must aid this interaction. 
 
The C-terminus of Ela1 interacts with Def1, via a UbH–CUE interaction. This 
interaction is ablated when the CUE domain is mutated. Similarly, when Def1’s 
CUE domain is mutated in vivo, Rpb1 ubiquitylation is reduced. If the key role of 
the CUE domain is to bind the C-terminus of Ela1 and recruit the Elongin-Cullin 
complex to persistently stalled RNAPII, removal of the UbH section should mirror 
mutation of the CUE domain. To test this hypothesis, a strain with genomically 
truncated Ela1 was created (ela11-250, JSY 1203). In this strain, Rpb1 was not 
degraded after 4-NQO treatment, in a manner akin to the cells completely lacking 
Ela1 protein (Figure 7.6 A). Poly-ubiquitylation of Rpb1 was similarly reduced when 
the C-terminus of Ela1 was absent (Figure 7.6 B). Def1 processing was unaffected 
in these strains. This suggests that removal of the C-terminus, including the UbH 
domain, of Ela1 functionally debilitates the Elongin-Cullin complex, in all probability 
because the protein can no longer interact with Def1. Critically, deletion of the C-
terminus of Ela1 still allowed association with Elc1, in both a recombinant system 
(Figure 7.5 B) and in yeast IPs (Figure 7.6 C). The Elongin-Cullin complex can 
interact with RNAPII in Elc1 IPs (Harreman et al., 2009) (Figure 7.6 C, lane 3). This 
interaction is reduced in Elc1 IPs from the ela1-250 strain (Figure 7.6 C, lane 6), 
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suggesting that RNAPII-Elongin-Cullin association is also mediated through the 
UbH domain, in all likelihood via Def1. 
 
It is unclear from these experiments whether the truncated Ela1 can still form an 
active complex with the other subunits of the Cullin ligase. Recombinant expression 
of Cullin complexes is notoriously complicated. In addition, no commercial 
antibodies are available to the Cul3 or Rbx1 subunits of the Elongin-Cullin complex. 
No other substrates of the Elongin-Cullin complex have been identified in yeast, 
making the effect of the UbH domain removal hard to assess. However, as the 
interaction of Ela11-250 with Elc1 is maintained, and the Skp1 component is 
proposed to principally mediate the interaction with the cullin (Zheng et al., 2002), 
we hypothesise that the truncation of Ela1 does not affect the ubiquitin ligase 
directly. Instead, according to this hypothesis, the removal of the UbH domain 
inactivates the E3 ligase principally through preventing the interaction with Def1 
and therefore RNAPII. 
 
As the C-terminus of Ela1 is sufficient to allow association with Def1, and Def1 can 
also bind to ubiquitin, we investigated if ubiquitin could replace the UbH domain of 
Ela1. In order to achieve this, a strain expressing the first 250 amino acids of Ela1 
followed by ubiquitin was created at the ELA1 locus (ela11-250-Ubi; JSY1207). To 
ensure the ubiquitin was not inappropriately linked to other proteins, the last amino 
acid was mutated from glycine to valine (Zhao and Ulrich, 2010). The expression of 
Ela1 in the ela11-250-Ubi strain was equivalent to that of ela11-250 and the wild-
type Ela1 strain used (data not shown). However, addition of ubiquitin to the C-
terminus of Ela1 did not seem to rescue the ela11-250 phenotype: Rpb1 degradation 
was not restored after DNA damage (Figure 7.6 D). This suggests that whilst the C-
terminus of Ela1 can mimic ubiquitin, ubiquitin cannot replace the UbH domain to 
restore the Def1 interaction. The ubiquitylation status of Rpb1 and Elc1 interaction 
were not assayed in this strain. Immobilised ubiquitin can interact with Def1 in vitro 
(Figure 7.2 a), but Def1 did not bind ubiquitylated proteins strongly ex vivo in 
extracts (Figure 7.4 B). Possibly, replacing Ela1’s UbH domain with ubiquitin did 
not provide the required specificity for the Def1-Ela1 interaction in vivo. 
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Figure 7.6: The UbH domain is necessary for Ela1 function in vivo 
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A. Western blot of extracts from Ela1 WT (JSY1204), ela11-250  – where the last 129 amino 
acids had been genomically truncated - or Δela1 (JSY1205) cells, were treated with 4-NQO at 
time point 0. The membrane was probed for Rpb1 (8WG16) and Pgk1. 
B. MultiDsk pull-down from Ela1 WT and ela11-250 strains. Western blot probed for ubiquitin 
(P4D1) and Rpb1 (4H8). 
C. Immunoprecipitation of Myc-Elc1 in WT Ela1 and Ela11-250 strains. Western blot using anti-
Rpb1 (4H8), anti-Def1, anti-myc (Elc1) and anti-Ela1. Note the black smear in the Ela1 blot is 
background signal. 
D. Western blot of 4-NQO treated extracts from WT, ela11-250 and ela11-250-Ubiquitin strains, 
probing for Rpb1 (8WG16) and Pgk1. 
 
 
7.2.4 Def1 helps to bridge between RNAPII substrate and Elongin-Cullin 
ligase 
 
pr-Def1, upon translocation to the nucleus, promotes the poly-ubiquitylation of 
RNAPII. It binds to a ubiquitin-like UbH in Ela1 and loss of this domain prevents the 
poly-ubiquitylation of Rpb1. As indicated above (Figure 7.6 C), the association of 
Def1 with Ela1 may have functional consequences. IPs of N-terminally tagged Def1 
co-precipitate both RNAPII and Ela1 (Figure 7.3 A and Figure 7.7 A). Mutation of 
the CUE domain does not ablate RNAPII binding, but greatly reduces Ela1 binding 
(Figure 7.7 A, compare lane 3 and lane 6). Despite normal RNAPII association in 
this strain, Rpb1 poly-ubiquitylation is ablated (Figure 7.1 B). One possible model 
to explain this observation is that Def1 is acting as a bridging factor between 
enzyme (Elongin-Cullin) and substrate (stalled mono-ubiquitylated RNAPII). When 
the Def1-interacting UbH domain of Ela1 is removed, its interaction with RNAPII is 
reduced (Figure 7.6 C), supporting this model. Similarly, if Myc-Elc1 is 
immunoprecipitated in the def1CUEm strain, both the interaction with Def1 is reduced, 
as expected, but so to is the interaction with Rpb1 (Figure 7.7 B). The common 
factor in these interactions is Def1.  
 
This interaction was reconstituted with purified components in vitro, to see if the 
proposed bridging ability of Def1 is direct and sufficient. RNAPII-HA was 
immobilised on HA-affinity beads. Def11-500-His and Def11-500/CUEm-His, bound to 
immobilised RNAPII, but not to empty control beads (Figure 7.7 C, compare lanes 
5-8). Def1 bound equally well to RNAPII, irrespective of the mutation in the CUE 
domain, as seen previously (Figure 7.2 B). The Ela1-Elc1 complex bound poorly to 
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RNAPII alone, with no detectable Elc1 binding (lane 10). Critically, this binding was 
substantially increased upon the addition of Def11-500-His (lane12). Moreover, the 
ability of Def1 to bridge the interaction between RNAPII and Ela1-Elc1 was 
dependent on the CUE domain: even though Def11-500/CUEm-His associated with 
RNAPII-containing beads as efficiently as its wild-type counterpart (compare lanes 
6 and 8), it had little or no stimulatory effect on Ela1-Elc1 binding to RNAPII 
(compare lanes 12 and 14). Interestingly, the addition of Ela1-Elc1 also clearly 
increased Def1-RNAPII interaction (compare Def1 binding in lane 12 with that in 6, 
8 and 14), contributing to a more stable RNAPII/Def1/Ela1-Elc1 ternary complex. 
 
 
 
Figure 7.7: Def1 binds RNAPII and Ela1-Elc1 
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A. Immunoprecipitation of N-terminally Myc-tagged Def1, with and without mutation of the CUE 
domain (JSY1198 & JSY1199). Cells were UV irradiated and allowed to recover for one hour, 
before harvest and extraction of proteins. Immunoblot for Rpb1 (4H8), Def1 and Ela1. Pure Ela1 
protein was loaded as an antibody control. 
B. Immunoprecipitation of N-terminally Myc-tagged Elc1, with and without mutation of the CUE 
domain of Def1 (JSY1116 & JSY1202). Cells were UV irradiated and allowed to recover for one 
hour. Immunoblot for Rpb1 (4H8), Def1, Ela1 and Elc1 (anti-myc). 
C. Binding of recombinant Ela1-Elc1 heterodimer to immobilized RNAPII (or empty control 
beads), in the absence or presence of recombinant Def11-500-His, or Def11-500/CUEm-His. Assay 
analysed by Western blotting. Schematics of results are shown below the relevant lanes. 
 
 
There is some residual Ela1-Elc1/RNAPII interaction in both in vitro and IP assays. 
Whether this is a genuine interaction remains to be determined, but in all cases it is 
above the level of ‘background’ empty-control beads, suggesting there is an 
element of Elongin-Cullin-RNAPII interaction, not mediated through Def1. This 
interaction appears to be very weak, but may explain why the mutation of the CUE 
domain of Def1 reduces RNAPII-ubiquitylation, but does not completely prevent it. 
Removal of the C-terminal 129 residues of Ela1 prevents RNAPII-ubiquitylation to a 
greater extent, suggesting that this residual interaction may be via the C-terminal 
UbH of Ela1. 
 
 
7.3 Conclusions 
 
pr-Def1 toxicity is due to the dysregulated activity of the N-terminal ubiquitin-
binding CUE domain. The principal target of the CUE domain is unmodified Ela1, 
which contains a ubiquitin-like, UbH domain. The UbH domain maps roughly to 
residues 250-379 of Ela1. Whilst the CUE domain can bind ubiquitin, we propose 
that the UbH-CUE domain interaction is specific to Ela1, ensuring that Def1 does 
not bind to ubiquitylated proteins and that other UBD-containing proteins do not 
bind Ela1.  
 
If the interaction between Def1 and Ela1 is ablated, then the Elongin-Cullin 
interaction with its substrate is also decreased, preventing the targeting of the 
ligase to stalled RNAPII. Def1 binds to both the Elongin-Cullin complex and RNAPII, 
bridging the interaction between substrate and enzyme. In some ways, Def1 can be 
considered an additional subunit, or bridging factor, of the Elongin-Cullin complex, 
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and it is this bridging factor that imposes both the specificity to RNAPII and control 
of RNAPII-ubiquitylation after transcription stress. 
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Chapter 8. Discussion II 
pr-Def1: A key Protein for the Poly-ubiquitylation of 
Rpb1 
 
Work over the past decade, from multiple laboratories, has helped to elucidate the 
mechanism of Rpb1 poly-ubiquitylation and degradation (reviewed in Wilson et al., 
2013, see introduction, 1.5.3). However, the mechanistic function of Def1 - one of 
the first factors identified to be involved in the Rpb1 poly-ubiquitylation process 
(Woudstra et al., 2002) – had not previously been expounded. Work presented in 
this thesis has suggested that Def1 acts at the confluence of a number of ubiquitin-
related processes. Def1 becomes ubiquitylated, thus targeting it for partial 
proteolytic processing by the proteasome. The proteasome degrades the C-
terminus of Def1 and releases a N-terminal fragment, which can then accumulate 
in the nucleus. Nuclear pr-Def1 binds to both stalled RNAPII and the Elongin-Cullin 
complex. Binding to the E3 ligase is mediated through Def1’s CUE ubiquitin binding 
domain (UBD), whose principle target is the newly identified ubiquitin homology 
(UbH) domain of Ela1, rather than ubiquitin. This allows the recruitment of the 
Elongin-Cullin E3 complex to RNAPII, which in turn promotes Rpb1 poly-
ubiquitylation and degradation by the proteasome (Figure 8.1). 
 
 
8.1 The Mechanistic Role of Def1 in RNAPII Ubiquitylation 
 
Rpb1 ubiquitylation and degradation occurs via a complex, multi-step mechanism 
(see Introduction 1.5.3) The initial, Rsp5-catalysed, Rpb1 mono-ubiquitylation is not 
dependent on Def1, but is accelerated by the protein in vitro (Woudstra et al., 2002, 
Somesh et al., 2005). The subsequent step is catalysed by another E3 ligase, the 
Elongin-Cullin complex, which takes over to perform poly-ubiquitylation (Ribar et al., 
2006, Ribar et al., 2007, Harreman et al., 2009). The data presented in this thesis 
explains how Def1 fits into this complex scheme: through promoting efficient Rpb1 
poly-ubiquitylation. 
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Figure 8.1: Proposed model of Def1-mediated Rpb1 poly-ubiquitylation 
 
 
The processing of Def1 occurs concurrently with the emergence of poly-
ubiquitylated Rpb1 and its subsequent degradation. These two processes are 
inherently interlinked, since expression of pr-Def1-like molecules is sufficient to 
induce Rpb1 poly-ubiquitylation in the absence of induced DNA damage. It is 
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interesting to note that the poly-ubiquitylation of Rpb1, observed when Def1 is 
cleaved by TEV protease (Figure 5.7 A), was less pronounced than normally 
observed after treating with a stalling agent, despite the production of similar levels 
of pr-Def1 and the mimicking, TEV-cut, pr*-Def1. It is possible that the TEV-cleaved 
Def1 was not as active as its properly processed, in vivo, counterpart. Similarly, 
multiple signals may be required to converge on stalled RNAPII to promote efficient 
poly-ubiquitylation, such as activation of the DNA damage response (DDR), which 
would be absent in this experiment. RNAPII stalling can activate the DDR 
(Derheimer et al., 2007, Chen et al., 2009) and may be important in Rpb1 poly-
ubiquitylation (Michael Taschner, unpublished results). The processing of Def1 
does not appear to be affected in preliminary experiments using DDR kinase null 
backgrounds (Δmec1, Δtel1, Δrad9, Δdun1 and Δrad53; data not shown). 
 
However, there was no induced RNAPII stall in the TEV experiment and as a result, 
little correct substrate for Rpb1 poly-ubiquitylation. In fact, it is surprising that any 
Rpb1 poly-ubiquitylation could be observed at all; the most likely explanation is that 
the cleaved Def1 is inappropriately recognising transiently stalled RNAPII and 
aberrantly causing its destruction. Under normal conditions this temporarily stalled 
RNAPII would be re-started by general elongation factors. Shifting the temperature 
sensitive def11-530 strain to 37oC was sufficient to promote wholesale Rpb1 
degradation. This effect may be more pronounced than for the TEV cleaved Def1, 
as RNAPII stall may be induced at the elevated temperature (see below), 
producing more poly-ubiquitylation competent RNAPII. The toxicity of the truncated 
forms of Def1 may also be due to the aberrant activation of Rpb1 ubiquitylation, 
whereby the ‘last-resort’, back-up pathway artificially becomes the detrimental 
primary pathway of choice. 
 
Indeed, the manner by which pr-Def1 is targeted to stalled, mono-ubiquitylated 
RNAPII is unclear. Def1 did not associate with mono-ubiquitylated RNAPII in vitro, 
but does with immobilised unmodified RNAPII (Figure 7.2 B). Targeting of the poly-
ubiquitylation machinery to only persistently stalled RNAPII is paramount to prevent 
futile Rpb1 degradation. Poly-ubiquitylation cannot occur unless Rsp5 has first 
mono-ubiquitylated RNAPII, however there is a distinct, basal population of mono-
ubiquitylated RNAPII in cells that does not appear to get degraded (see Discussion 
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I). Investigating how Rpb1 degradation is properly targeted to persistently stalled 
RNAPII is a key, unanswered, question remaining in the field. 
 
Def1 is processed under a number of different cellular assaults (Figure 5.2); 
whether these conditions also induce persistent transcription stall is unclear. 
Elevated temperature results in Def1 processing. Heating bacterial RNAP does not 
increase the length of frequency of pausing in vitro (Mejia et al., 2008, 
Abbondanzieri et al., 2005). Indeed, the promoter proximal pause of a number of 
genes is relieved upon heat shock in metazoa (Nechaev et al., 2010). It remains to 
be investigated whether Rpb1 poly-ubiquitylation is promoted after heat stress, or 
ethanol treatment. Alternatively, Def1 processing may occur as a general response 
to cellular stress. Artificial activation of Def11-530, did not affect global or control 
protein levels (Figure 5.5 C), but other targets of pr-Def1 may exist. This study has 
focused on the role of Def1 in Rpb1 degradation, but Def1 has been implicated in a 
number of other diverse processes in the cell, from telomere maintenance to 
glutathione biosynthesis (Jordan et al., 2007, Manogaran et al., 2011, Chen et al., 
2005, Cai et al., 2006, Suzuki et al., 2011). It would be interesting to investigate 
whether there is any potential role for the C-terminus of Def1 or pr-Def1 in these 
other cellular processes, and therefore, if there is any cross-talk with the Rpb1 
poly-ubiquitylation pathway. 
 
It is interesting to note that Def1 purifies with the RNAPII DUB, Ubp3 (Kvint et al., 
2008). The band annotated as Def1 - from a low stringency Ubp3 purification – 
runs at just over 100kDa by SDS-PAGE; both too small to be the full-length (p120), 
and too large to be the processed (p90) Def1 protein. In the mass spectrometry 
experiment presented in this thesis, Ubp3 was highly enriched from UV-irradiated 
extracts by immobilised Def11-500-His. Whether there is a direct functional association 
between Def1 and Ubp3 requires further study. Conceivably, Def1 could promote 
Rpb1 poly-ubiquitylation through multiple mechanisms, including the inhibition of 
Ubp3. 
 
Rpb1 poly-ubiquitylation is thought to be a last-resort mechanism, which is only 
used after unsuccessful TC-NER (Svejstrup, 2002). How the decision between TC-
NER and Rpb1 poly-ubiquitylation is made is unclear (see 1.5.3.7). One possible 
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switching mechanism could be mediated through Def1. Full-length Def1 co-purifies 
from chromatin with the only TC-NER specific factor in yeast, Rad26 (Woudstra et 
al., 2002). Since this complex was not present in the non-chromatin fraction, and 
cells that lack Rad26 exhibit accelerated Rpb1 degradation: Rad26 appears to 
antagonise Def1 activity. The role of Rad26 in the processing and activation of 
Def1 is unclear. Speculatively, Rad26 could protect Def1 from processing in 
chromatin, therefore inhibiting Rpb1 degradation. The presence of Rad26 at stalled 
RNAPII complexes would suggest that the preferable TC-NER pathway is in 
progress. According to the current model, for the ‘last-resort’ back-up pathway to 
proceed, Rad26 would need to be inactivated or diffuse away from the Def1 
complex. It would be interesting to investigate where Rad26 binds to Def1, and 
whether it still interacts with pr-Def1. No such interaction was investigated in this 
study.  
 
Interestingly, Def1 is not required for Rpb1 degradation in the absence of Rad26 
(Woudstra et al., 2002); suggesting Def1 is not absolutely mechanistically required 
for RNAPII poly-ubiquitylation. In support of this finding, pure Elongin-Cullin 
complex can catalyse the poly-ubiquitylation of RNAPII in vitro, in the absence of 
Def1 (Harreman et al., 2009). This Def1-independent degradation may be due to 
the weak Elongin-Cullin-RNAPII interaction observed (Figure 7.7 C), allowing some 
Rpb1 poly-ubiquitylation. Further investigation into the Rad26-Def1 switch is 
essential to help understand pathway choice after persistent transcription stall. 
 
 
 
8.2 Regulated Ubiquitin Partial Proteasomal Processing as a 
Control Mechanism 
 
Def1 is proteolytically cleaved to yield a processed fragment. The proteases 
responsible for the partial processing appear to be within the proteasome complex. 
Several similarities and differences between the partial proteolytic processing of 
Def1 and the other identified processed proteins have emerged throughout this 
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study. Partial proteasome processing was reconstituted in vitro with the relevant 
pure proteins. Previously, assays have been performed using cell extracts (Orian et 
al., 1995, Tian et al., 2005, Kravtsova-Ivantsiv et al., 2009) or with the 20S 
proteasome (Moorthy et al., 2006). The latter study concluded that processing was 
not reliant upon the 19S regulatory particle or ubiquitylation. Our studies have 
corroborated these findings with an important caveat: Neither the 19S nor 
ubiquitylation are absolutely required, but they do accelerate the processing 
reaction, perhaps achieving reaction rates that are more physiological. The 26S 
proteasome used in this assay is comprised of both the 20S core particle and 19S 
regulatory particles. The proteasome is known to differ in subunit composition; up 
to 20% of proteasomes in the cell include an accessory factor Blm1, which replaces 
the 19S regulatory particle (Schmidt et al., 2005). The in vitro system developed 
offers a unique opportunity to further study partial proteolytic processing. 
 
Despite repeated attempts, the C-terminal fragment derived from Def1 processing 
could not be detected. The C-terminus was assumed to be degraded, as observed 
for other proteasomal processed proteins (Hoppe et al., 2000, Fan and Maniatis, 
1991). The proteasome can act as an endo-protease, at internal initiation sites (Liu 
et al., 2003, Piwko and Jentsch, 2006, Kraut and Matouschek, 2011), as seems to 
be the case for Def1 (Figure 6.4 F). In order to degrade the C-terminus, the 
proteasome would have to work bi-directionally, as has been described previously 
(Liu et al., 2003, Piwko and Jentsch, 2006)(Figure 8.2 B). 
 
Def1 is targeted to the proteasome by Rsp5 mediated mono-ubiquitylation. This is 
inducible upon DNA damage (Figures 3.4 C & 6.2 A), but the mechanism by which 
Rsp5 is targeted to Def1 is unclear. Pre-ubiquitylating Def1 alters the 
electrophoretic mobility of the full-length band, compared to non-ubiquitylated Def1 
(Figure 6.1 C). Non-ubiquitylated, full-length Def1 can be processed in vitro, and 
this artificially created pr-Def1 runs at the equivalent size to the in vivo band (Figure 
6.4 B). This would suggest that the in vivo pr-Def1 band is not modified by ubiquitin. 
However, full-length Def1 is ubiquitylated and this greatly accelerates processing in 
vivo (Figure 6.2 A). Furthermore, the identified ubiquitylation sites were found in the 
N-terminus of Def1. In fact, adding ubiquitylation reagents to the proteasome 
processing reaction can lead to the ubiquitin attachment of the processed band 
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(data not shown), suggesting ubiquitylation is still possible in this region. If pr-Def1 
is not ubiquitylated then this moiety must be removed during the processing 
reaction. The 19S proteasome particle contains de-ubiquitylating activity (Verma et 
al., 2002, Guterman and Glickman, 2004). It is likely that the ubiquitin targeting 
signal on Def1 may be removed by one of these DUBs during proteasomal 
processing. However, it is important to note that the in vivo pr-Def1 band has not 
been directly confirmed to be un-ubiquitylated. 
 
The processed bands of NF-κB and Ci are not ubiquitylated, whilst their full-length 
precursors are (Orian et al., 1999, Price and Kalderon, 2002). However, in these 
cases the ubiquitylation sites lie in the degraded region. The proteasomal initiation 
site is thought to be near the ubiquitylation site (Inobe et al., 2011). However the 
Def1 ubiquitylation sites are far from the proposed processing site, which has to be 
upstream from the proteasome initiation site. It is possible that ubiquitylated protein 
recognition is different in yeast. In support of this hypothesis, Spt23 and Mga2 both 
retain their ubiquitin moieties after processing (Rape et al., 2001). The reason why 
Def1 loses its ubiquitin is unclear and requires further study. One possibility is that 
Def1 is not recruited to the proteasome by one of the 19S UBD subunits, therefore 
alleviating the spatial distance constraints between the initiation site and the 
ubiquitylation site. Instead, Def1 might be recruited by one of the proteasome 
shuttle factors, allowing greater flexibility in Def1 proteasome binding (Figure 8.2 B). 
Further study is required to investigate this hypothesis, both genetically and 
biochemically. 
 
Partial proteolysis occurs when the proteasome is blocked by a stop-transfer signal 
(see 1.1.7). Previous studies have shown that stop-transfer signals require both a 
low complexity region, which is followed by a tightly folded domain or strong protein-
protein interactions (Lin and Ghosh, 1996, Rape et al., 2001, Tian et al., 2005). The 
low complexity region is poorly bound to the proteasome, whilst the stable 
domain(s) are refractive to 19S unwinding. The identity of the stop-transfer signal in 
Def1 is unclear, but Def1 can form multimers in vivo (Figure 5.8 B) and has 
extensive regions of low complexity (Figure 8.2 A). 
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CUE domains are able to dimerise (Kang et al., 2003), and some UBDs can prevent 
protein degradation by the proteasome (Heessen et al., 2005, Heinen et al., 2011). 
However, the N-terminal CUE domain of Def1 is probably too far from the proposed 
processing site to block the proteasome. Def1 is predicted to contain coiled-coil 
domains (Figure 5.8 D), which end just before the proposed processing site. Coiled-
coil domains have been reported to be extremely stable, especially in glutamine rich 
regions (Fiumara et al., 2010). Indeed, others have previously reported that a 
glutamine rich region (residues 381-480) of Def1 runs uncharacteristically fast 
through a gel filtration column, suggesting that this section is capable forming 
coiled-coil based trimers or tetramers (Chen et al., 2005). Whether Def1 self-
association is mediated through the coiled-coil domain is unclear, but such self-
association may be critical in order to prevent the complete processivity of the 
proteasome, as has been observed for Spt23 and Mga2 (Rape et al., 2001). 
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Figure 8.2: A model of Def1 partial proteasomal processing 
 
A. Schematic of Def1 with the hypothesised stop transfer signals highlighted. Low complexity 
glutamine rich regions are highlighted in blue and the predicted coiled-coil oligomerisation 
domains in yellow. An arrow indicates the proposed site of processing. Note that the initiation 
site must lie downstream of this region 
B. Def1 proteolytic processing may be split into two steps. In the first the mono-ubiquitylated 
form of Def1 is recognised, potentially by an unknown protein (green) and targeted to the 
proteasome. The initiation site, buried in the C-terminus, is degraded bi-directionally (brown 
section). This is potentially blocked by the glutamine rich region (dark blue) and the coiled-coil, 
oligomerisation domains, allowing Def1 escape. For clarity only one other interacting Def1 is 
shown, but the oligomerisation status is unclear. Model not to scale. 
 
 
Glutamines account for 23% of all the residues in full-length Def1, with the area of 
highest density between Def1 residues 385-515. Poly-glutamine repeats reduce the 
unfolding ability of the proteasome in a length dependent manner (Kraut et al., 
2012). The stop-transfer signal for the processed protein Sp1 has not been 
identified, but the protein does have regions of high glutamine content, prior to the 
identified processing site (Su et al., 1999; Figure 1.4). The hypothesised bi-partite 
stop-transfer signal of Def1, therefore, might be formed from the final predicted 
coiled-coil domain of Def1, followed by a glutamine rich, low complexity region. The 
distance from the outside of the 20S proteasome to the active sites is equivalent to 
20 extended residues of a polypeptide chain (Piwko and Jentsch, 2006). Therefore 
it is conceivable that the proposed processing site, around residues 520-530, is 
chosen because it is 20 residues from this proposed stop-transfer signal (Figure 
8.2 B). This is a highly speculative model, which could be investigated using the in 
vitro reaction described in this study. 
 
If Def1 forms a homomultimer strong enough to block the proteasome, dissociation 
would require a large amount of unfolding energy. The Cdc48 ATPase is required 
for the dissociation of Spt23 and Mga2 from their unprocessed partners (Rape et 
al., 2001, Shcherbik et al., 2003). Whether Cdc48 also dissociates Def1 is unclear 
and difficult to assess, as it also has a role downstream in the ‘last-resort’ pathway: 
extracting poly-ubiquitylated Rpb1 from the RNAPII ternary complex on chromatin 
(Verma et al., 2011). It is interesting to note that both Ubx4/Ubx5 and the separate 
Ufd1-Npl4 substrate adaptors are required for proper Rpb1 degradation (Verma et 
al., 2011). Whilst Ubx4/Ubx5 is thought to directly feed poly-ubiquitylated Rpb1 into 
the proteasome, the authors of the aforementioned study did not speculate on the 
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role of Ufd1-Npl4 in the pathway. Ufd1-Npl4 depletion does not lead to increased 
Rpb1 poly-ubiquitylation, suggesting that these Cdc48 adaptors may be working 
upstream of the poly-ubiquitylation step of Rpb1 - possibly by promoting the 
dissociation of Def1 multimers. 
 
Unlike site-specific proteases, which often only nick the polypeptide backbone, the 
proteasome actively digests proteins. As a result, the site of proteasome initiation 
does not necessarily correspond to the eventual site of processing. The exact site 
of processing was not successfully mapped in this study. Mass spectrometry 
proved unsuccessful and mutation around the processing site shifted the eventual 
processed C-terminus. pr-Def1 is not a single species, but appears as a doublet 
under some running conditions (for example in Figure 6.4 B). This either suggests 
multiple, different length processed proteins are produced, or that the processed 
proteins are post-translationally modified. However, the pr-Def1 doublet is also 
observed in vitro in the absence of post-translationally modifying proteins, 
suggesting that there is an inherent stoichasticity in the processing of Def1. It is 
interesting to note that processed Spt23 also appears as a collection of bands 
(Hoppe et al., 2000), suggesting partial processing can produce multiple products. 
 
It appears that the regions that promote processing are redundant and poorly 
conserved. Internal deletion in processed proteins around the processing site does 
not prevent their processing (Sears et al., 1998, Piwko and Jentsch, 2006). Small 
deletions in Def1 affected both the full-length and processed band electrophoretic 
mobility and removal of residues surrounding the proposed processing site did not 
prevent processing. Furthermore, removal of the majority of the glutamine rich 
region or the terminal predicted coiled-coil domain did not prevent processing. 
However the extent of partial processing was unclear from this study, as there may 
have been some read-through by the proteasome leading to the total degradation 
of Def1. 
 
Interestingly, removal of Def1 residues 500-600 did prevent processing of the 
protein, whilst the removal of residues 506-575 still allowed Def1 processing. There 
are many potential explanations for these observations. This form of Def1 may be 
lacking a degron sequence and, as a result, may not be ubiquitylated and targeted 
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to the proteasome. However, levels of Def1Δ500-600 reduce after 4-NQO treatment, 
suggesting total degradation rather than partial processing is occurring. These 
findings suggest a role for this region, which is normally degraded, in preventing 
total degradation. Somewhat surprisingly, the strain expressing Def1Δ500-600 was still 
able to degrade Rpb1 after DNA damage, suggesting processing may be 
unnecessary for the relocalisation of this truncated form of Def1. Def11-530, Def11-400 
and Def1-500 proteins may similarly not require processing for their action. Further 
work to bolster this interesting preliminary result is required. The ubiquitylation 
status, localisation and effect on Rpb1-poly-ubiquitylation all require investigation in 
the Def1Δ500-600 strain. Furthermore, creating a strain with residues 575-600 deleted 
would prove very informative. 
 
Considering the high toxicity of the pr-Def1-like molecules used in this study, it 
would be imperative that activated pr-Def1 is removed after it has performed its 
function. The pr-Def1 protein is extremely short-lived in cell extracts and Def11-500 
rapidly disappears after the cessation of galactose induction (data not shown). 
Despite being unable to totally degrade Def1 previously, the proteasome may be 
able to degrade pr-Def1 after it has performed its function. Def1 is only tagged with 
mono-ubiquitin for partial proteasomal processing; poly-ubiquitylation - at another 
site on pr-Def1 or Def1 - could switch the signal to complete degradation, as has 
been observed for both NF-κB and Spt23 (Ciechanover et al., 2001, Siepe and 
Jentsch, 2009). Indeed, a number of other ubiquitylation sites in Def1 have been 
identified (Beltrao et al., 2012, Starita et al., 2012). The identity of the degradation-
targeting ubiquitin ligase, assuming such a ligase exists, is unclear, but could be 
the Elongin-Cullin E3. Auto-ubiquitylation by cullin ring ligases (CRLs) of their 
bound substrate adaptor proteins has been reported (Zhou and Howley, 1998, Yen 
et al., 2012). Mechanistically, the directionality of proteasomal digestion determines 
whether a protein is partially or completely degraded (Tian et al., 2005, Kraut and 
Matouschek, 2011) thus complete degradation of pr-Def1 could be mediated by the 
proteasome, using a different initiation site. Alternatively, other cellular proteases 
could be implicated in the short half-life of pr-Def1. 
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8.3 Self Cleavage 
Proteasomal processing is believed to be a two-step process: first the proteasome 
nicks the polypeptide backbone; then the processed-protein is progressively 
degraded up to a stop-transfer signal (Lin and Ghosh, 1996, Piwko and Jentsch, 
2006). The proteasome may only be required for the second step in Def1 
processing. Full-length Def1 used in this thesis was purified from yeast cells. 
Incubating this protein with inhibited proteasome or ubiquitylation components 
induces the formation of a pr-Def1-like band (Figures 6.4 C and 6.1 C). This may 
be due to contamination of active proteasome or other proteases in these assays. 
However, bacterially purified Def11-500 seemed to lose the C-terminal His tag upon 
binding to ubiquitin (Figure 7.2 A). Moreover, full-length Def1, purified from E.coli 
and incubated at room temperature, can also form a pr-Def1-like band, in the 
absence of any other agents (Kotryna Temcinaite, personal communication). This 
suggests that pure Def1 can exhibit an inherent instability, leading to the formation 
of a band similar to that exhibited in cells after DNA damage. One possible 
explanation could be that Def1 auto-catalytically cleaves itself. 
 
Some proteins do have the capacity to cleave themselves. A group of proteins 
have been found to self-splice, post-translationally (reviewed in Paulus, 2000). 
These remove an internal section of a polypeptide (termed an intein) and reform 
the amide backbone. Alternatively, auto-proteolysis can be achieved through the 
use of a more recognisable internal peptidase domain. For example, caspases only 
activate upon self-dimerisation, where they are induced to cleave their 
neighbouring protein (Hengartner, 2000). The NPC subunit Nup145 self cleaves, 
with each half associated with opposite sides of the nuclear pore (Teixeira et al., 
1997). The LexA repressor protein auto-cleaves as part of the bacterial SOS 
response, resulting in up-regulation of repair genes and promoting survival in the 
face of severe DNA damage (Schlacher and Goodman, 2007). How, or even if, 
Def1 auto-cleaves is not clear, but cleavage does seem to be promoted upon 
association with ubiquitin (Figure 7.2 A), RNAPII (Figure 7.2 B) or the proteasome 
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(Figure 6.4 D). No recognisable peptidase or intein-like domain can be found in 
Def1. Further experiments are required to assess these puzzling observations. 
 
8.4 Dynamic Compartmentalisation as a Method to Prevent 
Protein Interactions 
 
The shorter pr-Def1 is toxic when mis-expressed, compared to its full-length 
counterpart. § protein appears to function just as well as pr-Def1. Furthermore, the 
expression of the C-terminus of Def1 does not suppress the toxicity of the 1-500 
section, suggesting that the C-terminus may not be acting as an auto-inhibitory 
domain. Instead, this toxicity is mediated at the cellular level; pr-Def1 can 
accumulate in the nucleus, whereas full-length Def1 cannot. The steady state 
cytoplasmic localisation of Def1 is dependent upon the equilibrium between nuclear 
import and rapid nuclear export. Upon transcription stall, export is prevented via 
removal of Def1’s C-terminus, allowing the accumulation of pr-Def1 in the nucleus. 
Through dynamic compartmentalisation, the majority of Def1 is not allowed access 
to RNAPII, unless transcription has been stalled. The inducible movement of a toxic 
protein to the nucleus is not unprecedented. In mammalian cells, severe DNA-
damage can elicit apoptosis, triggering the caspase-dependent cleavage of ICAD. 
This frees the nuclease CAD, promoting its entry to the nucleus, leading to DNA 
fragmentation (Nagata, 2000). 
 
The C-terminus of Def1 can promote cytosolic location, through promoting the 
nuclear export of the protein (Figure 6.7). This was analysed by artificially 
appending the C-terminus of Def1 to an NLS-GFP sequence. The hybrid protein is 
present in both the nucleus and cytoplasm, suggesting that it is dynamically 
shuttling across the nuclear membrane, with the NLS targeting import and the C-
terminus of Def1 targeting export. The artificial nature of the assay used in this 
thesis does not prove that the C-terminus of Def1 promotes export in the context of 
the full-length protein, but provides strong evidence for this function. The identity of 
the export signal in Def1’s C-terminus is unclear. No short NES-like sequence 
could be found and the short Def1 500-540 section could not direct nuclear export 
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on its own (Figure 6.8 B). The glutamine rich nature of Def1’s C-terminus may act 
as the export signal. Poly-glutamine tracts can promote nuclear export in 
Drosophila (Chan et al., 2011), but can also prevent nuclear import, by forming 
cytoplasmic aggregates (Park et al., 2013). 
 
As the C-terminus of Def1 can promote nuclear export, this would suggest that full-
length Def1 is dynamically shuttling between compartments, rather than excluded 
from the nucleus altogether. Previous biochemical work confirms this finding: full-
length Def1 was purified from chromatin (Woudstra et al., 2002) and associates 
with the, primarily nuclear, RNAPII (Reid and Svejstrup, 2004). Furthermore, Def1 
is cleaved by expression of the TEV protease, which contains a NLS, and is 
localised to the nucleus upon expression (Uhlmann et al., 2000). As a result, at 
least a small proportion of Def1 is present in the nucleus in unstressed conditions, 
presumably below the detection limit of the microscope used in this work. However, 
when transcription stall is induced pr-Def1 temporarily accumulates in the nucleus. 
 
Def1 export does not appear to be dependent on the canonical CRM1-NES export 
pathway (Figure 6.8 A), and therefore must be reliant on one of the other, poorly 
characterised, karyopherin exportins or transportins. A possible indirect stress 
caused by transcription inhibition is the accumulation of proteins in the nucleus. A 
number of proteins - including but not limited to RNA processing factors - are 
dependent upon mRNA synthesis for their export (O'Hagan and Ljungman, 2004, 
Lee et al., 1999b). Whilst the exportin required for Def1 has not been identified, if 
Def1 were exported with mRNA then it would be expected to accumulate in the 
nucleus when RNAPII is inhibited: exactly what has been observed after UV-
induced transcription inhibtion. 
 
pr-Def1 is predicted to have a mass of approximately 60kDa (assuming processing 
at residue 520-530) and therefore is unlikely to be able to diffuse freely through the 
nuclear pore. Active import into the nucleus requires binding to an importin protein 
(Xu et al., 2010), the best characterised of which binds to a lysine-rich NLS on the 
cargo protein (Dingwall, 1991). A degenerate NLS can be identified within the CUE 
domain of Def1. Future mutation of this sequence would help to ascertain how Def1 
is imported to the nucleus. 
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Alternatively, Def1 does not necessarily need to directly contact a karyopherin 
protein; it could piggyback on another transiting protein. Rsp5 dynamically shuttles 
between the nucleus and cytoplasm, and accumulates in the nucleus after UV 
irradiation (Cholbinski et al., 2011). Def1 can interact with Rsp5 in vitro, and could 
bind and translocate with Rsp5. Rsp5 targets specifically to stalled RNAPII 
(Somesh et al., 2005, Somesh et al., 2007), possibly helping to target Def1 to the 
correct location. 
 
 
 
8.5 A New Component of the Elongin-Cullin Complex 
 
The Elc1-Ela1 complex is akin to the Skp1/F-box substrate adaptor of CRLs (Koth 
et al., 2000). However, this complex does not seem to be able recognise its target 
protein RNAPII efficiently (Figure 7.7). This may be due, in part, to the artificial 
nature of the in vitro experiment employed; immobilised RNAPII was not 
phosphorylated, stalled on DNA, or mono-ubiquitylated. Indeed, Human Elongin A 
has been shown to associate with hyper-phosphorylated RNAPII (Yasukawa et al., 
2008). However, in immunoprecipitations Ela1 association with RNAPII is 
dependent upon Def1 and its CUE domain. This suggests pr-Def1 is a bridging 
factor, which connects the Elongin-Cullin ligase to its target (Figure 8.3). CRLs 
typically employ different substrate adaptors, which can associate specifically 
during the cell cycle, or in response to external stimuli (Patton et al., 1998, Kaiser 
et al., 2006). Def1 may represent the first example of a discrete substrate-specific 
bridging factor being required for target recognition by a CRL, rather than an 
alternative, cullin binding, substrate adaptor. 
 
The Def1 protein facilitates the interaction between the Elongin-Cullin ligase and its 
Rpb1 substrate. The exact progression of events has not been determined; it is 
unclear whether Def1 binds first to the stalled RNAPII or to the Elongin-Cullin 
complex. Furthermore, the manner in which the signal of persistently stalled 
RNAPII is transduced to promote Def1 processing is unclear. One attractive model 
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is that full-length Def1 is proteolytically processed at the site of stalled RNAPII on 
chromatin. As a small portion of Def1 is present in the nucleus constitutively, it 
could sample the stall-status of transcribing RNAPII complexes. Under normal 
conditions, RNAPII pauses and stalls tend to be transient, promoting the 
predominantly cytoplasmic steady state localisation of Def1. Any possible 
background Rpb1 poly-ubiquitylation required, due to inherent persistent 
transcription stalling (such as reported in Hobson et al., 2012), could be dealt with 
by this minor nuclear Def1 fraction.  
 
 
 
Figure 8.3: The proposed Elongin-Cullin complex and substrate 
 
Proposed model of Elongin-cullin association with stalled RNAPII on chromatin, via pr-Def1. 
Activating Ubl Rub1 is coloured light blue. Ubiquitin moieties are coloured yellow. The dynamic 
catalytic RING finger protein, Rbx1, is coloured red. RNA is not included for clarity. pr-Def1 
associates via its CUE domain with the UbH domain in Ela1. Not to scale. 
 
 
However, in the presence of bulky helix-distorting DNA damage, RNAPII 
persistently arrests. Def1 associating with this RNAPII would be in close proximity 
to Rsp5, which is specifically targeted to stalled RNAPII only (Somesh et al., 2005, 
Somesh et al., 2007). Indeed, Rsp5 may even directly help to target Def1 to stalled 
RNAPII (see above). Furthermore, the proteasome directly associates with RNAPII, 
possibly at sites of stall (Auld et al., 2006, Gillette et al., 2004). As a result, Def1 
ubiquitylation and subsequent proteasomal activation could be spatially localised - 
in situ - to its site of action. RNAPII-associated pr-Def1 could then recruit the 
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Elongin-Cullin complex. If this model is correct then pr-Def1 could not be 
considered to be a part of the Elongin-Cullin complex. Alternatively, pr-Def1 could 
associate with Elongin-Cullin and subsequently be recruited to sites of RNAPII 
persistent stall. It would be intriguing to investigate whether there are other 
substrates of the Elongin-Cullin ligase and if these are also mediated through Def1. 
 
 
8.6 A Novel Ubiquitin Homology Domain 
 
The CUE UBD of Def1 does not bind primarily to a ubiquitylated target. Instead, the 
CUE domain is required to recruit the Elongin-Cullin ligase, through a newly 
identified UbH domain in Ela1. The C-terminus of Ela1 has not previously been 
predicted to share homology with ubiquitin. However, ubiquitin shares 47% 
sequence similarity to the C-terminus of Ela1, and key functional residues defining 
the 3-dimensional fold seem to be conserved (Kiel and Serrano, 2006). 
 
A UbH-UBD like interaction within a CRL has been reported previously (Ivantsiv et 
al., 2006). The UbH domain of the proteasome shuttling factor, Ddi, binds to the F-
box protein Ufo1, via its UIM domain. This UbH-UBD like interaction within the SCF 
CRL is the opposite polarity of the interaction observed between Def1 and Ela1. 
Moreover, the interaction is required for the degradation of the F-box protein, not 
for the CRL catalytic poly-ubiquitylation function. 
 
Def1 exhibits binding specificity to Ela1’s UbH domain, compared to ubiquitin 
(Figure 7.4 B). Unsurprisingly, simple replacement of the UbH domain with ubiquitin 
did not rescue the Rpb1 poly-ubiquitylation function attributed to Ela1 in the 
Elongin-Cullin complex (Figure 7.6 D). In another example, replacement of the 
kinase IKKβ’s UbH domain with ubiquitin abolishes kinase activity, whilst 
replacement with Rad23’s UbH domain fully restored the function of the kinase 
(May et al., 2004). The CUE domain of Def1 appears to have a regular CUE fold, 
but the key conserved residues - mutated in this study - are not positioned similarly 
to other CUE domains, and as a result Def1 is unlikely to bind ubiquitin in the same 
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manner (James Omichinski, personal communication). The co-crystal structure of 
Def1’s CUE domain with the UbH domain from Ela1 would be highly informative. 
 
UBD-ubiquitin interactions are often weak and are consequently supplemented with 
accessory protein-specific interactions (Panier et al., 2012, Parker et al., 2007). 
Reported cases of UbH–UBD interactions vary from weaker than their cognate 
ubiquitin interactions (Raasi et al., 2004), to extremely stable (Chartron et al., 2012, 
Zhang et al., 2009). Usually, standard UBD-ubiquitin like contacts are conserved, 
but supplemented with specific electrostatic interactions. The CUE domain of Def1 
might confer specificity directly, by displaying higher affinity to the UbH domain in 
Ela1 compared to ubiquitin. Alternatively, other binding surfaces of Def1, outside of 
the CUE domain, could contact the Ela1-Elc1 dimer. In order to investigate this 
further, shorter mutant Ela1-Elc1 and Def1 proteins could be purified. Preliminarily, 
the first 150 amino acids of Def1 (encompassing the majority of the CUE domain) 
could not interact with ubiquitin, whilst its binding to Ela1’s C-terminus was not 
investigated. 
 
In humans, the Elongin complex is comprised of three subunits, Elongin A, B, and 
C (Aso et al., 1995), which can form a CRL that catalyses the poly-ubiquitylation of 
Rpb1 (Yasukawa et al., 2008, Harreman et al., 2009). Budding yeast lack an 
Elongin B homologue (Koth et al., 2000) and Elongin A exhibits poor conservation 
with the C-terminus of yeast Ela1. Remarkably, the human Elongin B protein 
contains a UbH domain (Garrett et al., 1995). Therefore, the UbH of yeast Ela1 
may have split onto a separate gene during evolution, which then became human 
Elongin B. Elongin B helps to stabilise Elongin C (Brower et al., 1999, Bullock et al., 
2006), but critically its hydrophobic patch is free, possibly allowing interaction with 
other proteins, such as any possible human homologue of Def1. 
 
 
 
8.7 Relevance to Higher Eukaryotes 
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Poly-glutamine expansion diseases are caused by trinucleotide CAG amplifications 
within the coding region. Nine different expanded proteins have been identified in 
the humans to date; all leading to related but separate neurodegenerative disorders 
(Schols et al., 2004). Proteolytic cleavage and release of the toxic fragment is 
thought to activate these disease proteins (Tarlac and Storey, 2003) and the poly-
glutamine tract is able to interfere with the ubiquitin proteasome system 
(Venkatraman et al., 2004, Kraut et al., 2012). Current models suggest that the 
activated poly-glutamine proteins affect transcription (Tarlac and Storey, 2003), and 
that to perform this function they accumulate in the nucleus (Walsh et al., 2005). 
Exclusion of the poly-glutamine proteins from the nucleus prevents their toxicity 
(Yang et al., 2002). The many parallels to Def1 processing and activity are clear. 
The study of poly-glutamine expansion proteins is in its infancy and not yet at a 
molecular stage. The further study of Def1 and its function may help to elucidate 
the mechanism of toxicity in these neurodegenerative diseases. 
 
A human homologue of Def1 has not yet been identified. However, considering the 
high conservation of the rest of the Rpb1 poly-ubiquitylation system (Table 1.5), it 
would be highly surprising for Def1’s functions not to be conserved. The extensive 
low complexity regions within Def1 prevent the identification of direct sequence 
homologs. By amassing more data on the function of Def1 in yeast, the conserved 
requirements of a human Def1 could be ascertained. For example, assuming the 
conservation of the UbH within the Elongin-Cullin complex is not by chance, the 
human Def1 protein is likely to contain a UBD with specificity to this UbH. The 
future identification of the functional homologue of Def1 will be greatly aided by the 
knowledge gained from the yeast system. 
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